Page last updated: 2024-11-12

edoxaban

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

edoxaban : A monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10280735
CHEMBL ID1269025
CHEBI ID85973
SCHEMBL ID330046
MeSH IDM0549958

Synonyms (60)

Synonym
du-176b
AKOS005146069
480449-70-5
D09710
edoxaban (usan/inn)
CHEMBL1269025 ,
bdbm50328731
chebi:85973 ,
edoxaban
du-176
ndu3j18apo ,
ethanediamide, n1-(5-chloro-2-pyridinyl)-n2-((1s,2r,4s)-4- ((dimethylamino)carbonyl)- 2-(((4,5,6,7-tetrahydro-5-methylthiazolo(5,4-c)pyridin-2-yl)carbonyl)amino)cyclohexyl)-
n-(5-chloropyridin-2-yl)-n'-((1s,2r,4s)-4-(n,n-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro(1,3)thiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)oxamide
hsdb 8406
unii-ndu3j18apo
edoxaban [usan:inn]
S4429
HY-10264
CS-1331
n-(5-chloro-2-pyridinyl)-n'-[(1s,2r,4s)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]ethanediamide
edoxaban [usan]
edoxaban [who-dd]
edoxaban [inn]
edoxaban [mart.]
edoxaban [mi]
n'-(5-chloropyridin-2-yl)-n-[(1s,2r,4s)-4-(dimethylcarbamoyl)-2-[(5-methyl6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide
gtpl7575
SCHEMBL330046
n1-(5-chloropyridin-2-yl)-n2-((1s,2r,4s)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5, 6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl) ethanediamide
HGVDHZBSSITLCT-JLJPHGGASA-N
n-(5-chloropyridin-2-yl)-n'-[(1s,2r,4s)-4-(dimethylcarbamoyl)-2-{[(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl]ethanediamide
n1-(5-chloropyridin-2-yl)-n2-((1s,2r,4s)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide
n1-(5-chloropyridin-2-yl)-n2-[(1s,2r,4s)-4-(dimethylcarbamoyl)-2-{[(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl]ethanediamide
n(1)-(5-chloropyridin-2-yl)-n(2)-{(1s,2r,4s)-4-(dimethylcarbamoyl)-2-[(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl}ethanediamide
DB09075
DTXSID50197398 ,
912273-65-5
n1-(5-chloropyridin-2-yl)-n2-((1s,2r,4s)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide
mfcd13195544
NCGC00378907-03
Z2301684749
AS-35107
Q21011234
AC-35419
AMY508
NCGC00378907-01
480449-70-5 (free base)
NCGC00378907-02
A860576
n-(5-chloro-2-pyridinyl)-n'-[4-(dimethylcarbamoyl)-2-{[(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl]ethanediamide;
n'-(5-chloropyridin-2-yl)-n-[(1s,2r,4s)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide
EX-A5582
edoxabanum
dtxcid60119889
n-(5-chloropyridin-2-yl)-n'-((1s,2r,4s)-4-(n,n-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydro(1,3)thiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)oxamide
edoxaban (mart.)
n-(5-chloropyridin-2-yl)-n'-((1s,2r,4s)-4-(n,n-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro(1,3)thiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)
b01af03
EN300-20605508
n'-(5-chloropyridin-2-yl)-n-[(1s,2r,4s)-4-(dimethylcarbamoyl)-2-{5-methyl-4h,5h,6h,7h-[1,3]thiazolo[5,4-c]pyridine-2-amido}cyclohexyl]ethanediamide

Research Excerpts

Overview

Edoxaban is a non-vitamin K antagonist oral anticoagulant (NOAC) widely used for the long-term prevention of stroke in patients with non-valvular atrial fibrillation (NVAF) Edoxaban 60 mg is a safe and effective treatment for venous thrombosis.

ExcerptReferenceRelevance
"Edoxaban is a non-vitamin K antagonist oral anticoagulant (NOAC) widely used for the long-term prevention of stroke in patients with non-valvular atrial fibrillation (NVAF). "( How to handle a delayed or missed dose of edoxaban in patients with non-valvular atrial fibrillation? A model-informed remedial strategy.
Gu, JQ; Jiao, Z; Li, ZR; Liu, XQ; Yin, YW, 2023
)
2.62
"Edoxaban (EDX) is an oral anticoagulant suitable for pharmacologic thromboprophylaxis."( Development and validation of capillary zone electrophoresis and high-performance liquid chromatography methods for the determination of oral anticoagulant edoxaban in pharmaceutical tablets.
Arguello Da Silva, J; Bordignon Primieri, G; Oliveira Rocha, M; Ribeiro Wingert, N; Steppe, M, 2022
)
1.64
"Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for stroke prevention in atrial fibrillation (SPAF). "( Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY.
Beyer-Westendorf, J; Fache, K; Köhler, C; Marten, S; Naue, C; Spindler, M; Stannek, L; Tittl, L, 2022
)
2.46
"Edoxaban is an orally administered anticoagulant treatment that is used in patients with cerebral infarction, venous thrombosis, or other conditions, with a reported incidence of gastrointestinal hemorrhage at approximately 1%. "( Gallbladder hemorrhage during orally administered edoxaban therapy: a case report.
Itagaki, H; Katuhiko, S, 2019
)
2.21
"Edoxaban is an oral anticoagulant drug and a direct factor Xa inhibitor. "( Edoxaban affects TRAP-dependent platelet aggregation.
Ivankova, J; Mokan, M; Nehaj, F; Sokol, J; Stasko, J, 2020
)
3.44
"Edoxaban is a safe and structural stabilizing factor for endothelial cells and also has remarkable anti-inflammatory action, preventing PBMC adhesion and transmigration through the endothelium. "( Edoxaban's contribution to key endothelial cell functions.
Almengló, C; Álvarez, E; González-Juanatey, JR; González-Peteiro, M; Mosquera-Garrote, N, 2020
)
3.44
"Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. "( The risk of bleeding and all-cause mortality with edoxaban versus vitamin K antagonists: A meta-analysis of phase III randomized controlled trials.
Chen, HB; Li, YH; Xiu, J; Yu, TH, 2020
)
2.25
"Edoxaban 60 mg is a safe and effective treatment compared with warfarin for stroke prevention in routine clinical care for Danish (mainly Caucasian) patients with AF, with non-significantly different risks for stroke and clinically relevant bleeding, but lower all-cause mortality."( Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study.
Jensen, M; Lip, GY; Nielsen, PB; Ording, AG; Søgaard, M, 2022
)
2.43
"Edoxaban is an oral direct factor Xa inhibitor without need of monitoring."( ENNOBLE-ATE trial: an open-label, randomised, multi-centre, observational study of edoxaban for children with cardiac diseases at risk of thromboembolism.
Berger, F; Bhatt, MD; Dave, J; Duggal, A; Goldenberg, NA; Grosso, M; Jacobs, JP; Newburger, J; Pandya, G; Portman, MA, 2021
)
1.57
"Edoxaban is an orally active, direct factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation and for the treatment of venous thromboembolism."( An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
Atiee, GJ; Duchin, K; Duggal, A; He, L; Kakkar, T; Kidokoro, M; Shipitofsky, NL; Takatani, T; Zhang, G, 2018
)
2.16
"Edoxaban is a welcome addition to the NOAC's armamentarium. "( Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation.
Aronow, WS; Shamliyan, TA,
)
1.86
"Edoxaban is an oral direct factor Xa inhibitor for prophylaxis and treatment of thromboembolic disorders. "( Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
Baghaei, F; Fagerberg Blixter, I; Gustafsson, KM; Hillarp, A; Lindahl, TL; Strandberg, K,
)
1.83
"Edoxaban is a direct factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF). "( Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
Abozguia, K; Camm, J; Cappato, R; Diener, HC; Grimaldi, M; Heidbüchel, H; Hohnloser, SH; Kautzner, J; Mönninghoff, C; Mont, L; Morillo, CA; Rauer, H; Reimitz, PE; Smolnik, R, 2019
)
2.32
"Edoxaban is a cost-effective alternative to acenocoumarol in the prevention of stroke and systemic embolism in patients with NVAF in Spain."( Would the Use of Edoxaban Be Cost-effective for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation in Spain?
Anguita, M; Barja de Soroa, P; Lekuona, I; Pérez-Alcántara, F; Rodríguez, JM; Zamorano, JL, 2019
)
2.3
"Edoxaban is an oral, direct inhibitor of factor Xa that is given in a fixed dose once daily."( Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.
Büller, H; Mercuri, M; Prins, M; Raskob, G; Schwocho, L; Segers, A; Shi, M; van Kranen, R, 2013
)
2.55
"Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention in patients with atrial fibrillation, an elderly population that frequently receives aspirin (ASA) and/or nonsteroidal anti-inflammatory drugs for concurrent illnesses. "( The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
Chen, S; Lee, F; Mendell, J; Samama, MM; Shi, M; Worland, V, 2013
)
2.04
"Edoxaban is a novel, potent and orally active direct Factor Xa (FXa) inhibitor under development for prophylaxis and treatment of thromboembolic diseases. "( Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Honda, Y; Kamisato, C; Morishima, Y; Shibano, T, 2013
)
2.08
"Edoxaban is a P-gp substrate, and several cardiovascular (CV) drugs have the potential to inhibit P-gp and increase drug exposure."( Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
Chen, S; Lee, F; Matsushima, N; Mendell, J; Noveck, R; Shi, M; Zahir, H; Zhang, G, 2013
)
1.32
"Edoxaban is an oral, once-daily, selective, direct factor Xa inhibitor approved in Japan for the prevention of venous thromboembolism following major orthopedic surgery. "( Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery.
Hirayama, C; Hotoda, H; Kuroda, Y; Nishikawa, Y; Nishiwaki, A, 2013
)
2.11
"Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. "( Edoxaban versus warfarin in patients with atrial fibrillation.
Antman, EM; Betcher, J; Braunwald, E; Ezekowitz, MD; Giugliano, RP; Grip, LT; Halperin, JL; Hanyok, JJ; Koretsune, Y; Mercuri, M; Murphy, SA; Patel, I; Patel, SP; Ruda, M; Ruff, CT; Ruzyllo, W; Shi, M; Špinar, J; Waldo, AL; Weitz, JI; Wiviott, SD, 2013
)
3.28
"Edoxaban is a direct and specific inhibitor of activated factor X, delivered orally. "( The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism.
Arellano-Rodrigo, E; Diaz-Ricart, M; Escolar, G; Galán, AM, 2014
)
2.15
"Edoxaban is a direct activated factor X inhibitor with attractive features among which are once daily dosing, no need for routine monitoring, and minimal drug-drug interactions."( Edoxaban: Review of pharmacology and key phase I to III clinical trials.
Giugliano, RP; Plitt, A, 2014
)
2.57
"Edoxaban is an oral, direct, once-daily factor Xa inhibitor. "( Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
Abe, K; Fuji, T; Fujita, S; Kawai, Y; Kimura, T; Kiuchi, Y; Nakamura, M; Tachibana, S, 2014
)
2.16
"Edoxaban is an oral, once-daily, direct factor Xa (FXa) inhibitor that has been evaluated for the prevention of stroke in patients with atrial fibrillation (AF) and for the treatment and prevention of venous thromboembolism (VTE) recurrence. "( Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment.
Halim, AB; Kang, D; Miller, R; Song, S, 2014
)
2.06
"Edoxaban is an oral direct factor Xa (FXa) inhibitor and its efficacy as an oral anticoagulant is less subject to drug-food and drug-drug interaction than existing vitamin K antagonists. "( Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban.
Ishihara, H; Morishima, Y; Murata, M; Noguchi, K; Shibano, T; Takahashi, S, 2015
)
2.07
"Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. "( Edoxaban: an update on the new oral direct factor Xa inhibitor.
Bounameaux, H; Camm, AJ, 2014
)
3.29
"Edoxaban is an oral, once-daily direct factor Xa (FXa) inhibitor. "( Ex vivo reversal of the anticoagulant effects of edoxaban.
Halim, AB; Mendell, J; Samama, MM, 2014
)
2.1
"Edoxaban is an oral and direct activated factor X inhibitor. "( Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
Honda, Y; Kamisato, C; Morishima, Y, 2014
)
2.08
"Edoxaban is a novel direct inhibitor of activated factor Xa. "( Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers.
Miller, R; Yin, OQ, 2014
)
2.08
"Edoxaban is an oral, selective direct factor Xa inhibitor approved in Japan for venous thromboembolism prevention after orthopedic surgery. "( Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage.
Dickneite, G; Doerr, B; Herzog, E; Kaspereit, F; Krege, W; Morishima, Y; Mueller-Cohrs, J; Pragst, I, 2015
)
2.17
"Edoxaban is an oral, direct, once-daily, factor Xa inhibitor developed for stroke prevention in patients with atrial fibrillation and for the treatment and secondary prevention of recurrent thromboembolism in patients with acute symptomatic venous thromboembolism. "( Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Brown, KS; Chen, S; Dishy, V; He, L; Marbury, T; Matsushima, N; Parasrampuria, DA; Wickremasingha, PK, 2015
)
2.12
"Edoxaban is an oral, once-daily factor Xa inhibitor that is non-inferior to well-managed warfarin in patients with atrial fibrillation (AF) for the prevention of stroke and systemic embolic events (SEEs). "( Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.
Antman, EM; Braunwald, E; Cermak, O; Giugliano, RP; Grip, LT; Kania, G; Mercuri, MF; Murphy, SA; O'Donoghue, ML; Ruff, CT; Rutman, H; Shi, M, 2015
)
3.3
"Edoxaban is a target-specific oral anticoagulant, specifically a factor Xa inhibitor. "( Edoxaban, a Novel Oral Factor Xa Inhibitor.
Armbruster, AL; Minor, C; Tellor, KB, 2015
)
3.3
"Edoxaban is a safe and effective anticoagulant to reduce the risk of stroke in patients with NVAF and for the treatment of VTE."( Edoxaban, a Novel Oral Factor Xa Inhibitor.
Armbruster, AL; Minor, C; Tellor, KB, 2015
)
3.3
"Edoxaban is an oral once-daily factor Xa inhibitor with a predictable anticoagulant effect. "( Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
Barrios, V; Escobar, C, 2015
)
3.3
"Edoxaban is an effective and safer alternative to warfarin in East Asian patients with acute VTE who require anticoagulant therapy, consistent with overall study findings from the Hokusai-VTE trial."( Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.
Abe, K; Büller, H; Kimura, T; Lee, LH; Mercuri, M; Miyazaki, K; Nakamura, M; Oh, D; Segers, A; Wang, C; Wang, YQ; Yin, WH, 2015
)
2.17
"Edoxaban is a potential alternative to warfarin for preventing thromboembolism in atrial fibrillation. "( Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
Chen, J; Long, M; Su, C; Wang, L; Zhuang, X, 2015
)
2.17
"Edoxaban is a direct factor Xa inhibitor and has become the fourth direct oral anticoagulant (DOAC) approved for stroke prevention in atrial fibrillation (AF) and for treatment and secondary prevention of venous thromboembolism (VTE). "( Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Brekelmans, M; Coppens, M; Middeldorp, S, 2015
)
2.16
"Edoxaban is an oral, once-daily direct factor Xa inhibitor. "( Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.
Brown, KS; Dishy, V; Kochan, J; Maa, JF; Parasrampuria, DA; Shi, M; Weilert, D, 2016
)
2.1
"Edoxaban is a factor Xa inhibitor that is approved for prevention of stroke in individuals with atrial fibrillation and treatment of venous thromboembolic disease at once daily 60 mg dose for individuals with normal renal function. "( Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy.
Gosavi, S; Mukherjee, D; Switzer, MP; Wani, P, 2015
)
2.14
"Edoxaban is a specific anti-Xa inhibitor that, in comparison to warfarin, has been found to be noninferior for the prevention of stroke or systemic embolism (SSE) and to reduce bleeding significantly in patients with nonvalvular atrial fibrillation (AF). "( Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardi
Antman, EM; Awasty, VR; Braunwald, E; Eisen, A; Giugliano, RP; Gogia, HS; Henderson, DA; Mercuri, MF; Nordio, F; Ruff, CT; Rutman, H, 2016
)
3.32
"Edoxaban is a novel factor Xa inhibitor. "( Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial.
Jönsson, S; Karlsson, KE; Karlsson, MO; Krekels, EH; Miller, R; Niebecker, R; Ruff, CT; Shimizu, T; Simonsson, US, 2016
)
2.16
"Edoxaban is a factor Xa inhibitor approved for the prevention of stroke/systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of venous thromboembolism."( Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
Cheng-Lai, A; Kubli, KA; Snead, JA,
)
2.3
"Edoxaban is an oral, once-daily, selective, direct factor Xa inhibitor that is safe and easy to handle. "( The use of factor Xa inhibitors following opening-wedge high tibial osteotomy for venous thromboembolism prophylaxis.
Akamatsu, Y; Aratake, M; Ishigatsubo, R; Kobayashi, A; Kobayashi, H; Kumagai, K; Kusayama, Y; Mitsuhashi, S; Saito, T, 2017
)
1.9
"Edoxaban is a once-daily direct oral anticoagulant (DOAC). "( Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
Bauersachs, R; Bleker, SM; Boda, Z; Brekelmans, MP; Büller, HR; Choi, Y; Cohen, AT; Gallus, A; Grosso, MA; Middeldorp, S; Oh, D; Raskob, G; Schwocho, L, 2016
)
2.13
"Edoxaban is a once-daily oral inhibitor of factor Xa, currently indicated to reduce the risk of stroke or systemic embolism in nonvalvular atrial fibrillation patients and for the treatment and prevention of venous thromboembolism (EMA, FDA and Japan). "( Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
Barrios, V; Escobar, C, 2016
)
2.22
"Edoxaban is a fast-acting oral anticoagulant, approved for use in the prevention of stroke in patients with nonvalvular atrial fibrillation (AF) and in the treatment of acute VTE."( Risk impact of edoxaban in the management of stroke and venous thromboembolism.
Handa, A; Hurst, KV; O'Callaghan, JM, 2016
)
1.51
"Edoxaban is an attractive alternative to warfarin in patients at increased risk of falling, because it is associated with an even greater absolute reduction in severe bleeding events and mortality. "( Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
Antman, EM; Aylward, P; Braunwald, E; Choi, Y; Giugliano, RP; Mercuri, M; Murphy, SA; Ruff, CT; Steffel, J; White, H; Zamorano, JL, 2016
)
3.32
"Edoxaban is a new oral direct factor Xa inhibitor that has been recently approved for treating VTE in patients who have already been treated with a parenteral anticoagulant and for the prevention of stroke and non-central nervous system systemic embolism in patients with nonvalvular atrial fibrillation."( The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
AlEmad, H; AlHajri, L; AlKitbi, N; AlMahri, K; AlMahri, M; Jabbari, S, 2017
)
1.47
"Edoxaban is a new oral direct factor Xa inhibitor. "( Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Bocanegra, T; Cohen, AT; Eriksson, BI; Puskas, D; Raskob, G; Shi, M; Weitz, JI, 2010
)
2.07
"Edoxaban is a selective and direct factor Xa inhibitor that may provide effective, safe, and more convenient anticoagulation."( Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infar
Antman, EM; Bocanegra, T; Braunwald, E; Crugnale, SE; Giugliano, RP; Hanyok, J; McCabe, CH; Mercuri, M; Patel, I; Ruff, CT; Salazar, D; Shi, M, 2010
)
1.34
"Edoxaban is an oral, reversible, direct factor Xa inhibitor in phase III clinical development for the prevention of stroke in atrial fibrillation (AF). "( Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.
Chen, SA; Chung, N; Chung, WS; Jeon, HK; Lai, WT; Lee, TH; Lien, LM; Tse, HF, 2011
)
2.21
"Edoxaban is a novel, oral, reversible, direct factor Xa inhibitor with rapid absorption and predictable dose-dependent anticoagulation effects."( Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.
Giugliano, RP; Partida, RA, 2011
)
2.53
"Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic events (VTE). "( Edoxaban: a new oral direct factor xa inhibitor.
Bounameaux, H; Camm, AJ, 2011
)
3.25
"Edoxaban is an oral, direct factor Xa (FXa) inhibitor under late-phase clinical development. "( Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
Fukuda, T; Honda, Y; Kamisato, C; Morishima, Y; Shibano, T; Tsuji, N, 2011
)
2.07
"Edoxaban is a novel, orally available, highly specific direct inhibitor of factor Xa and is currently being developed for the treatment and prevention of venous thromboembolism and prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). "( Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Antman, EM; Bocanegra, TS; Carrothers, TJ; Dornseif, B; Giugliano, RP; Green, M; Kastrissios, H; Kunitada, S; Mendell, J; Patel, I; Rohatagi, S; Salazar, DE; Shi, M; Song, S; Tachibana, M; Zhou, S, 2012
)
2.12
"Edoxaban is an oral direct factor (F)Xa inhibitor in advanced stages of clinical development. "( Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
Halim, AB; He, L; Lee, F; Matsushima, N; Mendell, J; Worland, V; Zahir, H; Zhang, G, 2012
)
3.26
"Edoxaban is an oral, selective and direct FXa inhibitor."( Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
Edo, N; Honda, Y; Kamisato, C; Kita, A; Morishima, Y; Shibano, T; Tsuji, N, 2012
)
1.35
"Edoxaban is a once-daily (QD) oral, direct factor Xa inhibitor in clinical development for the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF). "( Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation.
Inoue, H; Kawai, Y; Koretsune, Y; Matsumoto, M; Ogawa, S; Uchiyama, S; Yamaguchi, T; Yamashita, T; Yasaka, M, 2012
)
2.06
"Edoxaban is an oral direct factor Xa inhibitor approved for the prevention of venous thromboembolism (VTE) in Japan. "( Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.
Green, M; Kastrissios, H; Mendell, J; Patel, I; Rohatagi, S; Salazar, DE; Shi, M, 2012
)
2.08

Effects

Edoxaban has a rapid onset of action, a short half-life and few drug interactions. Edoxaban offers the convenience of oral, once-daily, fixed-dose administration without the need for coagulation monitoring and without regard to food.

Edoxaban (Edx) is approved to prevent venous thromboembolism after total knee and/or hip arthroplasty in Japan. Edoxaban has been extensively studied in three clinical scenarios.

ExcerptReferenceRelevance
"Edoxaban has a similar risk-benefit ratio to dalteparin in most cancer groups. "( Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study.
Büller, HR; Carrier, M; Di Nisio, M; Duggal, A; Gaddh, M; Garcia, D; Grosso, MA; Kakkar, AK; Kraaijpoel, N; Mercuri, MF; Middeldorp, S; Mulder, FI; Raskob, G; Royle, G; Segers, A; Shivakumar, S; van Es, N; Verhamme, P; Wang, T; Weitz, JI; Zhang, G, 2020
)
3.44
"Edoxaban has a rapid onset of action, a short half-life, few drug interactions and offers the convenience of oral, once-daily, fixed-dose administration, without the need for coagulation monitoring and without regard to food."( Edoxaban: a review in nonvalvular atrial fibrillation.
McCormack, PL, 2015
)
2.58
"Edoxaban has a favorable pharmacokinetic profile that supports its use in special patient populations, including patients aged ≥75 years, with HF, renal impairment, poor adherence, and on polypharmacy."( Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.
Aspromonte, N; Colivicchi, F, 2017
)
1.41
"Edoxaban has a time to peak plasma concentrations of 1-2 hours and a half-life of approximately 10 hours after multiple doses."( Oral anticoagulation with edoxaban. Focus on current phase III clinical development.
Ahrens, I; Bode, C, 2012
)
1.4
"Edoxaban (Edx) has been approved to prevent venous thromboembolism after total knee and/or hip arthroplasty in Japan. "( The importance of renal function in anemic patients treated with edoxaban after orthopedic surgery in a real-world clinical setting: A retrospective study.
Izushi, Y; Kitamura, Y; Sato, T; Shiota, N; Takami, Y; Tetsunaga, T; Ushio, S; Yamamoto, H, 2022
)
2.4
"Edoxaban has been extensively studied in three clinical scenarios."( Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
Barrios, V; Escobar, C, 2015
)
2.58

Actions

Edoxaban did not increase the incidence of stroke, systemic embolic events, myocardial infarction, and adverse events compared with warfarin. Edoxaban favored lower risks of major bleeding compared with rivaroxaban and VKA.

ExcerptReferenceRelevance
"Edoxaban favored lower risks of major bleeding compared with rivaroxaban (HR: 0.74) and VKA (HR: 0.47)."( Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study.
Brüggenjürgen, B; Gao, X; Marston, XL; Unverdorben, M; Wang, R; Ye, X; Yeh, YC; Zimmermann, L, 2022
)
1.72
"Edoxaban 30 mg can increase the incidence of major bleeding events."( Short-term efficacy and safety of edoxaban for venous thromboembolism after total hip or knee arthroplasty: a systematic review and meta-analysis.
Chen, S; Gong, DW; Li, JL; Ma, YH; Mai, JL; Wang, HB; Xiao, JC; Zhang, M, 2022
)
1.72
"Edoxaban did not increase the incidence of stroke, systemic embolic events, myocardial infarction, and adverse events compared with warfarin (RR: 1.00, 95% CI: 0.90-1.11, I2 : 42.8%; RR: 1.00, 95% CI: 0.67-1.49, I2 : 0.0%; RR: 1.08, 95% CI: 0.93-1.27, I2 : 0.0%; RR: 1.00, 95% CI: 0.91-1.10, I2: 46.4%, respectively)."( The efficacy and safety of edoxaban versus warfarin in preventing clinical events in atrial fibrillation: A systematic review and meta-analysis.
Liang, X; Lin, Z; Liu, M; Xie, W, 2021
)
1.64
"Edoxaban levels were lower in the 30 mg edoxaban group."( Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
Ageno, W; Brekelmans, MP; Buller, H; Cohen, AT; Grosso, MA; Meyer, G; Raskob, G; Segers, A; Verhamme, P; Weitz, JI; Wells, PS; Zhang, G, 2016
)
1.49

Treatment

Edoxaban treatment for stroke prevention in atrial fibrillation (AF) has mainly been investigated in randomized controlled trials. Both edoxaban and warfarin treatment improved thrombotic burden and decreased prothrombin fragment F1+2, and D-dimer.

ExcerptReferenceRelevance
"Edoxaban treatment may be safe and effective in preventing the recurrence of VTE/PE in patients with isolated LAC positivity, without the occurrence of arterial events."( Real-life experience of edoxaban treatment for venous thromboembolism (VTE)/pulmonary embolism (PE) in patients with isolated positive Lupus Anticoagulant (LAC) during the COVID-19 pandemic lockdown in Italy.
Bacchiarri, F; Bocchia, M; Calzoni, P; Fineschi, D; Puccetti, L; Sammartano, V; Santoni, A, 2022
)
2.47
"Edoxaban treatment led to reduction of urinary albumin excretion and plasma UN levels compared with vehicle group, which was accompanied with reduced glomerular cross-sectional area and cell number."( Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial-mesenchymal transition and inflammatory response.
Fang, L; Kawanishi, H; Murohara, T; Ogawa, H; Ohashi, K; Otaka, N; Ouchi, N; Ozaki, Y; Takahara, K; Takefuji, M; Takikawa, T; Tatsumi, M, 2022
)
1.76
"The Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (ETNA-AF) Europe (NCT02944019) is a prospective, multi-centre, post-authorisation, observational study with an overall 4-year follow-up conducted in 825 centres enrolling edoxaban-treated patients in 10 European countries. "( Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care.
Bakhai, A; de Asmundis, C; De Caterina, R; de Groot, JR; Deharo, JC; Kelly, P; Kirchhof, P; Laeis, P; Levy, P; Lopez-de-Sa, E; Manu, MC; Monteiro, P; Pecen, L; Souza, J; Steffel, J; Waltenberger, J; Weiss, TW, 2022
)
2.72
"In edoxaban- and VKA-treated patients, rates of ischemic stroke were 1.8%/year and 1.0%/year, respectively; fatal bleeding rates were 0.9%/year and 2.0 %/year."( Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients - A Subanalysis of the ENVISAGE-TAVI AF Trial.
Ando, K; Chen, C; Dangas, G; Hayashida, K; Hengstenberg, C; Izumo, M; Jin, J; Kimura, T; Mizutani, K; Morioka, N; Naganuma, T; Nakajima, Y; Nishina, H; Ohno, Y; Saito, S; Sugio, K; Tada, N; Takagi, K; Ueno, H; Unverdorben, M; Van Mieghem, NM; Watanabe, Y; Yamamoto, M; Yamanaka, F; Yamasaki, K; Yamawaki, M, 2022
)
2.68
"Edoxaban treatment for stroke prevention in atrial fibrillation (AF) has mainly been investigated in randomized controlled trials, and data reflecting clinical practice are limited. "( Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort.
Larsen, TB; Lip, GYH; Nielsen, PB; Skjøth, F; Søgaard, M, 2021
)
2.36
"Both edoxaban and warfarin treatment improved thrombotic burden and decreased prothrombin fragment F1+2, and D-dimer."( Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.
Akaike, M; Amano, R; Fukuda, D; Hara, T; Ise, T; Kadota, M; Kusunose, K; Matsuura, T; Oomichi, Y; Sangawa, T; Sata, M; Soeki, T; Tobiume, T; Torii, Y; Ueno, R; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K; Yamazaki, H, 2018
)
2.38
"edoxaban) in DVT treatment in SMID patients by means of an open-label, randomized controlled trial."( Multicenter, Open-Label, Randomized Controlled Trial of Warfarin and Edoxaban Tosilate Hydrate for the Treatment of Deep Vein Thrombosis in Persons with Severe Motor Intellectual Disabilities.
Akaboshi, S; Fujita, H; Inoue, M; Kada, A; Kaneko, H; Kawasaki, M; Koretsune, Y; Kumode, M; Maruhashi, K; Miyanomae, T; Murata, H; Nakamura, M; Ohmori, H; Okumura, A; Saito, AM; Sanayama, Y; Sano, N; Shinagawa, T; Sone, S; Sumimoto, R; Takechi, T; Takizawa, N; Taniguchi, H; Tanuma, N; Wakisaka, A, 2018
)
1.44
"The edoxaban treatment, especially, resulted in favorable and effective control of VTE."( [Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
Kawaguchi, M; Konuma, S; Nehashi, Y; Okuda, Y; Uchimura, N, 2015
)
1.13
"Treatment with edoxaban significantly reduced infarct volumes and improved neurological outcome and BBB function on day 1 and attenuated brain tissue inflammation."( Treatment with Edoxaban Attenuates Acute Stroke Severity in Mice by Reducing Blood-Brain Barrier Damage and Inflammation.
Bieber, M; Foerster, KI; Haefeli, WE; Kraft, P; Pham, M; Schuhmann, MK, 2021
)
1.31
"Treatment with edoxaban 60 mg cost $US127,520/QALY gained compared with warfarin with a TTR of 70% and cost $US41,860/QALY gained compared with warfarin with a TTR of 65%. "( Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Hernandez, I; Hospodar, AR; Smith, KJ; Zhang, Y, 2018
)
0.83
"Treatment with edoxaban reduced the incidence of VTE after OWHTO; however, there was no statistically significant difference between the two groups. "( The use of factor Xa inhibitors following opening-wedge high tibial osteotomy for venous thromboembolism prophylaxis.
Akamatsu, Y; Aratake, M; Ishigatsubo, R; Kobayashi, A; Kobayashi, H; Kumagai, K; Kusayama, Y; Mitsuhashi, S; Saito, T, 2017
)
0.81
"Treatment with edoxaban resulted in a greater absolute risk reduction in severe bleeding events and all-cause mortality compared with warfarin."( Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
Antman, EM; Aylward, P; Braunwald, E; Choi, Y; Giugliano, RP; Mercuri, M; Murphy, SA; Ruff, CT; Steffel, J; White, H; Zamorano, JL, 2016
)
2.22
"Treatment with edoxaban 60mg cost $77,565/QALY gained compared to warfarin, and apixaban 5mg cost $108,631/QALY gained compared to edoxaban 60mg. "( Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Hernandez, I; Smith, KJ; Zhang, Y, 2017
)
0.81

Toxicity

Edoxaban 60 mg administered 24 h post-warfarin appeared to be safe and well tolerated. Edoxaban was an efficacious and safe option to prevent and treat VTE in patients undergoing arthroplasty.

ExcerptReferenceRelevance
" Edoxaban is safe and well tolerated with no dose-dependent increases in adverse events."( Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
Kojima, M; Kunitada, S; Masumoto, H; Mendell-Harary, J; Ogata, K; Oguma, T; Tachibana, M, 2010
)
1.49
" Secondary endpoints included thromboembolic events, biomarkers of thrombus formation and all adverse events (AEs)."( Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.
Chen, SA; Chung, N; Chung, WS; Jeon, HK; Lai, WT; Lee, TH; Lien, LM; Tse, HF, 2011
)
0.77
" Edoxaban 60 mg administered 24 h post-warfarin appeared to be safe and well tolerated."( A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.
Mendell, J; Noveck, RJ; Shi, M, 2013
)
1.53
"In this study of healthy subjects, edoxaban administered 24 h after the last dose of warfarin was safe and well tolerated with transient increases across the various coagulation assays above post-warfarin baseline levels."( A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.
Mendell, J; Noveck, RJ; Shi, M, 2013
)
0.9
" This report describes the adverse drug reactions (ADRs) spontaneously reported during early postmarketing phase vigilance from the time of its commercial launch in Japan."( Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery.
Hirayama, C; Hotoda, H; Kuroda, Y; Nishikawa, Y; Nishiwaki, A, 2013
)
0.66
" Additional adverse events were recorded throughout the study."( Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
Abe, K; Fuji, T; Fujita, S; Kawai, Y; Kimura, T; Kiuchi, Y; Nakamura, M; Tachibana, S, 2014
)
0.71
" The incidence of adverse events was 72."( Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
Abe, K; Fuji, T; Fujita, S; Kawai, Y; Kimura, T; Kiuchi, Y; Nakamura, M; Tachibana, S, 2014
)
0.71
" Safety endpoints included the incidence of major bleeding, clinically relevant non-major (CRNM) bleeding, major bleeding or CRNM bleeding, all bleeding events, adverse events, and adverse drug reactions."( Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
Abe, K; Fuji, T; Fujita, S; Ibusuki, K; Kawai, Y; Kimura, T; Nakamura, M; Tachibana, S; Ushida, H; Wang, CJ, 2014
)
0.71
" Adverse events and thromboembolic events were recorded throughout the study."( Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment.
Abe, K; Fukuzawa, M; Kimura, T; Koretsune, Y; Yamashita, T; Yasaka, M, 2015
)
0.67
" Comparing the pharmacovigilance reports for the individual NOACs, more hepatic adverse events were reported for rivaroxaban than for dabigatran or apixaban."( Hepatotoxicity of New Oral Anticoagulants (NOACs).
Krähenbühl, S; Liakoni, E; Rätz Bravo, AE, 2015
)
0.42
" Non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as efficacious, safe and convenient stroke prevention agents."( Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Batson, S; Kachroo, S; Lip, GY; Liu, LZ; Liu, X; Mitchell, SA; Phatak, H, 2016
)
0.63
" Potentially related adverse events were periorbital and facial flushing and cool sensation following IV injection of ciraparantag."( Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban.
Ansell, JE; Bakhru, SH; Brown, K; Costin, JC; Dishy, V; Grosso, MA; Lanz, HJ; Laulicht, BE; Mercuri, MF; Noveck, RJ; Steiner, SS, 2017
)
0.68
" In addition, NOACs have been demonstrated to be safe and associated with a significant reduction in major and intracranial bleeding events."( [New oral anticoagulants in patients with atrial fibrillation: efficacy and safety data from the real world].
Di Pasquale, G; Riva, L, 2017
)
0.46
" Thus, there is increasing need for safe and effective medical prophylaxis of thromboembolic events."( The safety of edoxaban for treating atrial fibrillation.
Goette, A; Hammwöhner, M, 2017
)
0.82
"These data suggest that a once-daily fixed dose of edoxaban is more effective and at least as safe as warfarin in high-risk VTE patients identified by older age, more comorbidities, and polypharmacy."( Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.
Ageno, W; Brekelmans, MPA; Büller, HR; Chen, CZ; Cohen, AT; Grosso, MA; Medina, AP; Mercuri, MF; Raskob, GE; Segers, A; Vanassche, T; Verhamme, P; Weitz, JI; Wells, PS; Winters, SM; Zhang, G, 2018
)
0.96
" Uninterrupted OAC with edoxaban appeared to be as safe as uninterrupted OAC with phenprocoumon in patients who underwent LA RF ablation procedures."( Safety of Uninterrupted Periprocedural Edoxaban Versus Phenprocoumon for Patients Who Underwent Left Atrial Catheter Ablation Procedures.
Ammar-Busch, S; Bourier, F; Brkic, A; Brooks, S; Deisenhofer, I; Dillier, R; Grebmer, C; Hessling, G; Kaess, B; Koch-Büttner, K; Kolb, C; Kornmayer, M; Kottmaier, M; Lengauer, S; Lennerz, C; Pausch, H; Reents, T; Rousseva, E; Semmler, V; Telishevska, M, 2018
)
1.06
"Patients with atrial fibrillation (AF) and advanced chronic kidney disease (CKD) are at high risk of adverse events and are complicated to manage."( Safety of Edoxaban 30 mg in Elderly Patients with Severe Renal Impairment.
Alcamo, P; Colonna, P; Dentamaro, I; Fazio, G; Gambacurta, R, 2018
)
0.88
" While additional studies are necessary to confirm the results of this exploratory study, edoxaban 30 mg once daily appears to be safe in patients with severe CKD."( Safety of Edoxaban 30 mg in Elderly Patients with Severe Renal Impairment.
Alcamo, P; Colonna, P; Dentamaro, I; Fazio, G; Gambacurta, R, 2018
)
1.1
"The present meta-analysis of four trials supports that NOACs are safe and at least as effective as warfarin in patients with atrial fibrillation and established CAD."( The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials.
Antman, EM; Giugliano, RP; Ruff, CT; Zelniker, TA, 2019
)
0.51
"The safety of the NOACs compared with warfarin was generally favourable across different patient subgroups, including those perceived to be at "high risk" for adverse outcomes."( The safety of NOACs in atrial fibrillation patient subgroups: A narrative review.
Lip, GYH, 2019
)
0.51
" However, some patients who received the combination of dabrafenib and trametinib (CombiDT) or the combination of encorafenib and binimetinib (CombiEB) had adverse events (AEs) including pyrexia."( Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma.
Fukaya, S; Fukuyasu, A; Hayashi, K; Ishikawa, T; Kamata, M; Miyazaki, M; Mukai, K; Nagata, M; Ohnishi, T; Tada, Y; Tanaka, T, 2021
)
2.06
"Edoxaban 60 mg is a safe and effective treatment compared with warfarin for stroke prevention in routine clinical care for Danish (mainly Caucasian) patients with AF, with non-significantly different risks for stroke and clinically relevant bleeding, but lower all-cause mortality."( Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study.
Jensen, M; Lip, GY; Nielsen, PB; Ording, AG; Søgaard, M, 2022
)
2.43
" Endpoints included major adverse cardiovascular events (MACEs), SSE, and major bleeding."( Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.
Antman, EM; Bonaca, MP; Braunwald, E; Cunningham, JW; Giugliano, RP; Grosso, MA; Halperin, JL; Lanz, HJ; Murphy, SA; Ruff, CT; Weitz, JI; Wiviott, SD, 2022
)
0.92
" The incidence of adverse events (AEs) and adverse drug reactions (ADRs) in the edoxaban group was decreased than that in other groups."( Short-term efficacy and safety of edoxaban for venous thromboembolism after total hip or knee arthroplasty: a systematic review and meta-analysis.
Chen, S; Gong, DW; Li, JL; Ma, YH; Mai, JL; Wang, HB; Xiao, JC; Zhang, M, 2022
)
1.23
"Edoxaban was an efficacious and safe option to prevent and treat VTE in patients undergoing arthroplasty."( Short-term efficacy and safety of edoxaban for venous thromboembolism after total hip or knee arthroplasty: a systematic review and meta-analysis.
Chen, S; Gong, DW; Li, JL; Ma, YH; Mai, JL; Wang, HB; Xiao, JC; Zhang, M, 2022
)
2.44

Pharmacokinetics

The purpose of this study was to evaluate the impact of P-glycoprotein (P-GP) efflux on edoxaban absorption in gastrointestinal tracts. The physiologically based pharmacokinetic (PBPK) model was constructed with clinical and non-clinical observations (using GastroPlus™ software)

ExcerptReferenceRelevance
" Activated partial thromboplastin and prothrombin times were obtained as measures of pharmacodynamic effect."( Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers.
Kunitada, S; Mendell, J; Shi, M; Tachibana, M, 2011
)
0.63
" Serial blood samples were collected for PD (thrombin generation, anti-FXa) and pharmacokinetic (PK) variables (edoxaban and its principal metabolite M4 by LC-MS/MS, and anti-FIIa as a surrogate of enoxaparin)."( Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
Halim, AB; He, L; Lee, F; Matsushima, N; Mendell, J; Worland, V; Zahir, H; Zhang, G, 2012
)
2.03
" Three studies were conducted to evaluate the pharmacokinetic and pharmacodynamic interactions of edoxaban 60 mg coadministered with low-dose (100 mg) ASA, high-dose (325 mg) ASA, or naproxen (500 mg) in healthy subjects (n = 126)."( The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
Chen, S; Lee, F; Mendell, J; Samama, MM; Shi, M; Worland, V, 2013
)
0.81
"To assess the potential pharmacokinetic interactions of edoxaban and 6 cardiovascular drugs used in the management of AF and known P-gp substrates/inhibitors."( Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
Chen, S; Lee, F; Matsushima, N; Mendell, J; Noveck, R; Shi, M; Zahir, H; Zhang, G, 2013
)
0.84
" The possible relationship between the pharmacokinetic profile of edoxaban and the favorable results in clinical trials is discussed."( The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism.
Arellano-Rodrigo, E; Diaz-Ricart, M; Escolar, G; Galán, AM, 2014
)
0.95
"Edoxaban is perceived as a major advance, compared to vitamin K antagonists, in the prevention and treatment of thromboembolic disease given its favorable efficacy, safety, pharmacokinetic profile and renal clearance."( The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism.
Arellano-Rodrigo, E; Diaz-Ricart, M; Escolar, G; Galán, AM, 2014
)
2.15
" Pharmacokinetic (PK) and pharmacodynamic (PD) modeling and logistic regression analyses were used to explore the clinical data from phase 1 and 2 studies to determine the relationship among PK exposure, PD response, and bleeding risk."( Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment.
Halim, AB; Kang, D; Miller, R; Song, S, 2014
)
0.62
" A previous human pharmacokinetic study suggested a less than proportional increase in edoxaban exposure at higher dose concentrations, but the quantitative relationship, including the point of inflection, has not yet been fully characterized."( Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers.
Miller, R; Yin, OQ, 2014
)
0.86
"Concentration data from 278 subjects in five phase I clinical studies were used to perform a population pharmacokinetic analysis using non-linear mixed-effects modeling."( Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers.
Miller, R; Yin, OQ, 2014
)
0.64
"The population pharmacokinetic model provided an adequate description of the observed data."( Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers.
Miller, R; Yin, OQ, 2014
)
0.64
" Plasma concentrations of edoxaban and its metabolites M4 and M6 were measured, and limited assessments of pharmacodynamic markers of coagulation were performed."( The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults.
Chen, S; Desai, M; He, L; Mendell, J; Parasramupria, DA, 2015
)
0.97
" To support the possibility that patients may choose to switch treatment from another nonvitamin K antagonist oral anticoagulant to edoxaban, this clinical study was conducted to evaluate the pharmacokinetic and pharmacodynamic effects of edoxaban after switching from rivaroxaban or dabigatran etexilate to edoxaban."( Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.
Brown, KS; Dishy, V; Kochan, J; Maa, JF; Parasrampuria, DA; Shi, M; Weilert, D, 2016
)
0.86
"Day 4 edoxaban pharmacokinetic parameters were similar for all treatments."( Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.
Brown, KS; Dishy, V; Kochan, J; Maa, JF; Parasrampuria, DA; Shi, M; Weilert, D, 2016
)
1.14
" This review examines strategies to overcome ARC and summarizes current pharmacokinetic and pharmacodynamic literature in patients with ARC in an effort to provide dosing guidance for this patient population."( Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.
Daley, MJ; Hobbs, AL; Roberts, KM; Shea, KM, 2015
)
0.42
" The terminal elimination half-life in healthy subjects ranges from 10 to 14 h, with minimal accumulation upon repeat once daily dosing up to doses of 120 mg."( Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
Parasrampuria, DA; Truitt, KE, 2016
)
0.7
" The influence of body weight (WT), creatinine clearance (CLCR), concomitant P-glycoprotein (P-gp) inhibitors, age, sex, race, and NVAF on pharmacokinetic parameters was evaluated based on statistical significance and clinical relevance."( Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial.
Jönsson, S; Karlsson, KE; Karlsson, MO; Krekels, EH; Miller, R; Niebecker, R; Ruff, CT; Shimizu, T; Simonsson, US, 2016
)
0.72
" This potent and selective inhibitor of factor Xa shows predictable pharmacokinetic and pharmacodynamic profiles."( Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.
Aspromonte, N; Colivicchi, F, 2017
)
0.69
"We previously reported exogenous antifactor Xa (FXa) activity as a pharmacokinetic surrogate marker for edoxaban plasma concentrations."( Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.
Antman, EM; Braunwald, E; Giugliano, RP; Mercuri, MF; Miller, R; Morrow, D; Ruff, CT; Truitt, K; Weitz, JI; Yin, OQP, 2018
)
0.92
" The pharmacokinetics in patients treated with standard and reduced doses of the four anticoagulants using liquid chromatography-tandem mass spectrometry was compared with the concentration ranges estimated using physiologically based pharmacokinetic modeling."( Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
Endo, S; Kishi, H; Kogiku, M; Noda, M; Notsu, Y; Ota, M; Shimizu, M; Takekawa, M; Yamazaki, H; Yamazaki-Nishioka, M, 2019
)
0.76
"The purpose of this study was to evaluate the impact of P-glycoprotein (P-gp) efflux on edoxaban absorption in gastrointestinal tracts quantitatively by a physiologically based pharmacokinetic (PBPK) model constructed with clinical and non-clinical observations (using GastroPlus™ software)."( Quantitative analysis of an impact of P-glycoprotein on edoxaban's disposition using a human physiologically based pharmacokinetic (PBPK) model.
Ando, S; Izumi, T; Kato, T; Matsumoto, Y; Mikkaichi, T; Okudaira, N; Shimizu, T; Yoshigae, Y, 2021
)
1.09
"The objective of this study was to assess the pharmacokinetic and pharmacodynamic profiles and safety of edoxaban in patients with nonvalvular atrial fibrillation (NVAF) who were hospitalized with acute heart failure (AHF)."( Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure.
Akashi, YJ; Ako, J; Doi, S; Inomata, T; Ishida, M; Kida, K; Kimura, T; Matsumoto, N; Nabeta, T; Ohta, Y; Shiono, T; Suzuki, N; Takita, A; Tsukahara, M; Yamaguchi, K, 2021
)
1.1
"This is the first study of edoxaban pharmacokinetics and pharmacodynamics in patients with NVAF and AHF, and shows that the pharmacokinetic and pharmacodynamic profiles of edoxaban were constant during hospitalization."( Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure.
Akashi, YJ; Ako, J; Doi, S; Inomata, T; Ishida, M; Kida, K; Kimura, T; Matsumoto, N; Nabeta, T; Ohta, Y; Shiono, T; Suzuki, N; Takita, A; Tsukahara, M; Yamaguchi, K, 2021
)
1.18
"This study aimed to develop a physiologically-based pharmacokinetic pharmacodynamic (PBPK/PD) parent-metabolite model of edoxaban, an oral anticoagulant with a narrow therapeutic index, and to predict pharmacokinetic (PK)/PD profiles and potential drug-drug-disease interactions (DDDIs) in patients with renal impairment."( Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution.
Ge, W; He, H; Jiang, Q; Liu, W; Xu, R, 2023
)
1.34

Compound-Compound Interactions

Three edoxaban drug-drug interaction studies examined the effects of P-gp inhibitors with varying degrees of CYP3A4 inhibition. In this study, we determined antithrombotic effects of Edoxaban as both a monotherapy and in combination with antiplatelet agents in a rat model of arterial thrombosis.

ExcerptReferenceRelevance
" In this study, we determined antithrombotic effects of edoxaban, an oral factor Xa (FXa) inhibitor, as both a monotherapy and in combination with antiplatelet agents in a rat model of arterial thrombosis."( Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents.
Honda, Y; Kamisato, C; Morishima, Y, 2016
)
0.95
" Three edoxaban drug-drug interaction studies examined the effects of P-gp inhibitors with varying degrees of CYP3A4 inhibition."( Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Matsushima, N; Mendell, J; Parasrampuria, DA; Shi, M; Truitt, K; Zahir, H, 2016
)
2.33
" NOAC have also been studied in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease, and reduced doses will presumably emerge as routine treatment also in these conditions."( [NOAC in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease].
Gottsäter, A, 2018
)
0.48
" To evaluate drug-drug interactions, the impact of ketoconazole, a known strong inhibitor of cytochrome P450 3A4 and P-glycoprotein, was studied."( Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Burhenne, J; Foerster, KI; Haefeli, WE; Lehmann, ML; Mikus, G; Schaumaeker, M, 2019
)
0.51
" This is the first study that has been conducted to evaluate drug-drug interactions with a drug class, and the low administered doses also allow evaluation in vulnerable target populations."( Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Burhenne, J; Foerster, KI; Haefeli, WE; Lehmann, ML; Mikus, G; Schaumaeker, M, 2019
)
0.51
" In patients with multiple conditions, the contemporary administration of several drugs can cause relevant drug-drug interactions (DDIs), which can affect drugs' pharmacokinetics and pharmacodynamics."( Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice.
Boriani, G; Corsini, A; Ferri, N; Proietti, M, 2020
)
2
" The model was extrapolated to situations including renal impairment and drug-drug interactions (DDIs)."( Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution.
Ge, W; He, H; Jiang, Q; Liu, W; Xu, R, 2023
)
1.14

Bioavailability

Edoxaban is predominantly absorbed from the upper gastrointestinal tract. Edoxaban relative bioavailability (F 1) was estimated as 67%.

ExcerptReferenceRelevance
"DU-176b is a more potent and selective FXa inhibitor with high oral bioavailability compared with its prototype, DX-9065a."( DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.
Furugohri, T; Honda, Y; Isobe, K; Kamisato-Matsumoto, C; Morishima, Y; Nagahara, T; Shibano, T; Sugiyama, N, 2008
)
0.35
"5 h, has a half-life of 10-14 h, has relatively high bioavailability of 62% and exhibits highly selective, competitive, concentration-dependent inhibition of human factor Xa."( Edoxaban: a focused review of its clinical pharmacology.
Agnelli, G; Lip, GY, 2014
)
1.85
"Concentration data from 1,134 subjects in 11 clinical studies (eight phase I, one phase II, and two phase III) were used to perform a population PK analysis, including estimation of the bioavailability and quantification of the effects of P-glycoprotein (P-gp) inhibitors as well as renal impairment on edoxaban PK."( Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
Miller, R; Tetsuya, K; Yin, OQ, 2014
)
2.02
"Absolute bioavailability of edoxaban was estimated as 58."( Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
Miller, R; Tetsuya, K; Yin, OQ, 2014
)
2.14
"The model provided reasonable estimation with regard to the absolute bioavailability of edoxaban, the magnitude of change in edoxaban exposure upon co-administration of P-gp inhibitors, and the impact of renal impairment on edoxaban clearance."( Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
Miller, R; Tetsuya, K; Yin, OQ, 2014
)
2.07
" Edoxaban relative bioavailability (F 1) was estimated as 67."( Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers.
Miller, R; Yin, OQ, 2014
)
1.55
" Edoxaban is predominantly absorbed from the upper gastrointestinal tract, and oral bioavailability is approximately 62 %."( Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
Parasrampuria, DA; Truitt, KE, 2016
)
1.61
" Concomitant P-gp inhibitors increased the bioavailability statistically significantly, but this did not reach clinical relevance."( Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial.
Jönsson, S; Karlsson, KE; Karlsson, MO; Krekels, EH; Miller, R; Niebecker, R; Ruff, CT; Shimizu, T; Simonsson, US, 2016
)
0.72
" However, due to altered pharmacokinetics and bioavailability of these drugs in CKD, a significant risk of bleeding exists."( [The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease].
Mohebbi, N, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Rats were treated with single oral administration of edoxaban, repeated oral dosing of warfarin for 4 days and single subcutaneous administration of enoxaparin before thrombosis or haemorrhage induction. The slopes of the dose-response curves of ed Oxaban were significantly shallower than the slopes of UFH, dalteparin, and Warfarin. Co-administration of various P-gp inhibitors significantly increased Edoxaban bioa.

ExcerptRelevanceReference
" These drugs have predictable pharmacokinetics that allow fixed dosing without laboratory monitoring, and are being compared with vitamin K antagonists or aspirin in phase III clinical trials [corrected]."( New anticoagulants for atrial fibrillation.
Eikelboom, J; O'Donnell, M; Sobieraj-Teague, M, 2009
)
0.35
"001) dose-response for efficacy across the edoxaban dose groups for total VTE and for major VTE."( Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Bocanegra, T; Cohen, AT; Eriksson, BI; Puskas, D; Raskob, G; Shi, M; Weitz, JI, 2010
)
0.89
" Two dosing regimens of edoxaban tosylate are being compared with warfarin over 24 months in the ENGAGE AF TIMI 48 trial (NCT00781391) in over 21 000 patients with atrial fibrillation in North and South America, Africa, Asia, Europe, Australia, and New Zealand."( Edoxaban tosylate.
, 2011
)
2.12
" In addition, we must be aware to have a deliberate evaluation for each result, even pharmacological profiles of each Xa inhibitors with a 12 hour half-life period shows similarity, the difference in twice-daily dosing with once a day, or the difference in severity of patients' atrial fibrillation risk factor each trial contains might affect the results of phase III trials."( [Current status and future of anti-Xa inhibitors].
Nagao, T, 2011
)
0.37
" The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option."( Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Halperin, JL; Varughese, CJ, 2012
)
0.38
"Rats were treated with single oral administration of edoxaban, repeated oral dosing of warfarin for 4 days and single subcutaneous administration of enoxaparin before thrombosis or haemorrhage induction."( Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
Edo, N; Honda, Y; Kamisato, C; Kita, A; Morishima, Y; Shibano, T; Tsuji, N, 2012
)
0.87
" The slopes of the dose-response curves of edoxaban were significantly shallower than the slopes of UFH, dalteparin, and warfarin."( Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Honda, Y; Kamisato, C; Morishima, Y; Shibano, T, 2013
)
0.9
" Reducing the dosage of edoxaban to 30 mg once daily is safe in case of renal impairment and low body weight."( [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
Sprynger, M, 2013
)
1.06
" They are at least as effective and as safe as conventional therapy (heparins and vitamin-K inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring."( Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Bounameaux, H; Fontana, P; Goldhaber, SZ, 2014
)
0.4
" The more protracted suppression of FXa over the dosing interval for a 30-mg twice-daily dose compared with a 60-mg once-daily dose offers an explanation for the significantly higher bleeding rate at the former dose."( Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment.
Halim, AB; Kang, D; Miller, R; Song, S, 2014
)
0.62
" (Global Study to Assess the Safety and Effectiveness of Edoxaban [DU-176b] vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation [EngageAFTIMI48]; NCT00781391)."( Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Antman, EM; Betcher, J; Braunwald, E; Cange, AL; Crompton, AE; Curt, V; Deenadayalu, N; Giugliano, RP; Grip, L; Mercuri, M; Murphy, SA; Ruff, CT, 2014
)
0.65
" With oral dosing of edoxaban, co-administration of various P-gp inhibitors significantly increased edoxaban bioavailability and decreased volume of distribution (V 2), resulting in a predicted increase of 33-77 % in area under the curve (AUC) and 65-104 % in C max."( Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
Miller, R; Tetsuya, K; Yin, OQ, 2014
)
2.16
" A dosing limitation exists related to patients treated for NVAF with creatinine clearance >95 mL/min; these patients experienced decreased efficacy."( Edoxaban, a Novel Oral Factor Xa Inhibitor.
Armbruster, AL; Minor, C; Tellor, KB, 2015
)
1.86
" Higher PT and aPTT values were observed at baseline and after edoxaban dosing in the hepatic impairment groups compared with healthy controls."( An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
Chen, S; Johnson, L; Mendell, J, 2015
)
0.88
"To review current literature for target-specific oral anticoagulants (TSOACs) and provide critical analysis for dosing recommendations in special population groups."( Dosing of Target-Specific Oral Anticoagulants in Special Populations.
Ge, D; Morrill, AM; Willett, KC, 2015
)
0.42
" It is valuable to understand the rationale for labeled dosing recommendations in nonvalvular atrial fibrillation and venous thromboembolism treatment and prevention, particularly in patients that fall into special population groups."( Dosing of Target-Specific Oral Anticoagulants in Special Populations.
Ge, D; Morrill, AM; Willett, KC, 2015
)
0.42
" In addition, an 8-hour continuous urine collection should be considered to assess a measured creatinine clearance for evaluating the necessity of medication dosage adjustments."( Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.
Daley, MJ; Hobbs, AL; Roberts, KM; Shea, KM, 2015
)
0.42
" The terminal elimination half-life in healthy subjects ranges from 10 to 14 h, with minimal accumulation upon repeat once daily dosing up to doses of 120 mg."( Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
Parasrampuria, DA; Truitt, KE, 2016
)
0.7
"Recommended dosing should be followed for sufficient efficacy of edoxaban."( Distribution of Anti-Factor Xa Activity in Patients on Edoxaban Therapy for Non-Valvular Atrial Fibrillation.
Ajioka, M; Asano, H; Inoue, Y; Ishihama, S; Kanbara, T; Kuwayama, T; Masutomi, T; Nakashima, Y; Osanai, H; Sakai, K; Takahashi, M, 2016
)
0.92
"All the newer oral anticoagulants compared were more effective than adjusted dosed warfarin."( Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
Hayes, CJ; Martin, BC; Shah, A; Shewale, A, 2016
)
0.43
" However the peri-procedural dosing protocols used in various studies especially in terms of whether NOAC use is interrupted or uninterrupted during AF ablation, have significant inter-operator and inter-institution variability."( Are Some Anticoagulants More Equal Than Others? - Evaluating the Role of Novel Oral Anticoagulants in AF Ablation.
Fox, DJ; Sankaranarayanan, R,
)
0.13
" It will serve as an alternative anticoagulant for those with a preference for once-daily dosing and/or taking medications that interact with the CYP450 system."( Establishing Edoxaban's Role in Anticoagulation.
Brown, D; Grace, Y; Guirguis, E; Henningfield, S; Patel, D, 2016
)
0.8
" Nonetheless, the absence of the ability for clinicians to assess compliance or washout with a simple laboratory test (or to adjust dosing with a similar assessment) and the absence of an antidote to rapidly stop major hemorrhage or to enhance safety in the setting of emergent or urgent surgery/procedures have been limitations to greater non-vitamin K antagonist oral anticoagulant usage and better thromboembolic prevention."( NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank.
Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI, 2016
)
0.43
" In addition to familiarity with the dosing and monitoring of vitamin K antagonists, clinicians are accustomed to using vitamin K if there is a need to reverse the anticoagulant effect of vitamin K antagonists."( Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
Antman, EM; Giugliano, RP; Ruff, CT, 2016
)
0.43
" Outcome measures were dosing errors if GFR were to be substituted for CrCL-CG."( Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants.
Schwartz, JB, 2016
)
0.43
" At a CrCL-CG of less than 30 mL/min, GFR estimates missed indicated dosage reductions for dabigatran in 18% to 21% of NHANES subjects and 57% to 86% of research subjects."( Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants.
Schwartz, JB, 2016
)
0.43
" With similar efficacy, better safety, and the convenience of fixed dosing without the need for routine coagulation monitoring, guidelines now recommend DOACs over VKAs for VTE treatment in patients without active cancer."( Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
Jaffer, IH; Weitz, JI, 2016
)
0.43
" No treatment interaction was observed between either dosing regimens of edoxaban and warfarin for the efficacy and safety outcomes."( Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
Antman, EM; Aylward, P; Braunwald, E; Choi, Y; Giugliano, RP; Mercuri, M; Murphy, SA; Ruff, CT; Steffel, J; White, H; Zamorano, JL, 2016
)
2.11
" We collected data on type and dosage of anticoagulation; suspected or confirmed bleeding events, hospital admissions, and mortality; and pattern and management of vaginal bleeding events."( Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
Beyer-Westendorf, J; Hauswald-Dörschel, S; Marten, S; Michalski, F; Tittl, L, 2016
)
0.43
"Surgical procedures under NOACS can be scheduled at the beginning of next dosing interval or omitted in low/minimal bleeding risk patients, so that only 2-3 NOAC doses are not administered."( [Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?]
Buerke, M; Hoffmeister, HM, 2017
)
0.46
" To ensure responsible use of these agents, every hospital needs a bleeding management algorithm that identifies patients eligible for reversal and outlines appropriate dosing regimens."( Reversal of Direct Oral Anticoagulants: Current Status and Future Directions.
Weitz, JI, 2017
)
0.46
" The fact that the NOACs don't require routine monitoring to assure that patients remain within the therapeutic range and have relatively simple dosing requirements and a safer risk profile makes them attractive substitutes to warfarin in HF patients with atrial fibrillation and other conditions (e."( Anticoagulation Therapy and NOACs in Heart Failure.
EncisoSilva, J; Greenberg, B; Schlueter, M; Thomas, I, 2017
)
0.46
"Additionally, the once daily dosing of edoxaban, the clinically investigated strategy for dose-reduction based on clearly defined criteria and the favorable pharmacokinetic profile might further support the clinical applicability of the substance."( [Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper].
Ay, C; Dieplinger, B; Domanovits, H; Fries, D; Gary, T; Rohla, M; Vosko, MR; Weiss, TW, 2018
)
1.66
" Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation [ENGAGE AF-TIMI 48]; NCT00781391)."( Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
Antman, EM; Braunwald, E; Carnicelli, AP; De Caterina, R; Giugliano, RP; Mercuri, MF; Nordio, F; Renda, G; Ruff, CT; Trevisan, M, 2017
)
0.73
"We compared NOACs (as a group) to warfarin in non-valvular atrial fibrillation, studying all 12,694 patients starting NOAC treatment within the Swedish clinical register and dosing system Auricula, from July 1, 2011 to December 31, 2014, and matching them to 36,317 patients starting warfarin using propensity scoring."( Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
Byström, B; Norrving, B; Oldgren, J; Renlund, H; Själander, A; Sjögren, V; Svensson, PJ, 2017
)
0.46
"The direct oral anticoagulants (DOACs), also referred to as novel (or non-vitamin K antagonist) oral anticoagulants (NOACs), represent a major development in anticoagulation therapy due to their rapid onset of action, predictable dose-response with fixed doses and limited interactions with food and drugs."( An update on the bleeding risks associated with DOACs.
, 2017
)
0.46
"Direct acting non-Vitamin K antagonist oral anticoagulants (NOAC) are characterized by a fixed dosing regimen."( Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119).
Beyer-Westendorf, I; Beyer-Westendorf, J; Endig, S; Marten, S; Reitter, A; Tittl, L, 2018
)
0.48
" Future directions include identification of clinically relevant SNPs, and change in optimum dosage for patients who are carriers of significant variants."( Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives.
Ašić, A; Marjanović, D; Mirat, J; Primorac, D, 2018
)
0.48
"The extent of inhibition of endogenous FXa activity is influenced by edoxaban dosing and clinical characteristics, and it is associated with both antithrombotic benefit and risk of bleeding."( Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.
Antman, EM; Braunwald, E; Giugliano, RP; Mercuri, MF; Miller, R; Morrow, D; Ruff, CT; Truitt, K; Weitz, JI; Yin, OQP, 2018
)
0.94
" Chromogenic anti-Xa assays displayed linear dose-response curves with edoxaban up to approximately 500 µg/L."( Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
Baghaei, F; Fagerberg Blixter, I; Gustafsson, KM; Hillarp, A; Lindahl, TL; Strandberg, K,
)
0.62
" The observed effect could be a secondary consequence of dosage control or alternatively a result of different anticoagulant effects among the different medications."( Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants.
Cowperthwaite, M; Fanale, C; Nadasdy, Z; Ramakrishnan, A; Shpak, M, 2018
)
0.48
" Benefits of direct oral anticoagulants include a rapid onset of therapeutic effect, fixed dose-response relationships without the need for routine monitoring, a short half-life, and infrequent need for periprocedural bridging with a parenteral agent."( Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Pickett, JD, 2019
)
0.51
"It is unclear whether the two once-daily dosing non-vitamin K antagonist oral anticoagulants (NOACs), edoxaban and rivaroxaban, have similar effectiveness and safety in Asian patients with non-valvular atrial fibrillation (AF)."( Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation.
Choi, EK; Han, KD; Jung, JH; Lee, SR; Lip, GYH; Oh, S, 2019
)
0.99
" The prothrombin time (PT) and activated partial thromboplastin time (APTT) were averaged if they were measured more than twice depending on the respective DOAC and dosage across individuals."( Excessive Prolongation of Coagulation Time During Treatment With Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation.
Akiyoshi, K; Goya, M; Hirao, K; Kawabata, M; Koyama, T; Maeda, S; Sekigawa, M; Takahashi, Y; Yagishita, A; Yamamoto, T, 2019
)
0.51
"8%), was found to be significantly associated with inappropriately high DOAC dosage and body weight (≤ 60 kg)."( Excessive Prolongation of Coagulation Time During Treatment With Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation.
Akiyoshi, K; Goya, M; Hirao, K; Kawabata, M; Koyama, T; Maeda, S; Sekigawa, M; Takahashi, Y; Yagishita, A; Yamamoto, T, 2019
)
0.51
" Patients with the body weight of <60 kg should be considered for dosage reduction or DOAC withdrawal."( Excessive Prolongation of Coagulation Time During Treatment With Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation.
Akiyoshi, K; Goya, M; Hirao, K; Kawabata, M; Koyama, T; Maeda, S; Sekigawa, M; Takahashi, Y; Yagishita, A; Yamamoto, T, 2019
)
0.51
"8%) in accordance with the dosing recommendation in patients with renal insufficiency (creatinine clearance [CrCl] of 15-50 mL/min) and a low body weight of <60 kg."( Factors related to inappropriate edoxaban use.
Cho, EJ; Cho, YS; Jang, BM; Koo Lee, M; Lee, OS; Rhie, SJ; Shin, EJ; Suh, SY, 2019
)
0.8
" Most patients who were taking NOACs had excellent adherence regardless of the dosing frequency."( NOAC Adherence of Patients with Atrial Fibrillation in the Real World: Dosing Frequency Matters?
Bae, HJ; Cho, YK; Choi, SW; Han, S; Hur, SH; Hwang, J; Jun, SW; Kim, H; Kim, IC; Lee, CH; Lee, SH; Nam, CW; Park, HS; Yoon, HJ, 2020
)
0.56
" Population mean age was 75 years and 43% were female; 643 patients received the 30 mg edoxaban dosage regimen and 1642 initiated 60 mg edoxaban."( Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort.
Larsen, TB; Lip, GYH; Nielsen, PB; Skjøth, F; Søgaard, M, 2021
)
1.14
" Electrospray ionization and chromatographic separation were optimized for the simultaneous dosage of edoxaban and edoxaban-M4."( Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method.
Alpan, L; Devel, P; Dogné, JM; Douxfils, J; Elasaad, K; Laloy, J; Siriez, R, 2020
)
1.01
" Given the favourable safety profile of NOACs (especially if a reduced dosage of Apixaban or Rivaroxaban is initiated after at least six months of therapeutic anticoagulation), extended oral anticoagulation of indefinite duration should be considered for all patients with intermediate risk of recurrence."( [Antithrombotic Treatment of Pulmonary Embolism].
Ebner, M; Lankeit, M, 2020
)
0.56
" The approved dosing of edoxaban was chosen in 83%."( Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.
Bakhai, A; de Asmundis, C; De Caterina, R; de Groot, JR; Deharo, JC; Kelly, P; Kirchhof, P; Laeis, P; Levy, P; López-de-Sá, E; Manu, MC; Monteiro, P; Reimitz, PE; Steffel, J; Waltenberger, J; Weiss, TW; Zierhut, W, 2021
)
2.37
" A growing body of evidence shows that once-daily dosing improves adherence and persistence to therapy, without having an impact on bleeding risk."( Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence.
Haas, S; Patti, G, 2020
)
0.56
" Therefore, there are possibilities of other risk factors that should be given special consideration for dosage adjustment in this specific ethnic group."( Association of risk factors and bleeding complications in Asian patients taking edoxaban.
Cho, YS; Jang, BM; Kim, W; Lee, KE; Lee, MK; Lee, OS; Min, KH, 2021
)
0.85
" Therefore, more strict dosage guideline could be considered in populations with high proportions of Asian ethnicities."( Association of risk factors and bleeding complications in Asian patients taking edoxaban.
Cho, YS; Jang, BM; Kim, W; Lee, KE; Lee, MK; Lee, OS; Min, KH, 2021
)
0.85
"Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban."( Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study.
Blankoff, I; Casado Arroyo, R; Catez, E; Cools, F; Crijns, HJGM; de Asmundis, C; De Caterina, R; de Groot, JR; de Pauw, M; de Veer, A; de Vries, TAC; Hemels, MEW; Kirchhof, P; Lancellotti, P; Mairesse, GH; Vanacker, P; Vanassche, T; Yperzeele, L, 2021
)
1.05
"There were several notable differences between BeNe and OEC regarding clinical characteristics and dosing practices in patients prescribed edoxaban, which are relevant for the local implementation of dose evaluation and optimisation."( Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study.
Blankoff, I; Casado Arroyo, R; Catez, E; Cools, F; Crijns, HJGM; de Asmundis, C; De Caterina, R; de Groot, JR; de Pauw, M; de Veer, A; de Vries, TAC; Hemels, MEW; Kirchhof, P; Lancellotti, P; Mairesse, GH; Vanacker, P; Vanassche, T; Yperzeele, L, 2021
)
1.06
" The secondary (disabling stroke, life-threatening bleeding, or all-cause mortality) and tertiary pre-defined NCOs (stroke, SEE, life-threatening bleeding, or all-cause mortality) were similar between the 2 dosing regimens."( Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.
Antman, EM; Braunwald, E; Connolly, S; Giugliano, RP; Murphy, SA; Park, JG; Ruff, CT; Steffel, J; Yin, O, 2021
)
0.86
"In the ENGAGE AF-TIMI 48 trial, the primary NCO was reduced with LDER versus HDER, whereas the secondary and tertiary NCOs were similar between the 2 dosing regimens."( Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.
Antman, EM; Braunwald, E; Connolly, S; Giugliano, RP; Murphy, SA; Park, JG; Ruff, CT; Steffel, J; Yin, O, 2021
)
0.86
", bleeding risks) into consideration when deviating from the dosing recommendation per label."( Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program.
Chao, TF; Chen, C; De Caterina, R; Hong, KS; Kirchhof, P; Lee, BC; Reimitz, PE; Unverdorben, M; Wang, CC, 2021
)
0.89
" Both higher dose edoxaban (60/30 mg) and lower dose edoxaban (30/15 mg) were non-inferior to warfarin for stroke and systemic embolism (SSE) and significantly reduced major bleeding in AF patients in the global study to assess the safety and effectiveness of edoxaban vs standard practice of dosing with warfarin in patients with atrial fibrillation (ENGAGE AF-TIMI 48) trial."( Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.
Antman, EM; Bonaca, MP; Braunwald, E; Cunningham, JW; Giugliano, RP; Grosso, MA; Halperin, JL; Lanz, HJ; Murphy, SA; Ruff, CT; Weitz, JI; Wiviott, SD, 2022
)
1.26
" The aim of this study was to explore appropriate remedial dosing regimens for non-adherent edoxaban-treated NVAF patients through Monte Carlo simulation."( How to handle a delayed or missed dose of edoxaban in patients with non-valvular atrial fibrillation? A model-informed remedial strategy.
Gu, JQ; Jiao, Z; Li, ZR; Liu, XQ; Yin, YW, 2023
)
1.39
" When the delay is between 12 and 19 h, a half dose followed by a regular dosing schedule is recommended."( How to handle a delayed or missed dose of edoxaban in patients with non-valvular atrial fibrillation? A model-informed remedial strategy.
Gu, JQ; Jiao, Z; Li, ZR; Liu, XQ; Yin, YW, 2023
)
1.17
" In summary, the genotypes of CYP3A5, ABCB1, and SLCO1B1 and the dosage of edoxaban may affect the risk of bleeding by edoxaban when co-administered with cyclosporine, even at low doses."( Evaluation of bleeding and anticoagulation markers by edoxaban and low-dose cyclosporine: A case series study.
Hirai, T; Ikejiri, M; Iwamoto, T; Murata, T; Shinogi, Y, 2022
)
1.2
" The dosage and duration of FXa inhibitor therapy also differ."( Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors.
Fukushima, K; Hori, Y; Kobayashi, Y; Nishimura, K; Ono, R; Takahashi, H, 2023
)
0.91
"Per-label dosing of direct oral anticoagulants (DOACs) is important for the prevention of stroke and systemic embolism among patients with non-valvular atrial fibrillation (NVAF), especially those with poor renal function, advanced age, low body weight or concomitant P-glycoprotein inhibitors."( Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database.
Anastassopoulou, A; Doobaree, IU; Fay, M; Gusto, G; Khachatryan, A; Manu, M; Mughal, F; Spentzouris, G; Zawaneh, Y, 2023
)
0.91
"Although most patients received per-label dosing, ~ one in five patients was incorrectly dosed with DOAC, which may lead to serious clinical consequences and increased healthcare burden."( Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database.
Anastassopoulou, A; Doobaree, IU; Fay, M; Gusto, G; Khachatryan, A; Manu, M; Mughal, F; Spentzouris, G; Zawaneh, Y, 2023
)
0.91
" Hypothetically, an increased glomerular filtration rate (GFR) may lead to suboptimal dosing and a higher thromboembolic events incidence."( Impact of increased kidney function on clinical and biological outcomes in real-world patients treated with Direct Oral Anticoagulants.
Acosta-Isaac, R; Corrochano, M; Mojal, S; Moret, C; Muñoz, R; Plaza, M; Souto, JC, 2022
)
0.72
" Nevertheless, high interindividual variability in DOAC exposure in older adults was noted, which can be explained by distinctive older patient characteristics, such as kidney function, changes in body composition (especially reduced muscle mass), and co-medication with P-gp inhibitors, which is in line with the current dosing reduction criteria of apixaban, edoxaban, and rivaroxaban."( Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review.
Dia, N; Dreesen, E; Edwina, AE; Spriet, I; Tournoy, J; Van der Linden, L; Vanassche, T; Verhamme, P, 2023
)
1.08
"Twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) may reduce drug adherence compared with once-daily dosing of NOACs in patients with atrial fibrillation (AF), thus worsening clinical outcomes."( Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important?
Bae, YJ; Hwang, HJ; Jin, ES; Sohn, IS, 2023
)
0.91
" The proportion of patients with high adherence to NOACs was 95%, which did not significantly differ according to the dosing regimen."( Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important?
Bae, YJ; Hwang, HJ; Jin, ES; Sohn, IS, 2023
)
0.91
"Adherence between once- and twice-daily dosing NOACs in patients with AF was high and similar among both dosing regimens."( Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important?
Bae, YJ; Hwang, HJ; Jin, ES; Sohn, IS, 2023
)
0.91
" This analysis included randomized and dosed patients with an evaluable PACT-Q1 assessment at baseline and ≥1 postbaseline assessment (PACT-Q2)."( Treatment Satisfaction and Convenience for Patients With Atrial Fibrillation on Edoxaban or Vitamin K Antagonists After Transcatheter Aortic Valve Replacement: A Post Hoc Analysis from the ENVISAGE-TAVI AF Trial.
Chen, C; Dangas, G; Guo, S; Hengstenberg, C; Jin, J; Shi, L; Unverdorben, M; Van Mieghem, NM; Wang, R; Ye, X, 2023
)
1.14
" Duration of exposure to and dosing regimens of edoxaban, antiplatelet agents and other concomitant medications of interest will be monitored in line with the clinical practice."( Edoxaban in patients with non-valvular atrial fibrillation after percutaneous coronary intervention: ENCOURAGE-AF design.
Baldus, S; Beyer-Westendorf, J; Beyerlein, E; Goette, A; Möllmann, H; Rottbauer, W, 2023
)
2.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
anticoagulantAn agent that prevents blood clotting.
EC 3.4.21.6 (coagulation factor Xa) inhibitorAn EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of coagulation factor Xa (EC 3.4.21.6).
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
chloropyridineCompounds containing a pyridine nucleus substituted with one or more chlorine atoms.
thiazolopyridine
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Coagulation factor XHomo sapiens (human)IC50 (µMol)0.00340.00030.593710.0000AID1414363; AID1602882
Coagulation factor XHomo sapiens (human)Ki0.00060.00000.47089.0000AID527394
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
proteolysisCoagulation factor XHomo sapiens (human)
blood coagulationCoagulation factor XHomo sapiens (human)
positive regulation of cell migrationCoagulation factor XHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor XHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityCoagulation factor XHomo sapiens (human)
calcium ion bindingCoagulation factor XHomo sapiens (human)
protein bindingCoagulation factor XHomo sapiens (human)
phospholipid bindingCoagulation factor XHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionCoagulation factor XHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor XHomo sapiens (human)
Golgi lumenCoagulation factor XHomo sapiens (human)
plasma membraneCoagulation factor XHomo sapiens (human)
external side of plasma membraneCoagulation factor XHomo sapiens (human)
extracellular spaceCoagulation factor XHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1453444Inhibition of recombinant human C-MYC/DDK-tagged ENGase expressed in HEK293T cells at 100 uM using heat inactivated bovine ribonuclease B as substrate pretreated for 15 mins followed by substrate addition after 90 mins by SDS-PAGE analysis2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.
AID1414363Inhibition of human coagulation factor 10a using Z-D-Arg-Gly-Arg-pNA.2HCl as substrate preincubated for 15 mins followed by substrate addition by UV absorption assay2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
Semisynthesis of ent-norstrobane diterpenoids as potential inhibitor for factor Xa.
AID527405Oral bioavailability in monkey2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID1602882Inhibition of human factor Xa using Z-D-Arg-Gly-Arg-pNA.2HCl as substrate preincubated for 15 mins followed by substrate addition by UV absorption analysis2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Semisynthesis of epoxy-pimarane diterpenoids from kirenol and their FXa inhibition activities.
AID527398Anticoagulant activity in human platelet assessed as concentration required to double activated partial prothrombin time2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID527399Anticoagulant activity in human platelet assessed as concentration required to double prothrombin time2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID527394Inhibition of factor 10a2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1345896Human coagulation factor X (S1: Chymotrypsin)2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (885)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (0.23)29.6817
2010's618 (69.83)24.3611
2020's265 (29.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 101.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index101.91 (24.57)
Research Supply Index6.99 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index182.80 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (101.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials178 (19.56%)5.53%
Reviews280 (30.77%)6.00%
Case Studies56 (6.15%)4.05%
Observational36 (3.96%)0.25%
Other360 (39.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (124)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Lixiana Acute Stroke Evaluation Registry [NCT03494530]Phase 4150 participants (Anticipated)Interventional2018-06-01Recruiting
Treatment Patterns and Clinical Outcomes Among Venous Thromboembolism Patients Treated With Anticoagulants After the Entry of Non-vitamin K Antagonist Oral Anticoagulants in Korea [NCT05022563]55,759 participants (Actual)Observational2021-08-31Completed
Identification of Clinical and Pharmacogenetic Factors Predictive of Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation. [NCT04297150]700 participants (Anticipated)Observational2020-06-18Active, not recruiting
A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF) [NCT02942576]Phase 3632 participants (Actual)Interventional2017-03-21Completed
Relationship of Edoxaban Plamsa Concentration and Blood Coagulation in Healthy Volunteers Using Standard Laboratory Tests and Viscoelastic Analysis [NCT03666650]Phase 415 participants (Actual)Interventional2018-11-26Completed
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Andexanet Alfa Administered to Healthy Japanese and Caucasian Subjects [NCT03310021]Phase 2108 participants (Actual)Interventional2017-08-28Completed
An Open-label, Randomised, Parallel-group, Multicentre, Observational Trial to Evaluate Safety and Efficacy of Edoxaban Tosylate in Children From 38 Weeks Gestational Age to Less Than 18 Years of Age With Cardiac Diseases at Risk of Thromboembolic Events [NCT03395639]Phase 3168 participants (Actual)Interventional2018-05-15Completed
Evaluation of Non-Vitamin K Antagonist Oral Anticoagulants Concentration Among Patients With Acute Stroke (The Direct Oral AntiCoagulant Registry in Taiwan-Emergent Department, DOACT-ED) [NCT06144866]1,000 participants (Anticipated)Observational [Patient Registry]2020-05-01Recruiting
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism. [NCT03129555]Phase 45,000 participants (Anticipated)Interventional2023-04-01Recruiting
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Atrial Fibrillation (DANNOAC-AF). [NCT03129490]Phase 411,000 participants (Anticipated)Interventional2023-04-01Recruiting
Development of Precision Medicine Platform for Pharmacogenomics of Novel Oral Anticoagulants (NOACs) [NCT04056143]500 participants (Anticipated)Observational2019-01-02Recruiting
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation at High Risk of Stroke and Bleeding Compared to Medical Therapy: a Prospective Randomized Clinical Trial [NCT03463317]Phase 41,512 participants (Anticipated)Interventional2018-02-28Recruiting
Evaluation of the Safety and Efficacy of an Edoxaban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement. [NCT02866175]Phase 31,506 participants (Actual)Interventional2017-02-24Completed
Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation [NCT05320627]Phase 4120 participants (Anticipated)Interventional2022-03-30Recruiting
A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure [NCT03088072]Phase 475 participants (Anticipated)Interventional2017-03-23Recruiting
Safety and Efficacy of Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk (HBR) Patients With History of Paroxysmal Atrial Fibrillation [NCT04151680]100 participants (Anticipated)Observational [Patient Registry]2019-12-01Recruiting
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon [NCT03563937]64,920 participants (Actual)Observational2018-06-15Completed
Hamburg Edoxaban for Anticoagulation in COVID-19 Study [NCT04542408]Phase 3140 participants (Actual)Interventional2020-11-12Completed
A Randomized, Multicenter, Open-Label, Control, Clinical Trial to Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients [NCT06149533]Phase 3366 participants (Anticipated)Interventional2023-11-30Not yet recruiting
Treatment of Edoxaban Versus Aspirin for Non-disabling Cerebrovascular Events: Rationale, Objectives, and Design [NCT02221102]Phase 2/Phase 33,700 participants (Anticipated)Interventional2013-12-31Not yet recruiting
Novel Oral Anticoagulants in Oral and Maxillofacial Surgery: Impact on Bleeding Tendency, Surgical Difficulty and Post-operative Complications [NCT04662515]300 participants (Anticipated)Observational2016-06-01Recruiting
A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Second Generation Andexanet Alfa Administered to Healthy Subjects [NCT03083704]Phase 1153 participants (Actual)Interventional2017-02-26Completed
Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe [NCT02943993]2,809 participants (Actual)Observational2016-04-06Completed
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) [NCT02744092]811 participants (Actual)Interventional2016-12-13Completed
A Descriptive Non-interventional Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice for Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation [NCT05262322]234 participants (Actual)Observational2019-02-15Completed
Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention - German Non-interventional Study (ENCOURAGE-AF) [NCT04519944]666 participants (Actual)Observational2020-06-30Completed
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel (EDOX-APT): A Prospective Randomized Study [NCT02567461]Phase 480 participants (Actual)Interventional2016-03-31Completed
AF Patient Preferences Towards NOAC Versus VKA Treatment: a Patient Preference Study. [NCT02611635]382 participants (Actual)Observational2016-02-02Completed
Study on the Pharmacokinetics and Point of Care Testing After a Single Dose of 150 mg Dabigatran, 20 mg Rivaroxaban, 5 mg Apixaban, and 60 mg Edoxaban in Healthy Male Subjects [NCT05491460]Phase 124 participants (Anticipated)Interventional2022-07-01Active, not recruiting
OBServaToire INternational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs [NCT04262492]500 participants (Anticipated)Observational [Patient Registry]2020-10-21Recruiting
Antithrombotic Treatment in Patients With Effectively Maintained Sinus Rhythm After Atrial Fibrillation Ablation (The ATEMS-AF Study) [NCT03073850]Phase 448 participants (Actual)Interventional2017-02-23Terminated(stopped due to Majority of enrolled patients have withdrawn.)
Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study) [NCT03570281]Phase 2/Phase 340 participants (Anticipated)Interventional2018-06-15Recruiting
A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation [NCT02047565]Phase 1110 participants (Actual)Interventional2013-10-31Completed
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of DU-176b in Patients With NVAF Aged 80 Years or Older Who Are Ineligible for Available Oral Anticoagulation Therapy [NCT02801669]Phase 3984 participants (Actual)Interventional2016-08-05Completed
Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey (ETAF-TR) [NCT04594915]1,053 participants (Actual)Observational2020-08-14Completed
A Phase IV Study on Impact of Edoxaban Treatment in Italian Cancer Patients With Venous Thromboembolism (EDOI Cancer Study) During Antineoplastic Therapy [NCT04072068]Phase 4150 participants (Actual)Interventional2019-06-27Completed
Resolution of Thrombi in Left Atrial Appendage With Edoxaban [NCT03840291]Phase 460 participants (Anticipated)Interventional2019-05-19Recruiting
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial [NCT03568890]Phase 4510 participants (Anticipated)Interventional2018-09-01Recruiting
Clinical Application Model of Direct Oral Anticoagulants (MACACOD). Comprehensive Management of ACOD From a Specialized Center in Antithrombotic Therapy and Its Area of Influence [NCT04042155]1,600 participants (Anticipated)Observational [Patient Registry]2019-07-29Recruiting
A Phase 2, Randomized, Parallel Group, Multi-Center, Multi-National Study for the Evaluation of Safety and Efficacy of Two Fixed Dosages of DU-176b in Subjects With Non-Valvular Atrial Fibrillation [NCT00806624]Phase 2234 participants (Actual)Interventional2007-10-31Completed
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative Atrial Fibrillation After Noncardiac Surgery - The ASPIRE-AF Trial [NCT03968393]Phase 42,800 participants (Anticipated)Interventional2019-06-14Recruiting
AF Patient Preferences Towards NOAC Versus VKA Treatment: a Patient Preference Study [NCT02607371]198 participants (Actual)Observational2015-08-27Completed
Burden of Ischemic Stroke and Adherence to Oral Anticoagulants in Atrial Fibrillation in the UK Primary Care [NCT04099238]3,739 participants (Actual)Observational2019-10-01Completed
A Phase 2b, Randomized, Multi-Dose Efficacy,Safety Study of the Oral Factor Xa Inhibitor DU-176b Versus Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-2) [NCT01203098]Phase 2264 participants (Actual)Interventional2008-07-31Completed
Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction (TARGET-Type 2): A Pilot Randomised Controlled Trial [NCT05419583]60 participants (Anticipated)Interventional2022-11-14Recruiting
A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From B [NCT02798471]Phase 3290 participants (Actual)Interventional2017-03-27Completed
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of Edoxaban (DU-176b) Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor [NCT00781391]Phase 321,105 participants (Actual)Interventional2008-11-30Completed
Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation. A Multicenter Randomized Clinical Trial. (Occlusion-AF) [NCT03642509]750 participants (Anticipated)Interventional2019-01-01Recruiting
Safety Evaluation of Edoxaban in Elderly Patients With Frailty Criteria [NCT05732506]456 participants (Anticipated)Observational [Patient Registry]2023-02-01Recruiting
The Role of Additional Antiplatelet Therapy in the Ischemic Stroke With Atrial Fibrillation and Co-morbiD Atherosclerosis During edOxaban treatmeNt. (ADD-ON) Study, Multicenter Registry-based Analysis [NCT04010955]1,200 participants (Anticipated)Observational [Patient Registry]2019-10-01Recruiting
Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation [NCT02935855]Phase 4300 participants (Actual)Interventional2015-09-30Completed
A Phase IIb, Randomized, Parallel Group, Double-Blind, Double-Dummy, Multi-Center, Multi-National, Multi-Dose, Study of DU-176b Compared to Dalteparin in Patients Undergoing Elective Unilateral Total Hip Replacement [NCT00398216]Phase 2903 participants (Actual)Interventional2006-05-31Completed
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET [NCT02618577]Phase 32,608 participants (Actual)Interventional2016-02-29Terminated(stopped due to following a recommendation from the data safety and monitoring board due to safety concerns and a tendency towards futility.)
A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-5 Trial) [NCT01181167]Phase 3610 participants (Actual)Interventional2009-05-31Completed
A Phase IIa, Multi-center, Multi-national, Open Label, Dose Ranging Study of the Efficacy, Safety, and Tolerability of Oral DU-176b Administered Once or Twice Daily in the Treatment of Adult Patients Undergoing Total Hip Arthroplasty [NCT00107900]Phase 2606 participants (Actual)Interventional2005-01-31Completed
A Phase 2, Randomized, Parallel Group, Multi Center, Multi National Study for the Evaluation of Safety of Four Fixed Dose Regimens of DU-176b in Subjects With Non- Valvular Atrial Fibrillation [NCT00504556]Phase 21,146 participants (Actual)Interventional2007-06-30Completed
A Phase 3, Randomized, Open Label, Safety and Efficacy Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery (STARS J-4 Trial) [NCT01181141]Phase 392 participants (Actual)Interventional2008-10-31Completed
A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS E-3 Trial) [NCT01181102]Phase 3716 participants (Actual)Interventional2009-03-31Completed
A Randomized Dose-ranging Controlled Trial of DU-176b Versus Warfarin Potassium in Patients With Non-valvular Atrial Fibrillation [NCT00829933]Phase 2536 participants (Actual)Interventional2007-03-31Completed
A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism ( [NCT00986154]Phase 38,292 participants (Actual)Interventional2009-10-31Completed
A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients [NCT02303431]Phase 166 participants (Actual)Interventional2014-11-05Completed
A Multi-centre, Open-labelled, Randomized Controlled Trial Comparing Two Different Anticoagulation Strategies in High-risk Atrial Fibrillation and Stable Coronary Artery Disease [NCT03718559]Phase 41,050 participants (Actual)Interventional2019-05-14Active, not recruiting
MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention: The MOSES-study. An International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial [NCT03961334]Phase 3620 participants (Anticipated)Interventional2019-12-05Recruiting
The Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Extended Treatment of Venous Thromboembolism [NCT03292666]39,603 participants (Actual)Observational2010-01-01Completed
Phase II Randomized, Sequential Group, Evaluation of Ascending Reversal Doses of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban Following PER977 Reversal [NCT02207257]Phase 265 participants (Actual)Interventional2014-03-31Completed
Edoxaban Management in Diagnostic and Therapeutic Procedures [NCT02950168]1,197 participants (Actual)Observational [Patient Registry]2016-11-30Completed
Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation Using Healthcare Data for Pragmatic Research: A Randomised Controlled Trial [NCT04700826]Phase 43,000 participants (Anticipated)Interventional2021-06-01Recruiting
Start or STop Anticoagulants Randomised Trial (SoSTART) After Spontaneous Intracranial Haemorrhage [NCT03153150]Phase 3203 participants (Actual)Interventional2018-03-28Completed
Pharmacokinetics and Pharmacodynamics Assessment of Apixaban and Edoxaban in Patients With Child B Liver Cirrhosis [NCT05869591]Phase 232 participants (Anticipated)Interventional2023-10-31Not yet recruiting
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation (PRESTIGE-AF) [NCT03996772]Phase 3350 participants (Anticipated)Interventional2019-06-03Recruiting
The Dabigatran, Apixaban, Rivaroxaban, Edoxaban, Warfarin Comparative Effectiveness Research Study [NCT03271450]416,000 participants (Anticipated)Observational2017-07-01Enrolling by invitation
Oral Anticoagulation After Cardiac Surgery in the Era of Direct Oral Anticoagulants: is Large Use of Vitamin K Antagonists Still Justified? [NCT04002011]Phase 20 participants (Actual)Interventional2022-03-09Withdrawn(stopped due to Submission process abandoned. No patient enrolled.)
A Phase 2b, Randomized, Double-Blind, Multi-Dose Efficacy, Safety and Dose-finding Study of the Oral Factor Xa Inhibitor DU-176b Compared With Placebo for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS J-1) [NCT01203072]Phase 2523 participants (Actual)Interventional2006-07-31Completed
Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism (VTE) in Korea and Taiwan [NCT02952599]352 participants (Actual)Observational2017-03-27Completed
Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation (NVAF) [NCT02951039]3,008 participants (Actual)Observational2017-02-21Completed
Evaluation of Edoxaban in Anticoagulant Naïve Patients With Nonvalvular Atrial Fibrillation (NVAF) and High Creatinine Clearance [NCT02964949]607 participants (Actual)Interventional2017-01-24Completed
OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke: a Randomised Controlled Trial [NCT03759938]3,478 participants (Anticipated)Interventional2019-06-18Recruiting
An Investigator-initiated, Multicenter, Phase 3, Randomized, Single-blind, Double-dummy, Parallel-group Study of Evaluate the Efficacy and Safety of Edoxaban Versus Warfarin (Vitamin K Antagonist) in Subjects With Chronic Thromboembolic Pulmonary Hyperten [NCT04730037]Phase 374 participants (Actual)Interventional2021-03-23Completed
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms [NCT04192916]442 participants (Actual)Observational2019-09-01Completed
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study [NCT04684212]2,931 participants (Anticipated)Interventional2023-12-01Not yet recruiting
An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interaction Between Tegoprazan and Novel Oral Anticoagulants (NOACs) After Multiple Oral Dosing in Healthy Volunteers [NCT05723510]Phase 187 participants (Actual)Interventional2023-03-06Completed
Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation (TAVI) - in Atrial Fibrillation [NCT02943785]Phase 31,426 participants (Actual)Interventional2017-03-21Completed
A Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenously Administered VMX-C001 in Healthy Subjects (Part 1) and in Combination With Selected Dire [NCT05152420]Phase 1105 participants (Actual)Interventional2021-10-29Completed
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis - Edoxaban Thrombus Reduction Imaging Study [NCT01662908]Phase 285 participants (Actual)Interventional2012-08-31Completed
Non-interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Thailand) [NCT03247569]300 participants (Actual)Observational2017-10-18Completed
Efficacy and Safety of Vascular Boot Warming Program After Acute DVT±PE for Earlier Resolution of Venous Thromboembolism (VTE) and Prevention of Post Thrombotic Syndrome: A Pilot Study. [NCT03465735]15 participants (Actual)Interventional2017-01-13Terminated(stopped due to Due to lack of recruitment of eligible participants)
A Multicenter, Prospective, Non-interventional Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation [NCT05804747]1,100 participants (Anticipated)Observational2023-02-16Recruiting
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) [NCT03950076]Phase 41,200 participants (Anticipated)Interventional2019-09-20Recruiting
Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial [NCT03148457]2,013 participants (Actual)Interventional2017-11-06Completed
Safety and Efficacy of Edoxaban Versus Warfarin in Patients Undergoing a Thoracoscopic Ablation for Persistent Atrial Fibrillation [NCT04121767]60 participants (Actual)Interventional2017-12-01Completed
The Direct Oral Anticoagulation Versus Warfarin After Cardiac Surgery Trial [NCT04284839]Phase 36,215 participants (Anticipated)Interventional2021-07-18Recruiting
A Pilot Trial of Restarting Direct Oral Anticoagulants After Traumatic Intracranial Hemorrhage [NCT04891861]Phase 3100 participants (Anticipated)Interventional2021-07-01Not yet recruiting
A Randomized, Open, Phase 2 Study to Evaluate the Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis [NCT05540587]Phase 2240 participants (Anticipated)Interventional2022-05-20Recruiting
SafeTy and Efficacy of Direct Oral Anticoagulant Versus Aspirin for Reduction Of RisK of CErebrovascular Events in Patients Undergoing Ventricular Tachycardia Ablation (STROKE-VT) [NCT02666742]Phase 4246 participants (Actual)Interventional2017-02-16Completed
VICTORIE (VTE In Cancer - Treatment, Outcomes and Resource Use In Europe) [NCT04618913]1 participants (Anticipated)Observational2020-12-14Active, not recruiting
Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation [NCT04171726]Phase 3100 participants (Anticipated)Interventional2019-08-01Recruiting
Pilot Study of Post-thrombotic Syndrome & Predictors of Recurrence in Cancer Patients With Catheter-related Thrombosis [NCT01999179]27 participants (Actual)Interventional2014-06-30Completed
Efficacy and Safety of Edoxaban or Warfarin Therapy In Cardiovascular Implantable Electrical Device Procedures in Patients With Non-valvular Atrial Fibrillation [NCT02561897]Phase 45 participants (Actual)Interventional2015-12-31Terminated(stopped due to Did not meet enrolment target for phase 1)
Canadian EdoxAban (Lixiana®) Registry in Patients With ATrial Fibrillation and/or ATrial Flutter With Confirmed ValvUlar HeaRt DiseasE (CAPTURE) [NCT03488420]133 participants (Actual)Observational [Patient Registry]2019-04-30Active, not recruiting
Medical Need of Oral Anti-coagulant Reversal in Japan: Epidemiological Assessment of Head Trauma, Fracture, and Emergency Surgery Using Large Scale Claims Database (Please Note That This Study Contains no Patients Treated With Idarucizumab Although the St [NCT03254147]53,969 participants (Actual)Observational2017-10-15Completed
Prospective, Observational, Non-interventional Open-label Multicenter Registry Regarding the Incidence of Heavy Menstrual Bleeding in Women of Reproductive Age Treated With Direct Oral Anticoagulants Because of Venous Thromboembolism [NCT04477837]150 participants (Anticipated)Observational [Patient Registry]2020-10-15Recruiting
Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography [NCT02448901]40 participants (Anticipated)Observational2015-04-30Recruiting
Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial) [NCT03244319]Phase 3220 participants (Actual)Interventional2017-12-01Completed
A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer [NCT02073682]Phase 31,046 participants (Actual)Interventional2015-07-16Completed
A Prospective, Randomized, Open-Label Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) With Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned Electrical Cardioversion of Nonvalvular Atrial F [NCT02072434]Phase 32,199 participants (Actual)Interventional2014-03-25Completed
AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation [NCT05035277]Phase 3360 participants (Anticipated)Interventional2021-12-04Recruiting
A Randomized, Double-Blind, Vehicle-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect fXa Inhibit [NCT03551743]Phase 228 participants (Actual)Interventional2012-12-31Completed
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease [NCT02339415]Phase 244 participants (Actual)Interventional2015-07-31Completed
Phase III Clinical Study of DU-176b (Non-valvular Atrial Fibrillation): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Non-valvular Atrial Fibrillation and Severe Renal Impairment (SRI) [NCT01857622]Phase 393 participants (Actual)Interventional2011-11-30Completed
Non-interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong) [NCT03247582]234 participants (Actual)Observational2017-08-02Completed
Phase III Clinical Study of DU-176b (Venous Thromboembolism): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Severe Renal Impairment (SRI) Undergoing Orthopedic Surgery of the Lower Limbs [NCT01857583]Phase 380 participants (Actual)Interventional2012-03-31Completed
anticOagulanti oRali in pazIenti fraGili Con gAstrostoMia endoscopIca Percutanea e fIbrillazione Atriale [NCT04271293]12 participants (Actual)Observational2020-04-07Completed
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty [NCT04878497]1,000,000 participants (Anticipated)Observational2021-03-30Active, not recruiting
A Randomized Trial of the Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery: a Pilot Study [NCT05006287]Phase 2100 participants (Anticipated)Interventional2021-10-01Not yet recruiting
Real-world Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation in China [NCT04747496]5,000 participants (Actual)Observational2021-02-26Active, not recruiting
International Registry on the Use of the Direct Oral Anticoagulants for the Treatment of Unusual Site Venous Thromboembolism [NCT03778502]300 participants (Anticipated)Observational [Patient Registry]2019-10-01Recruiting
A Study to Determine the Inter/Intra Observer and Intra-Subject Variability of Whole Blood Clotting Time Measurements in Ex Vivo Human Blood Samples Spiked With Anticoagulants [NCT03296982]12 participants (Actual)Observational2014-12-31Completed
A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation [NCT03489395]Phase 225 participants (Actual)Interventional2018-01-30Completed
Efficacy and Safety of Edoxaban and or Colchicine for Patients With SARS-CoV-2 Infection Managed in the Out of Hospital Setting [NCT04516941]Phase 360 participants (Actual)Interventional2021-01-21Terminated(stopped due to Insufficient rate of patient accrual and newly available scientific evidence)
Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation: a Randomized, Multi-center, Parallel-group Trial (PILOT) [NCT03433235]Phase 268 participants (Actual)Interventional2018-06-19Completed
Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation [NCT02944019]13,980 participants (Actual)Observational2015-08-31Completed
Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease [NCT05122455]Phase 2/Phase 370 participants (Anticipated)Interventional2021-09-14Recruiting
A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention [NCT01802775]Phase 2203 participants (Actual)Interventional2013-02-06Completed
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study [NCT03895502]Phase 4605 participants (Actual)Interventional2019-05-27Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00107900 (4) [back to overview]Prevention of Venous Thromboembolism (VTE)
NCT00107900 (4) [back to overview]Change From Baseline for Prothrombin Time (PT) Results
NCT00107900 (4) [back to overview]Change From Baseline for International Normalized Ratio (INR) Results
NCT00107900 (4) [back to overview]Change From Baseline for Activated Partial Thromboplastin Time (aPTT) Results
NCT00398216 (4) [back to overview]Adjudicated Incidence of VTE
NCT00398216 (4) [back to overview]Adjudicated Incidence of Major or Clinically Relevant Non-major Bleeding Events
NCT00398216 (4) [back to overview]Change in Prothrombin Time (PT) From Baseline
NCT00398216 (4) [back to overview]Change in Activated Partial Thromboplastin Time (aPTT) From Baseline
NCT00504556 (12) [back to overview]Effects on Pharmacodynamic Biomarker PT in Subjects Receiving DU-176b
NCT00504556 (12) [back to overview]Effects on Biomarker D-dimer
NCT00504556 (12) [back to overview]Effects on Biomarker Prothrombin Fragments
NCT00504556 (12) [back to overview]Effects on Pharmacodynamic Biomarker (Endogenous FX Activity) in Subjects Receiving DU-176b
NCT00504556 (12) [back to overview]Effects on Pharmacodynamic Biomarker INR in Subjects Receiving DU-176b
NCT00504556 (12) [back to overview]Effects on Pharmacodynamic Biomarker PICT Activity in Subjects Receiving DU-176b
NCT00504556 (12) [back to overview]Pharmacokinetics (AUC) of DU-176b in Subjects Receiving DU-176b
NCT00504556 (12) [back to overview]Effects on Pharmacodynamic Biomarker Anti-Factor Xa Activity in Subjects Receiving DU-176b
NCT00504556 (12) [back to overview]Adjudicated Incidence of Bleeding Events
NCT00504556 (12) [back to overview]Incidence of Major Adverse Cardiac Events MACE)
NCT00504556 (12) [back to overview]Percent of Subjects With Liver-related Laboratory Marked Abnormalities (MA)
NCT00504556 (12) [back to overview]Pharmacokinetics (Cmin, Cmax) of DU-176b in Subjects Receiving DU-176b
NCT00781391 (9) [back to overview]Adjudicated Bleeding Events
NCT00781391 (9) [back to overview]Compare Edoxaban to Warfarin for Superiority for Composite of Stroke and Systemic Embolic Events (SEE).
NCT00781391 (9) [back to overview]Compare Edoxaban to Warfarin for Major Adverse Cardiac Event (MACE): a Composite of Non-fatal MI, Non-fatal Stroke, Non-fatal SEE, and Death Due to CV Cause or Bleeding
NCT00781391 (9) [back to overview]Compare Edoxaban to Warfarin for Composite of Stroke, Systemic Embolic Event (SEE), and Cardiovascular (CV) Mortality
NCT00781391 (9) [back to overview]Compare Edoxaban to Warfarin for Composite of Stroke, SEE, and All-cause Mortality
NCT00781391 (9) [back to overview]Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).
NCT00781391 (9) [back to overview]Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).
NCT00781391 (9) [back to overview]Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).
NCT00781391 (9) [back to overview]Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).
NCT00806624 (1) [back to overview]Incidence of All Bleeding
NCT00829933 (1) [back to overview]Incidence of Bleeding Events (Major Bleeding, Clinically Relevant Non-major Bleeding and Minor Bleeding ) Identified During the Period From the Entry Into the Treatment Period Until Completion or Termination of the Treatment.
NCT00986154 (3) [back to overview]Clinically Relevant Bleeding (i.e., Major or Clinically Relevant Non-major Bleeding) Occurring During Treatment
NCT00986154 (3) [back to overview]Symptomatic Recurrent VTE, i.e., the Composite of DVT, Non-fatal PE, and Fatal PE
NCT00986154 (3) [back to overview]The Composite Clinical Outcome of Symptomatic Recurrent VTE and All-cause Mortality
NCT01181102 (2) [back to overview]Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding.
NCT01181102 (2) [back to overview]Incidence of Subjects With Venous Thromboembolism Events.
NCT01181141 (1) [back to overview]The Incidence of Major or Clinically Relevant Non-major Bleeding
NCT01181167 (2) [back to overview]Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding
NCT01181167 (2) [back to overview]Incidence of Subjects With Venous Thromboembolism Events
NCT01203072 (2) [back to overview]Proportion of Subjects With Venous Thromboembolism Events.
NCT01203072 (2) [back to overview]Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding
NCT01203098 (2) [back to overview]Incidence of Major Bleeding or Clinically Relevant Non-major Bleedings.
NCT01203098 (2) [back to overview]Percentage of Subjects With Venous Thromboembolism Events
NCT01662908 (5) [back to overview]Number of Participants With Recurrence of Venous Thromboembolism (VTE)
NCT01662908 (5) [back to overview]Number of Participants With Clinically Relevant Bleeding
NCT01662908 (5) [back to overview]Number of Participants With Change From Baseline in the Presence or Absence of Thrombus by Vessel
NCT01662908 (5) [back to overview]Relative Change From Baseline in Thrombus Volume Assessed by MRI [Using the Magnetic Resonance Venography (MRV) Method]
NCT01662908 (5) [back to overview]Number of Participants With Major Adverse Cardiovascular Events (MACE)
NCT01802775 (6) [back to overview]Safety Assessments
NCT01802775 (6) [back to overview]Percentage of Participants With First Re-stenosis / Re-occlusion
NCT01802775 (6) [back to overview]Number of Participants With Amputations
NCT01802775 (6) [back to overview]Number of Adjudicated Major Adverse Cardiovascular Events During the Overall Study Period
NCT01802775 (6) [back to overview]Percentage of Participants With Clinically Relevant Bleeding During Treatment
NCT01802775 (6) [back to overview]Percentage of Participants With Major, Clinically Relevant Non-major (CRNM), and Minor Bleeding During Treatment
NCT01857583 (1) [back to overview]Incidence of Any Adjudicated Bleeding Events
NCT01857622 (1) [back to overview]Incidence of Any Adjudicated Bleeding Events
NCT01999179 (5) [back to overview]Number of Participants With Recurrent Thrombosis
NCT01999179 (5) [back to overview]PTS Assessment Completion
NCT01999179 (5) [back to overview]Biomarker Sample Collection
NCT01999179 (5) [back to overview]Number of Participants With Post-thrombotic Syndrome
NCT01999179 (5) [back to overview]Number of Participants With Major Bleeding
NCT02072434 (3) [back to overview]Percentage of Participants With Composite Endpoints of Stroke, SEE, MI, CV Mortality, and Major Bleeding
NCT02072434 (3) [back to overview]Percentage of Participants With Composite Endpoints of Major and Clinically-relevant Non-major (CRNM) Bleeding
NCT02072434 (3) [back to overview]Percentage of Participants With Composite Endpoint of Stroke, Systemic Embolic Stroke (SEE), Myocardial Infarction (MI) and Cardiovascular (CV) Mortality From Randomization to End of Follow up
NCT02073682 (7) [back to overview]Number of Participants With Recurrent Deep Vein Thrombosis (DVT) During the Overall Study Period
NCT02073682 (7) [back to overview]Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event
NCT02073682 (7) [back to overview]Number of Participants With Adjudicated Major Bleeding Events While on Treatment
NCT02073682 (7) [back to overview]Number of Participants With Recurrent Non-Fatal Pulmonary Embolism (PE) During the Overall Study Period
NCT02073682 (7) [back to overview]Number of Participants With Recurrent Venous Thromboembolism (VTE) During the Overall Study Period
NCT02073682 (7) [back to overview]Number of Participants With Recurrent VTE, Major Bleed or All-Cause Death
NCT02073682 (7) [back to overview]Number of Participants With VTE-Related Death
NCT02303431 (12) [back to overview]Pharmacodynamic Parameter Mean Anti-Factor Xa (FXa)
NCT02303431 (12) [back to overview]Pharmacodynamic Parameter Mean Anti-Factor Xa (FXa)
NCT02303431 (12) [back to overview]Pharmacodynamic Parameter Mean Activated Partial Thromboplastin Time (aPTT)
NCT02303431 (12) [back to overview]Mean Palatability Score for the Liquid Formulation on a 100 mm Visual Analog Scale (VAS)
NCT02303431 (12) [back to overview]Pharmacokinetic Parameter of Apparent Volume of Distribution (V/F)
NCT02303431 (12) [back to overview]Pharmacokinetic Parameter of Apparent Systemic Clearance (CL/F)
NCT02303431 (12) [back to overview]Pharmacodynamic Parameter Mean Activated Partial Thromboplastin Time (aPTT)
NCT02303431 (12) [back to overview]Pharmacodynamic Parameter Mean Prothrombin Time (PT)
NCT02303431 (12) [back to overview]Pharmacodynamic Parameter Mean Prothrombin Time (PT)
NCT02303431 (12) [back to overview]Pharmacodynamic Parameter Mean Activated Partial Thromboplastin Time (aPTT)
NCT02303431 (12) [back to overview]Pharmacodynamic Parameter Mean Prothrombin Time (PT)
NCT02303431 (12) [back to overview]Pharmacodynamic Parameter Mean Anti-Factor Xa (FXa)
NCT02339415 (3) [back to overview]Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 4 Months.
NCT02339415 (3) [back to overview]Change in D-Dimer Levels From Baseline to 4 Months
NCT02339415 (3) [back to overview]Safety (Bleeding Events)
NCT02561897 (2) [back to overview]Major Bleeding
NCT02561897 (2) [back to overview]Thromboembolic and Cardiovascular Events
NCT02666742 (12) [back to overview]Number of Participants With Cardiac Tamponade
NCT02666742 (12) [back to overview]Number of Participants With Transient Ischemic Attack
NCT02666742 (12) [back to overview]Number of Participants With Fatal Pulmonary Embolism
NCT02666742 (12) [back to overview]Number of Participants With Asymptomatic Cerebral Event on MRI - 30 Days
NCT02666742 (12) [back to overview]Number of Participants With Asymptomatic Cerebral Event on MRI - 24 Hours
NCT02666742 (12) [back to overview]Number of Participants With Acute Procedure Related Complications
NCT02666742 (12) [back to overview]Number of Participants With Stroke
NCT02666742 (12) [back to overview]Number of Participants With Groin Hematoma
NCT02666742 (12) [back to overview]Number of Participants With Heart Block
NCT02666742 (12) [back to overview]Number of Participants With In-hospital Mortality
NCT02666742 (12) [back to overview]Number of Participants With Progressive Heart Failure and Electromechanical Dissociation (EMD)
NCT02666742 (12) [back to overview]Number of Participants With Retroperitoneal Bleed
NCT02744092 (11) [back to overview]Benefit of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire
NCT02744092 (11) [back to overview]Benefit of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire
NCT02744092 (11) [back to overview]Burden of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire
NCT02744092 (11) [back to overview]Burden of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire
NCT02744092 (11) [back to overview]Cumulative Non-Fatal VTE Recurrence at 6 Months (%)
NCT02744092 (11) [back to overview]Cumulative Rates of Major Bleeding
NCT02744092 (11) [back to overview]Health Related Quality of Life (Mental Health) Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire at 3-months
NCT02744092 (11) [back to overview]Health Related Quality of Life (Mental Health) Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire at 6-months
NCT02744092 (11) [back to overview]Health Related Quality of Life Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire
NCT02744092 (11) [back to overview]Health Related Quality of Life Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire
NCT02744092 (11) [back to overview]Mortality Reported by Participants' Surrogates (Via Study-specific Questionnaire) or Clinicians (Via Study-specific Case Report Form)
NCT02798471 (14) [back to overview]Number of Participants With All Bleeding Events (On Treatment) During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)
NCT02798471 (14) [back to overview]Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events (On Treatment) During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)
NCT02798471 (14) [back to overview]Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events (On Treatment) During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)
NCT02798471 (14) [back to overview]Number of Participants With No Change or Extension of Thrombotic Burden During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)
NCT02798471 (14) [back to overview]Number of Participants With No Change or Extension of Thrombotic Burden During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)
NCT02798471 (14) [back to overview]Number of Participants With Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)
NCT02798471 (14) [back to overview]Number of Participants With Symptomatic Recurrent Venous Thromboembolism During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)
NCT02798471 (14) [back to overview]Number of Participants Reporting Adjudicated All-Cause Mortality During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated)
NCT02798471 (14) [back to overview]Number of Participants Who Died as a Result of VTE During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)
NCT02798471 (14) [back to overview]Number of Participants Who Died as a Result of VTE During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Individual Component of Primary Efficacy Endpoint)
NCT02798471 (14) [back to overview]Number of Participants Who Died as a Result of VTE During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)
NCT02798471 (14) [back to overview]Number of Participants With Adjudicated Individual Component of Primary Efficacy Endpoints During the Main Treatment Period Following Edoxaban or Standard of Care Treatment
NCT02798471 (14) [back to overview]Number of Participants With Deep Vein Thrombosis, Catheter-related Thrombosis, Sino-venous Thrombosis, and Pulmonary Embolism During the Main, Extension, and Overall Treatment Periods Following Edoxaban or Standard of Care Treatment
NCT02798471 (14) [back to overview]Number of Participants With Symptomatic Recurrent VTE During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Individual Component of Primary Efficacy Endpoint)
NCT02801669 (11) [back to overview]Number of Participants With Major Bleeding or Clinically Relevant Non-major Bleedings During On-Treatment Period in Participants Who Were Administered DU-176b Compared With Placebo
NCT02801669 (11) [back to overview]Number of Participants With All Bleeding Events and Minor Bleeding Events During On-Treatment Period in Participants Who Were Administered DU-176b Compared With Placebo
NCT02801669 (11) [back to overview]Number of Participants With Net Clinical Benefit in Participants Who Were Administered DU-176b Compared With Placebo
NCT02801669 (11) [back to overview]Number of Participants With All-Cause Mortality in Participants Who Were Administered DU-176b Compared With Placebo
NCT02801669 (11) [back to overview]Number of Participants With a Composite Endpoint of Stroke, Systemic Embolic Events (SEE), and Death Due to Cardiovascular in Participants Who Were Administered DU-176b Compared With Placebo
NCT02801669 (11) [back to overview]Number of Participants With a Composite Endpoint of Stroke, Systemic Embolic Events (SEE), and All-Cause Mortality in Participants Who Were Administered DU-176b Compared With Placebo
NCT02801669 (11) [back to overview]Number of Participants With a Composite Endpoint of Stroke and Systemic Embolic Events (SEE) in Participants Who Were Administered DU-176b Compared With Placebo
NCT02801669 (11) [back to overview]Plasma Concentration of DU-176 in Participants Who Were Administered DU-176b
NCT02801669 (11) [back to overview]Number of Participants With a Composite Endpoint of a Major Adverse Cardiovascular Event (MACE) in Participants Who Were Administered DU-176b Compared With Placebo
NCT02801669 (11) [back to overview]Number of Participants With Stroke and Systemic Embolic Events (SEE), Including Subcomponents of Stroke and Composite Event of Ischemic Stroke and SEE in Participants Who Were Administered DU-176b Compared With Placebo
NCT02801669 (11) [back to overview]Number of Participants With Major Bleeding During On-Treatment Period in Participants Who Were Administered DU-176b Compared With Placebo
NCT02866175 (7) [back to overview]Number of Participants With Main Efficacy Endpoints For the Overall Study Period Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]Number of Participants With Study Drug-related Treatment-emergent Adverse Events (TEAEs) Experienced by 2 or More Participants Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]Number of Participants With Treatment-emergent Adverse Events (TEAEs) Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]Number of Participants With Adjudicated Major or Clinically Relevant Non-major Bleeding As First Event Defined by International Society on Thrombosis and Haemostasis Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]Number of Participants With Adjudicated Major, Clinically Relevant Non-major and Minor Bleeding (All Events) Defined by International Society on Thrombosis and Haemostasis Following Edoxaban-based Regimen Compared With Vitamin K Antagonist-Based Regimen
NCT02866175 (7) [back to overview]Number of Participants With Adjudicated Major, Minor, and Minimal Bleeding by Thrombolysis in Myocardial Infarction (TIMI) Definition Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]Number of Participants With Bleeding Academic Research Consortium (BARC) Type 1, 2, 3, and 5 Bleeding According to the BARC Definitions Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02942576 (4) [back to overview]Number of Participants Who Experienced the Composite of All-cause Death, Stroke (Alternative), and Major Bleeding (ISTH) in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)
NCT02942576 (4) [back to overview]Number of Participants Who Experienced Major Bleeding (International Society on Thrombosis and Hemostasis [ISTH]) in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)
NCT02942576 (4) [back to overview]Number of Participants Who Experienced the Composite of All-cause Death, Stroke (VARC-2), and Major Bleeding (ISTH) in the Edoxaban Group Compared With Vitamin K Antagonist (VKA) Group in Participants Undergoing Catheter Ablation (Adjudicated Data)
NCT02942576 (4) [back to overview]Number of Participants Who Experienced the Composite of Stroke (VARC-2), Systemic Embolic Events (SEE), and Cardiovascular (CV) Mortality in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)
NCT02943785 (12) [back to overview]Number of Participants Who Experienced Major Bleeding (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA
NCT02943785 (12) [back to overview]Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on TIMI Criteria in Participants Taking Edoxaban vs VKA
NCT02943785 (12) [back to overview]Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on GUSTO Criteria in Participants Taking Edoxaban vs VKA
NCT02943785 (12) [back to overview]Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on BARC Type 3 or 5 Criteria in Participants Taking Edoxaban vs VKA
NCT02943785 (12) [back to overview]Number of Participants Who Experienced Valve Thrombosis in Participants Taking Edoxaban vs VKA (Adjudicated Data)
NCT02943785 (12) [back to overview]Number of Participants Who Experienced Stroke Events (Ischemic, Hemorrhagic, Undetermined) in Participants Taking Edoxaban vs VKA (Adjudicated Data)
NCT02943785 (12) [back to overview]Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA
NCT02943785 (12) [back to overview]Number of Participants Who Experienced Systemic Embolic Events in Participants Taking Edoxaban vs VKA (Adjudicated Data)
NCT02943785 (12) [back to overview]Number of Participants Who Experienced Myocardial Infarctions (MI) in Participants Taking Edoxaban vs VKA (Adjudicated Data)
NCT02943785 (12) [back to overview]Number of Participants Who Experienced Major Adverse Cardiac and Cerebrovascular Events (MACCE) in Participants Taking Edoxaban vs VKA (Adjudicated Data)
NCT02943785 (12) [back to overview]Number of Participants Who Experienced Major Adverse Cardiac Events (MACE) in Participants Taking Edoxaban vs VKA (Adjudicated Data)
NCT02943785 (12) [back to overview]Number of Participants Who Experienced a Composite of Adverse Events in Participants Taking Edoxaban vs VKA (Adjudicated Data)
NCT02943993 (15) [back to overview]Number of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - Overall
NCT02943993 (15) [back to overview]Overview of Participants With Adverse Drug Reactions
NCT02943993 (15) [back to overview]Duration of Venous Thromboembolism Events (On Edoxaban Treatment)
NCT02943993 (15) [back to overview]Duration of Edoxaban Treatment
NCT02943993 (15) [back to overview]Number of Participants With Adverse Drug Reactions by Preferred Term (≥0.2%)
NCT02943993 (15) [back to overview]Number of Participants Experiencing At Least 1 Real World Safety Event - Overall
NCT02943993 (15) [back to overview]Duration of Venous Thromboembolism Recurrences, by Type - Overall
NCT02943993 (15) [back to overview]Number of Systemic Embolic Events - Overall
NCT02943993 (15) [back to overview]Total Number of Venous Thromboembolism Recurrences (On Edoxaban Treatment)
NCT02943993 (15) [back to overview]Total Number of Venous Thromboembolism Recurrences By Type - Overall
NCT02943993 (15) [back to overview]Number of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - On Edoxaban Treatment
NCT02943993 (15) [back to overview]Number of Participants With Risk Factors for Thromboembolic Events at Baseline
NCT02943993 (15) [back to overview]Number of Stroke Events
NCT02943993 (15) [back to overview]Number of Participants With Pre-defined Adverse Drug Reactions
NCT02943993 (15) [back to overview]Number of Participants With Bleeding Events (Adjudicated) While On Edoxaban Treatment
NCT03254147 (2) [back to overview]The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma.
NCT03254147 (2) [back to overview]The Number of Patients With Cardiac Tamponade and Pericardiocentesis.
NCT03310021 (6) [back to overview]Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir.
NCT03310021 (6) [back to overview]Percent Change in Anti-Fxa Activity From Baseline to the End of Bolus (EOB) Nadir.
NCT03310021 (6) [back to overview]Change in Thrombin Generation From Baseline to the End of Infusion (EOI) Nadir.
NCT03310021 (6) [back to overview]Change in Thrombin Generation From Baseline to the End of Bolus (EOB) Nadir.
NCT03310021 (6) [back to overview]Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Infusion (EOI) Nadir.
NCT03310021 (6) [back to overview]Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Bolus (EOB) Nadir.
NCT03395639 (8) [back to overview]Number of Participants Who Died as a Result of Any Cause (All-Cause Mortality) Within the Main Treatment Period
NCT03395639 (8) [back to overview]Number of Participants Who Died as a Result of Any Cause (All-Cause Mortality) During the Extension Period
NCT03395639 (8) [back to overview]Number of Participants Who Died as a Result of Thromboembolic Event Within the Main Treatment Period
NCT03395639 (8) [back to overview]Number of Participants With Symptomatic Thromboembolic Events (TE) in the Systemic Arterial or Venous Pathways Within the Main Treatment Period
NCT03395639 (8) [back to overview]Number of Participants With Symptomatic Thromboembolic Events (TE) in the Systemic Arterial or Venous Pathways During the Extension Period
NCT03395639 (8) [back to overview]Number of Participants With Adjudicated Bleeding Events Within the Main Treatment Period
NCT03395639 (8) [back to overview]Number of Participants With Adjudicated Bleeding Events During the Extension Period
NCT03395639 (8) [back to overview]Number of Participants Who Died as a Result of Thromboembolic Event During the Extension Period
NCT03551743 (9) [back to overview]Andexanet Apparent Terminal Elimination Half-life (t1/2)
NCT03551743 (9) [back to overview]Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )
NCT03551743 (9) [back to overview]Andexanet Maximum Observed Plasma Concentration (Cmax)
NCT03551743 (9) [back to overview]Andexanet Time of Maximum Observed Plasma Concentration (Tmax)
NCT03551743 (9) [back to overview]Andexanet Total Systemic Clearance (CL)
NCT03551743 (9) [back to overview]Andexanet Total Volume of Distribution (Vss)
NCT03551743 (9) [back to overview]Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration
NCT03551743 (9) [back to overview]Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration
NCT03551743 (9) [back to overview]Efficacy: Percent Change From Baseline in Unbound Edoxaban Plasma Concentration at 2 Mins Following Andexanet/Placebo Administration
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]Time to Treatment Discontinuation
NCT05022563 (60) [back to overview]Overall Index Anticoagulant Treatment Duration
NCT05022563 (60) [back to overview]Number of Participants With Interruption in Index Anticoagulant Treatment
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]Number of Participants Who Switched to Another Anticoagulant Therapy
NCT05022563 (60) [back to overview]Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months
NCT05022563 (60) [back to overview]Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months
NCT05022563 (60) [back to overview]Time to Treatment Switch
NCT05022563 (60) [back to overview]Time to Treatment Interruption
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
NCT05022563 (60) [back to overview]Number of Participants Who Completely Discontinued Index Anticoagulant Treatment

Prevention of Venous Thromboembolism (VTE)

"The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment (approximately 2 weeks post surgery).~Confirmed deep vein thrombosis ( both proximal and distal ) as assessed by unilateral or bilateral ascending contrast venograms 7 to 10 days following surgery Symptomatic and objectively proven Pulmonary Embolism (PE) prior to venography Symptomatic and objectively proven Deep Vein Thrombosis (DVT) prior to venography" (NCT00107900)
Timeframe: 2 weeks

Interventionpercentage of patients with event (Number)
15mg BID13
30mg QD13
30mg BID10
60mg QD13
60mg BID16
120mg QD17

[back to top]

Change From Baseline for Prothrombin Time (PT) Results

Intent to Treat (ITT) population (NCT00107900)
Timeframe: end of treatment

Interventionseconds (Mean)
15mg BID-.2
30mg QD-.1
30mg BID.7
60mg QD.8
60mg BID1.1
120mg QD1.8

[back to top]

Change From Baseline for International Normalized Ratio (INR) Results

Intent to Treat (ITT) population (NCT00107900)
Timeframe: end of treatment

InterventionINR ratio (Mean)
15mg BID0
30mg QD0
30mg BID.1
60mg QD.1
60mg BID.1
120mg QD.2

[back to top]

Change From Baseline for Activated Partial Thromboplastin Time (aPTT) Results

Intent to Treat (ITT) population (NCT00107900)
Timeframe: end of treatment

Interventionseconds (Mean)
15mg BID-5.1
30mg QD-1.6
30mg BID2.5
60mg QD4.1
60mg BID5.8
120mg QD11.3

[back to top]

Adjudicated Incidence of VTE

"Assess the efficacy of DU-176b in the prevention of venous thromboembolism (VTE) from 6 to 8 hours after hip replacement surgery to 7 to 10 days after the surgery.~A subject was judged to have a VTE if one or more of the following criteria were met:~Observed lower extremity deep vein thrombosis (DVT) (either proximal, distal, or both ) as assessed by bilateral or unilateral ascending contrast venography prior to or at the end-of-treatment (EOT) visit~Symptomatic and objectively proven pulmonary embolism prior to or at the EOT visit~Symptomatic and objectively proven DVT prior to or at EOT visit end of treatment defined as 6 to 8 hours after after hip replacement surgery to 7 to 10 days after the surgery." (NCT00398216)
Timeframe: end of treatment

Interventionpercentage of participants with VTE (Number)
Edoxaban 15mg QD29.0
Edoxaban 30mg QD20.3
Edoxaban 60mg QD15.7
Edoxaban 90mg QD11.5
Dalteparin46.0

[back to top]

Adjudicated Incidence of Major or Clinically Relevant Non-major Bleeding Events

adjudicated incidence of major or clinically relevant non-major bleeding events through 10 days after first dose (NCT00398216)
Timeframe: 10 days after first dose

Interventionpercentage of subjects with bleed events (Number)
Edoxaban 15mg QD1.6
Edoxaban 30mg QD1.8
Edoxaban 60mg QD2.2
Edoxaban 90mg QD2.3
Dalteparin0

[back to top]

Change in Prothrombin Time (PT) From Baseline

change in prothrombin time (PT) from baseline to end of treatment end of treatment defined as 6-8 hours after hip replacement surgery to 7 to 10 days after the surgery (NCT00398216)
Timeframe: end of treatment

Interventionseconds (Mean)
Edoxaban 15mg QD.90
Edoxaban 30mg QD1.07
Edoxaban 60mg QD2.87
Edoxaban 90mg QD2.74
Dalteparin.67

[back to top]

Change in Activated Partial Thromboplastin Time (aPTT) From Baseline

change in Activated Partial Thromboplastin Time (aPTT) from baseline to end of treatment end of treatment defined as 6-8 hours after hip replacement surgery to 7 to 10 days after the surgery (NCT00398216)
Timeframe: end of treatment

Interventionseconds (Mean)
Edoxaban 15mg QD-0.33
Edoxaban 30mg QD1.67
Edoxaban 60mg QD4.39
Edoxaban 90mg QD3.26
Dalteparin2.34

[back to top]

Effects on Pharmacodynamic Biomarker PT in Subjects Receiving DU-176b

Mean (SD) change from baseline in biomarker prothrombin time (PT) on Day 28, 1-3 hours post dose. (NCT00504556)
Timeframe: Day 28

Interventionseconds (Mean)
DU-176b 30mg qd0.6
DU-176b 30mg Bid0.4
DU-176b 60mg qd2.0
DU-176b 60mg Bid2.1

[back to top]

Effects on Biomarker D-dimer

Mean (SD) change from baseline in D-dimer (NCT00504556)
Timeframe: 3 months

Interventionng/mL (Mean)
DU-176b 30mg qd-225
DU-176b 30mg Bid-187.8
DU-176b 60mg qd-100.5
DU-176b 60mg Bid-129.8
Warfarin Tablets-160.7

[back to top]

Effects on Biomarker Prothrombin Fragments

Mean (SD) change from baseline in Prothrombin Fragments 1 and 2 (F1 and F2) (NCT00504556)
Timeframe: 3 months

Interventionpmol/L (Mean)
DU-176b 30mg qd-23.5
DU-176b 30mg Bid-47.4
DU-176b 60mg qd-51.4
DU-176b 60mg Bid6.4
Warfarin Tablets-74.6

[back to top]

Effects on Pharmacodynamic Biomarker (Endogenous FX Activity) in Subjects Receiving DU-176b

Mean (SD) change from baseline in biomarker endogenous FX activity on Day 28, 1-3 hours post dose. (NCT00504556)
Timeframe: Day 28

Interventionpercent change of Endogenous FX activity (Mean)
DU-176b 30mg qd-40.3
DU-176b 30mg Bid-40.2
DU-176b 60mg qd-44.4
DU-176b 60mg Bid-45.2

[back to top]

Effects on Pharmacodynamic Biomarker INR in Subjects Receiving DU-176b

Mean (SD) change from baseline in biomarker International Normalized Ratio (INR) on Day 28, 1-3 hours post dose. (NCT00504556)
Timeframe: Day 28

Interventionratio (Mean)
DU-176b 30mg qd0.05
DU-176b 30mg Bid0.03
DU-176b 60mg qd0.17
DU-176b 60mg Bid0.26

[back to top]

Effects on Pharmacodynamic Biomarker PICT Activity in Subjects Receiving DU-176b

"Mean (SD) change from baseline in biomarker prothrombinase induced clotting time [PICT] on Day 28, 1-3 hours post dose.~PICT was determined by PICT aasay which is a plasma based functional assay to determine the anticoagulant activity on FXa and FIIa inhibition." (NCT00504556)
Timeframe: Day 28

Interventionseconds (Mean)
DU-176b 30mg qd14.0
DU-176b 30mg Bid15.4
DU-176b 60mg qd18.3
DU-176b 60mg Bid19.6

[back to top]

Pharmacokinetics (AUC) of DU-176b in Subjects Receiving DU-176b

Median (min, max) values of AUCss (NCT00504556)
Timeframe: 3 months

Interventionng*h/mL (Median)
DU-176b 30mg qd825
DU-176b 30mg Bid1729
DU-176b 60mg qd1728
DU-176b 60mg Bid3301

[back to top]

Effects on Pharmacodynamic Biomarker Anti-Factor Xa Activity in Subjects Receiving DU-176b

Mean (SD) change from baseline in biomarker anti-Factor Xa [FXa] activity on Day 28, 1-3 hours post dose. (NCT00504556)
Timeframe: Day 28

InterventionIU/mL (Mean)
DU-176b 30mg qd1.46
DU-176b 30mg Bid1.91
DU-176b 60mg qd2.42
DU-176b 60mg Bid3.28

[back to top]

Adjudicated Incidence of Bleeding Events

Adjudicated Incidence of Bleeding Events during treatment period (NCT00504556)
Timeframe: 3 months

,,,,
Interventionpercent of subjects with outcome event (Number)
All bleedingMajor or clinically relevant non-major bleedMajor bleed
DU-176b 30mg Bid12.77.82.0
DU-176b 30mg qd5.53.00
DU-176b 60mg Bid18.310.63.3
DU-176b 60mg qd7.33.80.4
Warfarin Tablets8.03.20.4

[back to top]

Incidence of Major Adverse Cardiac Events MACE)

MACE is defined as the composite of stroke [ischemic or hemorrhagic], Systemic embolic event (SEE), Myocardial Infarction (MI), Cardiovascular (CV) death, and hospitalization for any cardiac condition (NCT00504556)
Timeframe: 3 months

,,,,
Interventionpercent of subjects experiencing events (Number)
MACEany strokeSEEany stroke and/or SEEMICV deathhospitalization for any cardiac condition
DU-176b 30mg Bid2.5.8.41.2.41.6.8
DU-176b 30mg qd1.7.4.4.4.9.9.9
DU-176b 60mg Bid1.11.101.1000
DU-176b 60mg qd4.3.40.4.903.0
Warfarin Tablets2.41.601.60.8.4

[back to top] [back to top]

Pharmacokinetics (Cmin, Cmax) of DU-176b in Subjects Receiving DU-176b

Median (min, max) values of Cmin,ss; Cmax,ss (NCT00504556)
Timeframe: 3 months

,,,
Interventionng/mL (Median)
Cmin,ss (ng/mL)Cmax,ss (ng/mL)
DU-176b 30mg Bid21.2173.0
DU-176b 30mg qd10.384.9
DU-176b 60mg Bid75.7221.4
DU-176b 60mg qd39.6115.0

[back to top]

Adjudicated Bleeding Events

"Compare edoxaban versus warfarin for Adjudicated Bleeding Events during the on-treatment period in the Safety Analysis set.~Major bleeding was adjudicated by the Clinical Events Committee (CEC) and defined based on published guidance from the International Society on Thrombosis and Haemostasis (ISTH), with minor modifications for Hgb decrease and blood transfusion requirements." (NCT00781391)
Timeframe: on-treatment period 2.5 years of median study drug exposure and 2.8 year of median follow-up

,,
Interventionnumber of participants with event (Number)
Major bleedICH Major bleedNon-ICH Major bleedFatal bleednon-fatal (Major) bleedlife-threatening bleedclinically relevant non-major bleedmajor or clinically relevant non-majorminorany confirmed bleed
High Dose Edoxaban/Placebo Warfarin418613593238662121415286041865
Low Dose Edoxaban/Placebo Warfarin25441214212344096911615331499
Warfarin/Placebo Edoxaban52413239859466122139617617142114

[back to top]

Compare Edoxaban to Warfarin for Superiority for Composite of Stroke and Systemic Embolic Events (SEE).

Compare edoxaban to warfarin for the composite of stroke and Systemic Embolic Events (SEE) during the overall study period in the ITT analysis set with a superiority analysis. (NCT00781391)
Timeframe: overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up

Interventionnumber of participants with event (Number)
Low Dose Edoxaban/Placebo Warfarin383
High Dose Edoxaban/Placebo Warfarin296
Warfarin/Placebo Edoxaban337

[back to top]

Compare Edoxaban to Warfarin for Major Adverse Cardiac Event (MACE): a Composite of Non-fatal MI, Non-fatal Stroke, Non-fatal SEE, and Death Due to CV Cause or Bleeding

Compare edoxaban to warfarin for Major Adverse Cardiac Event (MACE): a composite of non-fatal Myocardial Infarction, non-fatal stroke, non-fatal Systemic Embolic Events, and death due to Cardiovascular cause or bleeding during the overall study period in the ITT analysis set. (NCT00781391)
Timeframe: overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up

Interventionnumber of participants with event (Number)
Low Dose Edoxaban/Placebo Warfarin913
High Dose Edoxaban/Placebo Warfarin827
Warfarin/Placebo Edoxaban926

[back to top]

Compare Edoxaban to Warfarin for Composite of Stroke, Systemic Embolic Event (SEE), and Cardiovascular (CV) Mortality

Compare edoxaban to warfarin for the composite of stroke, Systemic Embolic Events, and Cardiovascular mortality during the overall study period in the ITT analysis set. (NCT00781391)
Timeframe: overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up

Interventionnumber of participants with event (Number)
Low Dose Edoxaban/Placebo Warfarin796
High Dose Edoxaban/Placebo Warfarin728
Warfarin/Placebo Edoxaban831

[back to top]

Compare Edoxaban to Warfarin for Composite of Stroke, SEE, and All-cause Mortality

Compare Edoxaban to warfarin for Composite of stroke, Systemic Embolic Events, and all-cause mortality during the overall study period in the ITT analysis set. (NCT00781391)
Timeframe: overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up

Interventionnumber of participants with event (Number)
Low Dose Edoxaban/Placebo Warfarin985
High Dose Edoxaban/Placebo Warfarin949
Warfarin/Placebo Edoxaban1046

[back to top]

Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).

The composite of stroke and Systemic Embolic Events (SEE) during the overall study period in the PP (per protocol) analysis set population. (NCT00781391)
Timeframe: overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up

Interventionnumber of participants with event (Number)
Low Dose Edoxaban/Placebo Warfarin382
High Dose Edoxaban/Placebo Warfarin292
Warfarin/Placebo Edoxaban335

[back to top]

Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).

The composite of stroke and Systemic Embolic Events (SEE) during the on treatment period in the mITT analysis population with a non-inferiority analysis. (NCT00781391)
Timeframe: on-treatment period 2.5 years of median study drug exposure and 2.8 year of median follow-up

Interventionnumber of participants with event (Number)
Low Dose Edoxaban/Placebo Warfarin253
High Dose Edoxaban/Placebo Warfarin182
Warfarin/Placebo Edoxaban232

[back to top]

Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).

The composite of stroke and Systemic Embolic Events (SEE) during the on treatment period in the PP (per protocol) analysis set population. (NCT00781391)
Timeframe: on-treatment period 2.5 years of median study drug exposure and 2.8 year of median follow-up

Interventionnumber of participants with event (Number)
Low Dose Edoxaban/Placebo Warfarin253
High Dose Edoxaban/Placebo Warfarin182
Warfarin/Placebo Edoxaban231

[back to top]

Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).

The composite of stroke and Systemic Embolic Events (SEE) during the overall study period in the mITT analysis population. (NCT00781391)
Timeframe: overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up

InterventionNumber of participants with event (Number)
Low Dose Edoxaban/Placebo Warfarin382
High Dose Edoxaban/Placebo Warfarin292
Warfarin/Placebo Edoxaban336

[back to top]

Incidence of All Bleeding

Incidence of all bleeding (major, clinically relevant non-major and minor) in two fixed dosage of DU-176b in comparison with warfarin as active control in subjects with non-valvular AF. (NCT00806624)
Timeframe: 6 months

Interventionpercentage of subjects with bleeds (Number)
DU176b 30mg20.3
DU-176b 60 mg23.8
Warfarin Potassium29.3

[back to top]

Incidence of Bleeding Events (Major Bleeding, Clinically Relevant Non-major Bleeding and Minor Bleeding ) Identified During the Period From the Entry Into the Treatment Period Until Completion or Termination of the Treatment.

The primary endpoint was the incidence of bleeding events (major bleeding, clinically relevant non-major bleeding, or minor bleeding) that occurred during the treatment period. (NCT00829933)
Timeframe: 12 weeks

Interventionpercent of subjects with bleeding event (Number)
DU-176b Low Dose 30mg18.5
DU-176b Intermediate Dose 45mg22.4
DU-176b High Dose 60mg27.7
Warfarin20.0

[back to top]

Clinically Relevant Bleeding (i.e., Major or Clinically Relevant Non-major Bleeding) Occurring During Treatment

Clinically relevant bleeding (i.e., major or clinically relevant non-major bleeding) occurring during treatment plus 3 days after their last dose for that time period. (NCT00986154)
Timeframe: 12 months from time of randomization

Interventionparticipants with an event (Number)
Heparin/Edoxaban Tosylate349
Heparin/Warfarin423

[back to top]

Symptomatic Recurrent VTE, i.e., the Composite of DVT, Non-fatal PE, and Fatal PE

"Symptomatic recurrent Venous Thromboembolism (VTE), i.e., the composite of deep Vein Thrombosis (DVT), non-fatal Pulmonary Embolism (PE), and fatal PE occurring during the Overall Study Period.~Overall Study Period defined as The time from the reference date (randomization date/initial dose of study drug date) to the last study follow-up visit." (NCT00986154)
Timeframe: 12 months from time of randomization

Interventionnumber or participants with an event (Number)
Heparin/Edoxaban Tosylate130
Heparin/Warfarin146

[back to top]

The Composite Clinical Outcome of Symptomatic Recurrent VTE and All-cause Mortality

(NCT00986154)
Timeframe: 12 months from time of randomization

Interventionnumber of participants with event (Number)
Heparin/Edoxaban Tosylate228
Heparin/Warfarin228

[back to top]

Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding.

(NCT01181102)
Timeframe: 2 weeks

Interventionpercentage of subjects with bleeds (Number)
DU-176b6.2
Enoxaparin Sodium3.7

[back to top]

Incidence of Subjects With Venous Thromboembolism Events.

"The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment.~Lower extremity Deep Vein Thrombosis (DVT) confirmed by unilateral venography at the end of study treatment~Definite diagnosis of symptomatic Pulmonary Embolism (PE)~Symptomatic DVT confirmed before the venography at the end of study treatment The objectives were to verify the non-inferiority of edoxaban to enoxaparin with regard to prevention of venous Thromboembolism (VTE)" (NCT01181102)
Timeframe: 2 weeks

Interventionpercent of participants with VTE events (Number)
DU-176b7.4
Enoxaparin Sodium13.9

[back to top]

The Incidence of Major or Clinically Relevant Non-major Bleeding

Bleeding events during the period from the start of treatment with the study drug (study treatment) to the day of the follow-up examination were assessed as the primary endpoints. (NCT01181141)
Timeframe: 2 weeks

Interventionpercentage of subjects with bleeds (Number)
DU-176b3.4
Enoxaparin Sodium6.9

[back to top]

Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding

(NCT01181167)
Timeframe: 2 weeks

Interventionpercentage of subjects with bleeds (Number)
DU-176b2.6
Enoxaparin Sodium3.7

[back to top]

Incidence of Subjects With Venous Thromboembolism Events

"The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment.~Lower extremity DVT confirmed by bilateral venography at the end of study treatment~Definite diagnosis of symptomatic PE~Symptomatic DVT confirmed before the venography at the end of study treatment The objectives were to verify the non-inferiority of edoxaban to enoxaparin with regard to prevention of VTE" (NCT01181167)
Timeframe: 2 weeks

Interventionpercentage of subjects with vte events (Number)
DU-176b2.4
Enoxaparin Sodium6.9

[back to top]

Proportion of Subjects With Venous Thromboembolism Events.

"The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment.~Lower extremity DVT confirmed by bilateral venography at the end of study treatment~Definite diagnosis of symptomatic PE~Symptomatic DVT confirmed before the venography at the end of study treatment The objectives were to verify the non-inferiority of edoxaban to enoxaparin with regard to prevention of VTE" (NCT01203072)
Timeframe: 2 weeks

Interventionpercentage of participants (Number)
DU-176b 5 mg29.5
DU-176b 15 mg26.1
DU-176b 30 mg12.5
DU-176b 60 mg9.1
Placebo48.3

[back to top]

Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding

Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding. Related to the study drug (NCT01203072)
Timeframe: 2 weeks

Interventionpercentage of subjects with bleeds (Number)
DU-176b 5 mg1.9
DU-176b 15 mg3.8
DU-176b 30 mg3.9
DU-176b 60 mg4.7
Placebo3.9

[back to top]

Incidence of Major Bleeding or Clinically Relevant Non-major Bleedings.

(NCT01203098)
Timeframe: 2 weeks

Interventionpercentage of subjects with bleeds (Number)
DU-176b 15 mg2.2
DU-176b 30 mg1.2
Enoxaparin Sodium 20mg (2000IU)2.3

[back to top]

Percentage of Subjects With Venous Thromboembolism Events

"The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment.~Lower extremity DVT confirmed by bilateral venography at the end of study treatment~Definite diagnosis of symptomatic PE~Symptomatic DVT confirmed before the venography at the end of study treatment The objectives were to verify the non-inferiority of edoxaban to enoxaparin with regard to prevention of VTE" (NCT01203098)
Timeframe: 2 weeks

Interventionpercent of participants with VTE event (Number)
DU-176b 15 mg3.8
DU-176b 30 mg2.8
Enoxaparin Sodium 20mg (2000IU)4.1

[back to top]

Number of Participants With Recurrence of Venous Thromboembolism (VTE)

Number of participants with investigator-confirmed recurrent VTE events that start or worsen after the first dose of study drug and prior to the date of the final visit or telephone contact (inclusive) (NCT01662908)
Timeframe: Baseline to final visit (Day 14-21)

InterventionParticipants (Count of Participants)
Edoxaban4
Warfarin2

[back to top]

Number of Participants With Clinically Relevant Bleeding

Clinically relevant bleeding was defined as major or clinically relevant non-major bleeding (NCT01662908)
Timeframe: Initial dose of study drug up to 3 days after last dose

InterventionParticipants (Count of Participants)
Edoxaban3
Warfarin2

[back to top]

Number of Participants With Change From Baseline in the Presence or Absence of Thrombus by Vessel

(NCT01662908)
Timeframe: Baseline to final visit (Day 14-21)

InterventionParticipants (Count of Participants)
Edoxaban0
Warfarin0

[back to top]

Relative Change From Baseline in Thrombus Volume Assessed by MRI [Using the Magnetic Resonance Venography (MRV) Method]

Thrombus Volume (mm^3) was measured at baseline and between days 14 to 21 using MRI results as determined by Magnetic Resonance Venography (MRV) method, and the relative percentage change from baseline was calculated (NCT01662908)
Timeframe: Baseline to final visit (Day 14-21)

Interventionpercentage of change (Mean)
Edoxaban-46.6
Warfarin-51.4

[back to top]

Number of Participants With Major Adverse Cardiovascular Events (MACE)

MACE is defined as a composite of non-fatal myocardial infarction (MI), non-fatal stroke, non-fatal systemic embolic event (SEE) and cardiovascular death (NCT01662908)
Timeframe: Initial dose of study drug up to 3 days after last dose

InterventionParticipants (Count of Participants)
Edoxaban2
Warfarin0

[back to top]

Safety Assessments

"Number of participants with serious adverse events (SAEs) within 6 months~Note: Based on changes to the database structure, clinically significant changes in physical or laboratory parameters are recorded as adverse events (AEs). Details of non-serious adverse events are reported at the 5% reporting threshold in the AE module, as is all-cause mortality." (NCT01802775)
Timeframe: within 6 months

InterventionParticipants (Count of Participants)
Clopidogrel30
Edoxaban31

[back to top]

Percentage of Participants With First Re-stenosis / Re-occlusion

Percentage of participants with re-stenosis/re-occlusion during treatment within 6 months - only the first occurrence of re-stenosis / re-occlusion was counted for each participant (NCT01802775)
Timeframe: within 6 months

Interventionpercentage of participants (Number)
Clopidogrel34.7
Edoxaban30.9

[back to top]

Number of Participants With Amputations

Number of participants with amputations within 6 months (NCT01802775)
Timeframe: within 6 months

InterventionParticipants (Count of Participants)
Clopidogrel3
Edoxaban1

[back to top]

Number of Adjudicated Major Adverse Cardiovascular Events During the Overall Study Period

Number of Adjudicated Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death (NCT01802775)
Timeframe: within 6 months

InterventionParticipants (Count of Participants)
Clopidogrel1
Edoxaban3

[back to top]

Percentage of Participants With Clinically Relevant Bleeding During Treatment

Percentage of participants with clinically relevant bleeding, defined as major bleeding or clinical relevant non-major bleeding, in the on-treatment period based on International Society of Thrombosis and Haemostasis (ISTH) (NCT01802775)
Timeframe: at 3 months

,
Interventionpercentage of participants (Number)
Including Access Site Bleeding (IASB)Excluding Access Site Bleed (EASB)
Clopidogrel86
Edoxaban116

[back to top]

Percentage of Participants With Major, Clinically Relevant Non-major (CRNM), and Minor Bleeding During Treatment

The percentage of participants with major, clinically relevant non-major, and minor bleeding occurring during treatment, within 3 months (NCT01802775)
Timeframe: within 3 months

,
Interventionpercentage of participants (Number)
IASB : Major BleedingIASB: CRNM BleedingIASB: Minor BleedingEASB : Major BleedingEASB : CRNM BleedingEASB : Minor Bleeding
Clopidogrel5420.84317.8
Edoxaban110201519

[back to top]

Incidence of Any Adjudicated Bleeding Events

Incidence of any adjudicated bleeding events (including major bleeding, clinically relevant non-major bleeding, and minor bleeding). (NCT01857583)
Timeframe: 14 days

Interventionpercentage of subjects with bleeds (Number)
MiRI 30mg DU 176b (50 mL/Min ≤ CLCR ≤ 80 mL/Min)33.3
SRI 15mg DU 176b (15 mL/Min ≤ CLCR < 20 mL/Min)14.3
SRI 15mg DU 176b (20 mL/Min ≤ CLCR < 30 mL/Min)22.7
Fondaparinux (20 mL/Min ≤ CLCR < 30mL/Min)40.0

[back to top]

Incidence of Any Adjudicated Bleeding Events

Incidence of any adjudicated bleeding events (including major bleeding, clinically relevant non-major bleeding, and minor bleeding) (NCT01857622)
Timeframe: 3 months

Interventionpercentage of subjects with bleeds (Number)
SRI 15mg20.0
Normal/MiRI Low-dose Group22.7
Normal/MiRI High-dose Group23.8

[back to top]

Number of Participants With Recurrent Thrombosis

Number of participants with recurrent thrombosis in cancer patients with catheter-related thrombosis treated with 1 month of anticoagulation (NCT01999179)
Timeframe: 6 months after catheter removal

InterventionParticipants (Count of Participants)
Low-molecular-weight Heparin or Direct Oral Anticoagulant0

[back to top]

PTS Assessment Completion

Percentage of participants who completed post-thrombotic syndrome assessments (NCT01999179)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Low-molecular-weight Heparin or Direct Oral Anticoagulant17

[back to top]

Biomarker Sample Collection

Number of participants that completed sample collection for biomarker analysis to predict recurrent venous thrombosis (NCT01999179)
Timeframe: 1 year

Interventionparticipants (Number)
Low-molecular-weight Heparin or Direct Oral Anticoagulant7

[back to top]

Number of Participants With Post-thrombotic Syndrome

The number of participants with post-thrombotic syndrome 6 months after catheter removal in cancer patients with catheter-related thrombosis treated with 1 month of anticoagulation (NCT01999179)
Timeframe: 6 months after catheter removal

InterventionParticipants (Count of Participants)
Low-molecular-weight Heparin or Direct Oral Anticoagulant0

[back to top]

Number of Participants With Major Bleeding

Number of participants with major bleeding in cancer patients with catheter-related thrombosis treated with 1 month of anticoagulation (NCT01999179)
Timeframe: 6 months after catheter removal

InterventionParticipants (Count of Participants)
Low-molecular-weight Heparin or Direct Oral Anticoagulant1

[back to top]

Percentage of Participants With Composite Endpoints of Stroke, SEE, MI, CV Mortality, and Major Bleeding

(NCT02072434)
Timeframe: From randomization to the end of follow-up (within 2 years)

InterventionPercentage of participants (Number)
Edoxaban0.7
Warfarin1.4

[back to top]

Percentage of Participants With Composite Endpoints of Major and Clinically-relevant Non-major (CRNM) Bleeding

(NCT02072434)
Timeframe: During treatment period (within 2 years)

InterventionPercentage of participants (Number)
Edoxaban1.5
Warfarin1

[back to top]

Percentage of Participants With Composite Endpoint of Stroke, Systemic Embolic Stroke (SEE), Myocardial Infarction (MI) and Cardiovascular (CV) Mortality From Randomization to End of Follow up

(NCT02072434)
Timeframe: Randomization to end of follow-up (within 2 years)

InterventionPercentage of participants (Number)
Edoxaban0.5
Warfarin1

[back to top]

Number of Participants With Recurrent Deep Vein Thrombosis (DVT) During the Overall Study Period

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group19
Dalteparin Group35

[back to top]

Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group67
Dalteparin Group71

[back to top]

Number of Participants With Adjudicated Major Bleeding Events While on Treatment

The primary safety endpoint was major bleeding events during the On-Treatment Study Period (defined as on-study drug or up to 3 days after the last dose of study drug). (NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group32
Dalteparin Group16

[back to top]

Number of Participants With Recurrent Non-Fatal Pulmonary Embolism (PE) During the Overall Study Period

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group21
Dalteparin Group24

[back to top]

Number of Participants With Recurrent Venous Thromboembolism (VTE) During the Overall Study Period

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group41
Dalteparin Group59

[back to top]

Number of Participants With Recurrent VTE, Major Bleed or All-Cause Death

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group235
Dalteparin Group228

[back to top] [back to top]

Pharmacodynamic Parameter Mean Anti-Factor Xa (FXa)

Descriptive statistics were used to assess Mean Anti-Factor Xa (FXa) by cohort for a total of 6 blood samplings. (NCT02303431)
Timeframe: Pre-dose and 0.25 to 1 hours (except for Cohorts 4a, 4b, 5a, and 5b, 0.5 to 2 hours), 1.5 to 3 hours, 4 to 8 hours, 9 to 14 hours, and 24 to 36 hours post-dose

,,
InterventionIU/mL (Mean)
Pre-dose: 0.25 to 1 hoursPost-dose: 0.25 to 1 hoursPre-dose: 1.5 to 3 hoursPost-dose: 1.5 to 3 hoursPre-dose: 3.5 to 6 hoursPost-dose: 3.5 to 6 hoursPre-dose: 4 to 8 hoursPost-dose: 4 to 8 hoursPre-dose: 6.5 to 8 hoursPost-dose: 6.5 to 8 hoursPre-dose: 9 to 14 hoursPost-dose: 9 to 14 hoursPre-dose: 24 to 36 hoursPost-dose: 24 to 36 hours
Cohort 1a: 30 mg Edoxaban0.10.50.11.30.10.90.11.00.10.40.10.40.10.1
Cohort 1b: 60 mg Edoxaban0.11.00.12.60.11.70.11.20.10.90.10.60.10.1
Cohort 2a: 24 mg Edoxaban0.11.80.11.30.11.40.10.80.10.80.10.30.10.1

[back to top]

Pharmacodynamic Parameter Mean Anti-Factor Xa (FXa)

Descriptive statistics were used to assess Mean Anti-Factor Xa (FXa) by cohort for a total of 6 blood samplings. (NCT02303431)
Timeframe: Pre-dose and 0.25 to 1 hours (except for Cohorts 4a, 4b, 5a, and 5b, 0.5 to 2 hours), 1.5 to 3 hours, 4 to 8 hours, 9 to 14 hours, and 24 to 36 hours post-dose

,,,
InterventionIU/mL (Mean)
Pre-dose: 0.25 to 1 hoursPost-dose: 0.25 to 1 hoursPre-dose: 1.5 to 3 hoursPost-dose: 1.5 to 3 hoursPre-dose: 4 to 8 hoursPost-dose: 4 to 8 hoursPre-dose: 9 to 14 hoursPost-dose: 9 to 14 hoursPre-dose: 24 to 36 hoursPost-dose: 24 to 36 hours
Cohort 3a: 0.7 mg/kg Edoxaban0.11.20.11.70.10.70.10.20.10.3
Cohort 3b: 1.4 mg/kg Edoxaban0.11.90.11.90.10.80.10.40.10.4
Cohort 4a: 0.75 mg/kg Edoxaban0.12.00.12.00.11.20.10.30.10.1
Cohort 2b: 45 mg Edoxaban0.11.60.11.90.11.50.10.80.10.2

[back to top]

Pharmacodynamic Parameter Mean Activated Partial Thromboplastin Time (aPTT)

Descriptive statistics were used to assess Mean Activated Partial Thromboplastin Time by cohort for a total of 6 blood samplings. (NCT02303431)
Timeframe: Pre-dose and 0.25 to 1 hours (except for Cohorts 4a, 4b, 5a, and 5b, 0.5 to 2 hours), 1.5 to 3 hours, 4 to 8 hours, 9 to 14 hours, and 24 to 36 hours post-dose

,,
Interventionseconds (Mean)
Pre-dose: 0.25 to 1 hoursPost-dose: 0.25 to 1 hours
Cohort 4b: 1.5 mg/kg Edoxaban34.946.0
Cohort 5a: 0.4 mg/kg Edoxaban41.039.5
Cohort 5b: 0.8 mg/kg Edoxaban47.752.6

[back to top]

Mean Palatability Score for the Liquid Formulation on a 100 mm Visual Analog Scale (VAS)

Overall palatability, bitterness, sweetness, and overall taste or aroma were assessed by participants (or guardians) receiving the liquid oral suspension where each subscale used a 100 mm visual analog scale (VAS), where a 0 score corresponded to a sad face and indicated a low palatability, bitter (sharp, pungent taste or smell), not sweet, and no aroma score (eg, patients not pleased; worse outcome in terms of palatability) and a 100 score corresponded to a happy face and indicated a high palatability, not bitter, very sweet, very tasty, and high aroma score (eg, patients were pleased; best outcome in terms of palatability). Patients who were old enough scored the VAS themselves. For younger children, the parents provided this information, if possible. For the youngest children, there was free text input available to provide information on whether the patient spat it out or may not have liked the flavor, etc. (NCT02303431)
Timeframe: Baseline up to 30 minutes post-dose

,,,,,,,
Interventionmm (Mean)
Overall palatabilityBitternessSweetnessOverall tasteAroma
Cohort 2a: 24 mg Edoxaban53.666.139.157.953.4
Cohort 2b: 45 mg Edoxaban63.253.254.378.257.7
Cohort 3a: 0.7 mg/kg Edoxaban55.340.665.962.658.7
Cohort 3b: 1.4 mg/kg Edoxaban83.366.781.783.375.0
Cohort 4a: 0.75 mg/kg Edoxaban77.377.586.282.884.5
Cohort 4b: 1.5 mg/kg Edoxaban73.036.376.280.572.3
Cohort 5a: 0.4 mg/kg Edoxaban67.347.068.570.873.2
Cohort 5b: 0.8 mg/kg Edoxaban83.265.786.085.274.2

[back to top]

Pharmacokinetic Parameter of Apparent Volume of Distribution (V/F)

A model-based pooled population pharmacokinetic (PK) method was used to estimate apparent volume of distribution (V/F). As prespecified in the protocol, arms were pooled due to sparse PK samples being collected. the median PK estimate is reported in all participants at a total of 5 blood samplings. (NCT02303431)
Timeframe: 0.25 to 1 hours, 1.5 to 3 hours, 4 to 8 hours, 9 to 14 hours, and 24 to 36 hours post-dose

InterventionLiters (Median)
All Participants198

[back to top]

Pharmacokinetic Parameter of Apparent Systemic Clearance (CL/F)

A model-based pooled population pharmacokinetic (PK) method was used to estimate systemic clearance (CL/F). As prespecified in the protocol, arms were pooled due to sparse PK samples being collected. the median PK estimate is reported in all participants at a total of 5 blood samplings. (NCT02303431)
Timeframe: 0.25 to 1 hours, 1.5 to 3 hours, 4 to 8 hours, 9 to 14 hours, and 24 to 36 hours post-dose

InterventionL/h (Median)
All Participants42.9

[back to top]

Pharmacodynamic Parameter Mean Activated Partial Thromboplastin Time (aPTT)

Descriptive statistics were used to assess Mean Activated Partial Thromboplastin Time by cohort for a total of 6 blood samplings. (NCT02303431)
Timeframe: Pre-dose and 0.25 to 1 hours (except for Cohorts 4a, 4b, 5a, and 5b, 0.5 to 2 hours), 1.5 to 3 hours, 4 to 8 hours, 9 to 14 hours, and 24 to 36 hours post-dose

,,,
Interventionseconds (Mean)
Pre-dose: 0.25 to 1 hoursPost-dose: 0.25 to 1 hoursPre-dose: 1.5 to 3 hoursPost-dose: 1.5 to 3 hoursPre-dose: 4 to 8 hoursPost-dose: 4 to 8 hoursPre-dose: 9 to 14 hoursPost-dose: 9 to 14 hoursPre-dose: 24 to 36 hoursPost-dose: 24 to 36 hours
Cohort 2b: 45 mg Edoxaban32.742.432.743.032.838.832.735.932.738.2
Cohort 3a: 0.7 mg/kg Edoxaban34.339.430.1038.130.136.730.133.829.932.9
Cohort 3b: 1.4 mg/kg Edoxaban40.745.340.745.540.735.740.735.140.786.1
Cohort 4a: 0.75 mg/kg Edoxaban32.945.437.440.937.435.837.435.037.432.5

[back to top]

Pharmacodynamic Parameter Mean Prothrombin Time (PT)

Descriptive statistics were used to assess Mean Prothrombin Time (PT) by cohort at a total of 6 blood samplings. (NCT02303431)
Timeframe: Pre-dose and 0.25 to 1 hours (except for Cohorts 4a, 4b, 5a, and 5b, 0.5 to 2 hours), 1.5 to 3 hours, 4 to 8 hours, 9 to 14 hours, and 24 to 36 hours post-dose

,,
Interventionseconds (Mean)
Pre-dose: 0.25 to 1 hoursPost-dose: 0.25 to 1 hours
Cohort 4b: 1.5 mg/kg Edoxaban13.826.5
Cohort 5a: 0.4 mg/kg Edoxaban16.318.3
Cohort 5b: 0.8 mg/kg Edoxaban15.321.8

[back to top]

Pharmacodynamic Parameter Mean Prothrombin Time (PT)

Descriptive statistics were used to assess Mean Prothrombin Time (PT) by cohort at a total of 6 blood samplings. (NCT02303431)
Timeframe: Pre-dose and 0.25 to 1 hours (except for Cohorts 4a, 4b, 5a, and 5b, 0.5 to 2 hours), 1.5 to 3 hours, 4 to 8 hours, 9 to 14 hours, and 24 to 36 hours post-dose

,,
Interventionseconds (Mean)
Pre-dose: 0.25 to 1 hoursPost-dose: 0.25 to 1 hoursPre-dose: 1.5 to 3 hoursPost-dose: 1.5 to 3 hoursPre-dose: 3.5 to 6 hoursPost-dose: 3.5 to 6 hoursPre-dose: 4 to 8 hoursPost-dose: 4 to 8 hoursPre-dose: 6.5 to 8 hoursPost-dose: 6.5 to 8 hoursPre-dose: 9 to 14 hoursPost-dose: 9 to 14 hoursPre-dose: 24 to 36 hoursPost-dose: 24 to 36 hours
Cohort 1a: 30 mg Edoxaban13.315.013.317.613.417.912.915.913.414.712.913.913.413.1
Cohort 1b: 60 mg Edoxaban13.517.313.523.013.620.113.417.513.616.713.415.913.513.8
Cohort 2a: 24 mg Edoxaban14.019.114.026.813.416.514.217.913.715.814.415.814.214.5

[back to top]

Pharmacodynamic Parameter Mean Activated Partial Thromboplastin Time (aPTT)

Descriptive statistics were used to assess Mean Activated Partial Thromboplastin Time by cohort for a total of 6 blood samplings. (NCT02303431)
Timeframe: Pre-dose and 0.25 to 1 hours (except for Cohorts 4a, 4b, 5a, and 5b, 0.5 to 2 hours), 1.5 to 3 hours, 4 to 8 hours, 9 to 14 hours, and 24 to 36 hours post-dose

,,
Interventionseconds (Mean)
Pre-dose: 0.25 to 1 hoursPost-dose: 0.25 to 1 hoursPre-dose: 1.5 to 3 hoursPost-dose: 1.5 to 3 hoursPre-dose: 3.5 to 6 hoursPost-dose: 3.5 to 6 hoursPre-dose: 4 to 8 hoursPost-dose: 4 to 8 hoursPre-dose: 6.5 to 8 hoursPost-dose: 6.5 to 8 hoursPre-dose: 9 to 14 hoursPost-dose: 9 to 14 hoursPre-dose: 24 to 36 hoursPost-dose: 24 to 36 hours
Cohort 1a: 30 mg Edoxaban24.126.624.127.723.826.926.224.423.826.426.223.724.424.8
Cohort 1b: 60 mg Edoxaban26.028.426.032.826.130.825.528.926.730.225.527.726.025.8
Cohort 2a: 24 mg Edoxaban33.957.934.662.532.239.033.935.532.234.535.835.332.029.0

[back to top]

Pharmacodynamic Parameter Mean Prothrombin Time (PT)

Descriptive statistics were used to assess Mean Prothrombin Time (PT) by cohort at a total of 6 blood samplings. (NCT02303431)
Timeframe: Pre-dose and 0.25 to 1 hours (except for Cohorts 4a, 4b, 5a, and 5b, 0.5 to 2 hours), 1.5 to 3 hours, 4 to 8 hours, 9 to 14 hours, and 24 to 36 hours post-dose

,,,
Interventionseconds (Mean)
Pre-dose: 0.25 to 1 hoursPost-dose: 0.25 to 1 hoursPre-dose: 1.5 to 3 hoursPost-dose: 1.5 to 3 hoursPre-dose: 4 to 8 hoursPost-dose: 4 to 8 hoursPre-dose: 9 to 14 hoursPost-dose: 9 to 14 hoursPre-dose: 24 to 36 hoursPost-dose: 24 to 36 hours
Cohort 2b: 45 mg Edoxaban13.921.314.925.313.918.014.917.713.914.5
Cohort 3a: 0.7 mg/kg Edoxaban14.618.714.721.014.717.314.716.114.715.5
Cohort 3b: 1.4 mg/kg Edoxaban13.722.013.721.313.716.113.716.013.714.9
Cohort 4a: 0.75 mg/kg Edoxaban13.621.414.320.014.317.414.316.714.314.1

[back to top]

Pharmacodynamic Parameter Mean Anti-Factor Xa (FXa)

Descriptive statistics were used to assess Mean Anti-Factor Xa (FXa) by cohort for a total of 6 blood samplings. (NCT02303431)
Timeframe: Pre-dose and 0.25 to 1 hours (except for Cohorts 4a, 4b, 5a, and 5b, 0.5 to 2 hours), 1.5 to 3 hours, 4 to 8 hours, 9 to 14 hours, and 24 to 36 hours post-dose

,,
InterventionIU/mL (Mean)
Pre-dose: 0.25 to 1 hoursPost-dose: 0.25 to 1 hours
Cohort 4b: 1.5 mg/kg Edoxaban0.52.0
Cohort 5a: 0.4 mg/kg Edoxaban0.11.1
Cohort 5b: 0.8 mg/kg Edoxaban0.41.7

[back to top]

Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 4 Months.

Difference between treatment and control ln-transformed IL-6 plasma levels in change from pre-treatment to on-treatment values (NCT02339415)
Timeframe: Through study completion, an average of 4 months on each treatment.

Interventionln-pg/mL (Mean)
Placebo-0.02
Edoxaban0.09

[back to top]

Change in D-Dimer Levels From Baseline to 4 Months

Difference between treatment and control ln-transformed D-Dimer levels in change from pre-treatment to on-treatment values (NCT02339415)
Timeframe: Through study completion, an average of 4 months on each treatment.

Interventionln-μg/mL (Mean)
Placebo-0.13
Edoxaban-0.66

[back to top]

Safety (Bleeding Events)

Number of bleeding events on Edoxaban or Placebo. (NCT02339415)
Timeframe: 4 months while on Edoxaban or Placebo

,
Interventionevent (Number)
EpistaxisBruisingBleeding gumsBloody stoolHematuriaLaceration
Receiving Edoxaban8710415
Receiving Placebo253302

[back to top]

Major Bleeding

Major local or systemic bleeding as defined in the protocol at 30 days after implant procedure (NCT02561897)
Timeframe: Within 30 days of procedure

InterventionParticipants (Count of Participants)
Warfarin1
Edoxaban0

[back to top]

Thromboembolic and Cardiovascular Events

Thrombotic events (embolism or stroke) through 6 months following the procedure in the Edoxaban and Warfarin groups and the rates of MACE events through 6 months following the procedure in the Edoxaban and Warfarin groups (NCT02561897)
Timeframe: Within 6 months of procedure

InterventionParticipants (Count of Participants)
Warfarin0
Edoxaban0

[back to top]

Number of Participants With Cardiac Tamponade

Cardiac tamponade is a medical emergency that takes place when abnormal amounts of fluid accumulate in the pericardial sac compressing the heart and leading to a decrease in cardiac output and shock. (NCT02666742)
Timeframe: Day 30

InterventionParticipants (Count of Participants)
DOAC4
Aspirin3

[back to top]

Number of Participants With Transient Ischemic Attack

Transient ischemic attack(TIA) - defined as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. (NCT02666742)
Timeframe: First 30 days of post ablation

Interventionparticipants (Number)
DOAC6
Aspirin22

[back to top]

Number of Participants With Fatal Pulmonary Embolism

A pulmonary embolism is a blood clot in the lung that occurs when a clot in another part of the body (often the leg or arm) moves through the bloodstream and becomes lodged in the blood vessels of the lung. This restricts blood flow to the lungs, lowers oxygen levels in the lungs and increases blood pressure in the pulmonary arteries. (NCT02666742)
Timeframe: Day 30

InterventionParticipants (Count of Participants)
DOAC0
Aspirin1

[back to top]

Number of Participants With Asymptomatic Cerebral Event on MRI - 30 Days

MRI detected asymptomatic cerebrovascular events (ACE) at 30 days follow-up. (NCT02666742)
Timeframe: 24 Hours to 30 days of post ablation

InterventionParticipants (Count of Participants)
DOAC8
Aspirin22

[back to top]

Number of Participants With Asymptomatic Cerebral Event on MRI - 24 Hours

MRI detected asymptomatic cerebrovascular events (ACE) at 24 hours. (NCT02666742)
Timeframe: 24 Hours post ablation

InterventionParticipants (Count of Participants)
DOAC15
Aspirin28

[back to top] [back to top]

Number of Participants With Stroke

Stroke - incidence of ischemic stroke - defined as an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction. (NCT02666742)
Timeframe: First 30 days of post ablation

InterventionParticipants (Count of Participants)
DOAC0
Aspirin8

[back to top]

Number of Participants With Groin Hematoma

A hematoma is a collection of blood outside of a blood vessel. (NCT02666742)
Timeframe: Day 30

InterventionParticipants (Count of Participants)
DOAC3
Aspirin4

[back to top]

Number of Participants With Heart Block

Heart block is a type of heart rhythm disorder (arrhythmia). It is the slowing down or interruption of the electrical signal from the upper chambers of the heart (the atria) to the lower chambers (the ventricles). The electrical signal causes the heart muscle to contract and the heart to beat. (NCT02666742)
Timeframe: Day 30

InterventionParticipants (Count of Participants)
DOAC2
Aspirin3

[back to top]

Number of Participants With In-hospital Mortality

Death occurring during the hospital stay. (NCT02666742)
Timeframe: Day 30

InterventionParticipants (Count of Participants)
DOAC5
Aspirin3

[back to top]

Number of Participants With Progressive Heart Failure and Electromechanical Dissociation (EMD)

Heart failure means that the heart isn't pumping as well as it should be. (NCT02666742)
Timeframe: Day 30

InterventionParticipants (Count of Participants)
DOAC4
Aspirin4

[back to top]

Number of Participants With Retroperitoneal Bleed

Retroperitoneal bleeding occurs when blood enters into space immediately behind the posterior reflection of the abdominal peritoneum. The organs of this space include the esophagus, aorta, inferior vena cava, kidneys, ureters, adrenals, rectum, parts of the duodenum, parts of the pancreas, and parts of the colon. (NCT02666742)
Timeframe: Day 30

InterventionParticipants (Count of Participants)
DOAC2
Aspirin2

[back to top]

Benefit of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire

To compare the benefit of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 3 months. The benefits scale has 3 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS benefits tool is then scored using the totals from each question with a total score from 3 to 15 possible. Higher scores signify greater satisfaction (greater benefits). (NCT02744092)
Timeframe: 3-months

Interventionscore on a scale (Mean)
Randomized Arm 1 (DOACs)11.2
Randomized Arm 2 (LMWH)10.7
Preference Cohort 1 (DOACs)10.3
Preference Cohort 2 (LMWH)10.5

[back to top]

Benefit of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire

To compare the benefit of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 6 months. The benefits scale has 3 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS benefits tool is then scored using the totals from each question with a total score from 3 to 15 possible. Higher scores signify greater satisfaction (greater benefits). (NCT02744092)
Timeframe: 6-months

Interventionscore on a scale (Mean)
Randomized Arm 1 (DOACs)11.6
Randomized Arm 2 (LMWH)11.3
Preference Cohort 1 (DOACs)11.5
Preference Cohort 2 (LMWH)10.1

[back to top]

Burden of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire

To compare the burden of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 3 months. The burden scale has12 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS burden tool is then scored using the totals from each question with a total score from 12 to 60 possible. Higher scores signify greater satisfaction (lower burden). (NCT02744092)
Timeframe: 3 months

Interventionscore on a scale (Mean)
Randomized Arm 1 (DOACs)56.7
Randomized Arm 2 (LMWH)53.3
Preference Cohort 1 (DOACs)55.8
Preference Cohort 2 (LMWH)54.9

[back to top]

Burden of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire

To compare the burden of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 6 months. The burden scale has12 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS burden tool is then scored using the totals from each question with a total score from 12 to 60 possible. Higher scores signify greater satisfaction (lower burden). (NCT02744092)
Timeframe: 6 months

Interventionscore on a scale (Mean)
Randomized Arm 1 (DOACs)56.5
Randomized Arm 2 (LMWH)54.1
Preference Cohort 1 (DOACs)54.9
Preference Cohort 2 (LMWH)53.1

[back to top]

Cumulative Non-Fatal VTE Recurrence at 6 Months (%)

To compare the effectiveness of anticoagulation with a DOAC (intervention) with LMWH/warfarin (comparator) for preventing VTE recurrence in patients with cancer based on cumulative VTE recurrence reported by patients or clinicians at 6 months. Only VTEs that were nonfatal were considered because of the challenges of attributing cause of death in cancer patients to tumor progression vs. VTE. (NCT02744092)
Timeframe: 6 months

Interventionpercentage of patients (Number)
Randomized Arm 1 (DOACs)6.1
Randomized Arm 2 (LMWH)8.8
Preference Cohort 1 (DOACs)7.5
Preference Cohort 2 (LMWH)4.1

[back to top]

Cumulative Rates of Major Bleeding

To compare the harms of DOAC vs. LMWH/warfarin therapy for cancer patients with VTE based on the cumulative rate of major bleeding at 6 months. d. Major bleeding was defined as Grade >=3 on the Common Terminology Criteria for Adverse Events from the National Cancer Institute (NCI CTCAE) criteria version 5.0 (i.e., severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living). (NCT02744092)
Timeframe: 6 months

Interventionpercentage of patients (Number)
Randomized Arm 1 (DOACs)5.2
Randomized Arm 2 (LMWH)5.6
Preference Cohort 1 (DOACs)11.5
Preference Cohort 2 (LMWH)7.6

[back to top] [back to top] [back to top] [back to top] [back to top]

Mortality Reported by Participants' Surrogates (Via Study-specific Questionnaire) or Clinicians (Via Study-specific Case Report Form)

To compare the impact of DOAC vs. LMWH/warfarin therapy on mortality in cancer patients with VTE based on survival at 6 months. Mortality was reported by participants' surrogates (via study-specific questionnaire) or clinicians (via study-specific case report form) (NCT02744092)
Timeframe: 6 months

Interventionpercentage of patients (Number)
Randomized Arm 1 (DOACs)21.5
Randomized Arm 2 (LMWH)18.4
Preference Cohort 1 (DOACs)16.3
Preference Cohort 2 (LMWH)23.8

[back to top]

Number of Participants With All Bleeding Events (On Treatment) During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

All bleeding events included major bleeding defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells (RBCs), clinically relevant non-major bleeding defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug), nuisance bleeding, or a combination of bleeding events. (NCT02798471)
Timeframe: From randomization up to Month 12

InterventionParticipants (Count of Participants)
Edoxaban25
Standard of Care24

[back to top]

Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events (On Treatment) During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

Any bleeding event defined as major and clinically relevant non-major bleeding (CRNM) events was reported. Major bleeding was defined as defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells. CRNM was defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug). (NCT02798471)
Timeframe: Randomization to Month 3

InterventionParticipants (Count of Participants)
Edoxaban3
Standard of Care5

[back to top]

Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events (On Treatment) During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

Any bleeding event defined as major and clinically relevant non-major bleeding (CRNM) events was reported. Major bleeding was defined as defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells. CRNM was defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug). (NCT02798471)
Timeframe: From randomization up to Month 12

InterventionParticipants (Count of Participants)
Edoxaban8
Standard of Care5

[back to top]

Number of Participants With No Change or Extension of Thrombotic Burden During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

No change or extension of thrombotic burden as assessed by quantitative diagnostic imaging of the index qualifying VTE thrombus at baseline and at Month 3. Imaging criteria for VTE included: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: Randomization to Month 3

InterventionParticipants (Count of Participants)
Edoxaban21
Standard of Care29

[back to top]

Number of Participants With No Change or Extension of Thrombotic Burden During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

No change or extension of thrombotic burden as assessed by quantitative diagnostic imaging of the index qualifying VTE thrombus. Imaging criteria for VTE included: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: From randomization up to Month 12

InterventionParticipants (Count of Participants)
Edoxaban35
Standard of Care47

[back to top]

Number of Participants With Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: Randomization to Month 3

InterventionParticipants (Count of Participants)
Edoxaban5
Standard of Care2

[back to top]

Number of Participants With Symptomatic Recurrent Venous Thromboembolism During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: From randomization up to Month 12

InterventionParticipants (Count of Participants)
Edoxaban7
Standard of Care2

[back to top]

Number of Participants Reporting Adjudicated All-Cause Mortality During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated)

All-cause mortality is defined as death due to any cause. Adjudicated data are reported for overall all-cause mortality, all-cause mortality by the primary cause of death, and primary cause of death further described by additional specifications. (NCT02798471)
Timeframe: From randomization up to Month 12

,
InterventionParticipants (Count of Participants)
Participants with adjudicated all-cause mortalityVenous thromboembolism (VTE)-related deathVenous thromboembolism (VTE)-related death: Unexplained death which VTE cannot be ruled outOther known causes of deathOther known causes of death: CancerOther known causes of death: Infectious diseaseOther known causes of death: Other
Edoxaban2111001
Standard of Care3112110

[back to top]

Number of Participants Who Died as a Result of VTE During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: Randomization to Month 3

,
InterventionParticipants (Count of Participants)
Pulmonary embolism (PE) with or without deep vein thrombosis (DVT)Fatal PENon-fatal PEDeep vein thrombosis (DVT) onlyFatal DVTNon-fatal DVTUnexplained death which VTE cannot be ruled out
Edoxaban0005041
Standard of Care1011001

[back to top]

Number of Participants Who Died as a Result of VTE During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Individual Component of Primary Efficacy Endpoint)

Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: Randomization to Month 3

,
InterventionParticipants (Count of Participants)
Death as a result of VTEUnexplained death which VTE cannot be ruled out
Edoxaban11
Standard of Care11

[back to top]

Number of Participants Who Died as a Result of VTE During the Overall Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)

Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: From randomization up to Month 12

,
InterventionParticipants (Count of Participants)
Pulmonary embolism (PE) with or without deep vein thrombosis (DVT)Fatal PENon-fatal PEDeep vein thrombosis (DVT) onlyFatal DVTNon-fatal DVTUnexplained death which VTE cannot be ruled out
Edoxaban1016051
Standard of Care1011001

[back to top]

Number of Participants With Adjudicated Individual Component of Primary Efficacy Endpoints During the Main Treatment Period Following Edoxaban or Standard of Care Treatment

Diagnosis of recurrent VTE requires the confirmation imaging and ≥1 symptom of VTE. Death from VTE is based on diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. No change or extension of thrombotic burden (quantitative diagnostic imaging) of the index qualifying VTE thrombus. Imaging criteria for VTE: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: Randomization to Month 3

,
InterventionParticipants (Count of Participants)
Symptomatic recurrent VTEPE with or without DVTDVT onlyDeath as a result of VTEUnexplained death which VTE cannot be ruled outNo change or extension of thrombotic burden
Edoxaban4041121
Standard of Care1101129

[back to top] [back to top]

Number of Participants With Symptomatic Recurrent VTE During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Individual Component of Primary Efficacy Endpoint)

Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: Randomization to Month 3

,
InterventionParticipants (Count of Participants)
Symptomatic VTEPulmonary embolism (PE) with or without deep vein thrombosis (DVT)Deep vein thrombosis (DVT) only
Edoxaban404
Standard of Care110

[back to top]

Number of Participants With Major Bleeding or Clinically Relevant Non-major Bleedings During On-Treatment Period in Participants Who Were Administered DU-176b Compared With Placebo

Major bleeding was defined as overt bleeding that met at least 1 of the following criteria: fatal bleeding; retroperitoneal, intracranial, intraocular, intrathecal, intraarticular, or pericardial bleeding, or symptomatic intramuscular bleeding accompanied by compartment syndrome; or clinically overt bleeding that decreased hemoglobin by at least 2.0 g/dL and required blood transfusion. Clinically overt bleeding that required treatment was taken to be clinically relevant non-major bleeding, including for example (but was not limited to) the bleeding that led to the diagnostic tests and treatments as specified in the protocol. The clinically overt bleeding requiring treatment did not include outpatient examinations that did not involve any of the medical procedures (diagnostic tests or treatments) as specified in the protocol. (NCT02801669)
Timeframe: Baseline up to study discontinuation or end of study (whichever comes first), up to 3 years 2 months postdose (maximum follow-up time)

,
InterventionParticipants (Count of Participants)
Major or clinically relevant non-major bleedingClinically relevant non-major bleeding
DU-176b 15 mg9781
Placebo6252

[back to top]

Number of Participants With All Bleeding Events and Minor Bleeding Events During On-Treatment Period in Participants Who Were Administered DU-176b Compared With Placebo

"All bleeding events include major and clinically relevant non-major bleeding events.~Other overt bleeding events that did not meet the criteria for major bleeding or clinically relevant non-major bleeding were taken to be minor bleeding (for example, epistaxis that did not require treatment). All events other than the above (such as a decrease in hemoglobin without overt bleeding) were classified as non-bleeding event." (NCT02801669)
Timeframe: Baseline up to study discontinuation or end of study (whichever comes first), up to 3 years 2 months postdose (maximum follow-up time)

,
InterventionParticipants (Count of Participants)
All bleedingMinor bleeding
DU-176b 15 mg241190
Placebo202177

[back to top]

Number of Participants With Net Clinical Benefit in Participants Who Were Administered DU-176b Compared With Placebo

Net clinical benefit included a composite of stroke, systemic embolic events (SEE), major bleeding, and all-cause mortality. Stroke was defined as an abrupt onset of symptoms representing focal neurological deficit in the domain supplied by a single brain artery that was not due to an identifiable non-vascular cause. The deficit symptoms had to either last >24 hours or result in death within 24 hours of symptom onset. A SEE was defined as an abrupt episode of arterial insufficiency associated with clinical or radiologic evidence of arterial occlusion in the absence of other likely mechanisms. Major bleeding was defined as overt bleeding that met at least 1 of the following criteria: fatal bleeding; retroperitoneal, intracranial, intraocular, intrathecal, intraarticular, or pericardial bleeding, or symptomatic intramuscular bleeding accompanied by compartment syndrome; or clinically overt bleeding that decreased hemoglobin by at least 2.0 g/dL and required blood transfusion. (NCT02801669)
Timeframe: Randomization up to the time of onset of the initial composite event of stroke, SEE, major bleeding, all-cause mortality, or study discontinuation, or end of study (whichever comes first), up to 3 years 2 months postdose (maximum follow-up time)

InterventionParticipants (Count of Participants)
DU-176b 15 mg87
Placebo103

[back to top]

Number of Participants With All-Cause Mortality in Participants Who Were Administered DU-176b Compared With Placebo

All-cause mortality was defined as death due to cardiovascular and mortality due to all other causes. (NCT02801669)
Timeframe: Randomization up to death (due to any cause), or study discontinuation, or end of study (whichever comes first), up to 3 years 2 months postdose (maximum follow-up time)

InterventionParticipants (Count of Participants)
DU-176b 15 mg66
Placebo69

[back to top]

Number of Participants With a Composite Endpoint of Stroke, Systemic Embolic Events (SEE), and Death Due to Cardiovascular in Participants Who Were Administered DU-176b Compared With Placebo

"Stroke was defined as an abrupt onset, over minutes to hours, of symptoms representing focal neurological deficit in the domain supplied by a single brain artery (including the retinal artery) and that was not due to an identifiable non-vascular cause (such as brain tumor or trauma). The deficit symptoms had to either last for more than 24 hours or result in death within 24 hours of symptom onset.~A systemic embolic event (SEE) was defined as an abrupt episode of arterial insufficiency associated with clinical or radiologic evidence of arterial occlusion in the absence of other likely mechanisms (eg, atherosclerosis and instrumentation)." (NCT02801669)
Timeframe: Randomization up to the time of onset of the initial composite event of stroke, systemic embolic event, or death due to CV, or study discontinuation, or end of study (whichever comes first), up to 3 years 2 months postdose (maximum follow-up time)

InterventionParticipants (Count of Participants)
DU-176b 15 mg52
Placebo72

[back to top]

Number of Participants With a Composite Endpoint of Stroke, Systemic Embolic Events (SEE), and All-Cause Mortality in Participants Who Were Administered DU-176b Compared With Placebo

"Stroke was defined as an abrupt onset, over minutes to hours, of symptoms representing focal neurological deficit in the domain supplied by a single brain artery (including the retinal artery) and that was not due to an identifiable non-vascular cause (such as brain tumor or trauma). The deficit symptoms had to either last for more than 24 hours or result in death within 24 hours of symptom onset.~A systemic embolic event (SEE) was defined as an abrupt episode of arterial insufficiency associated with clinical or radiologic evidence of arterial occlusion in the absence of other likely mechanisms (eg, atherosclerosis and instrumentation).~All-cause mortality was defined as death due to cardiovascular and mortality due to all other causes." (NCT02801669)
Timeframe: Randomization up to the time of onset of the initial composite event of stroke, SEE, all-cause mortality, or study discontinuation, or end of study (whichever comes first), up to 3 years 2 months postdose (maximum follow-up time)

InterventionParticipants (Count of Participants)
DU-176b 15 mg74
Placebo98

[back to top]

Number of Participants With a Composite Endpoint of Stroke and Systemic Embolic Events (SEE) in Participants Who Were Administered DU-176b Compared With Placebo

"Stroke was defined as an abrupt onset, over minutes to hours, of symptoms representing focal neurological deficit in the domain supplied by a single brain artery (including the retinal artery) and that was not due to an identifiable non-vascular cause (such as brain tumor or trauma). The deficit symptoms had to either last for more than 24 hours or result in death within 24 hours of symptom onset.~A systemic embolic event (SEE) was defined as an abrupt episode of arterial insufficiency associated with clinical or radiologic evidence of arterial occlusion in the absence of other likely mechanisms (eg, atherosclerosis and instrumentation)." (NCT02801669)
Timeframe: Randomization up to the time of onset of the initial composite event of stroke or systemic embolic event, or study discontinuation, or end of study (whichever comes first), up to 3 years 2 months postdose (maximum follow-up time)

InterventionParticipants (Count of Participants)
DU-176b 15 mg15
Placebo44

[back to top]

Plasma Concentration of DU-176 in Participants Who Were Administered DU-176b

(NCT02801669)
Timeframe: Week 8: Predose,1-3 hours (h) and 4-8 h postdose

Interventionng/mL (Mean)
Week 8: Predose (trough)Week 8: 1-3 hWeek 8: 4-8 h
DU-176b 15 mg17.393.393.4

[back to top]

Number of Participants With a Composite Endpoint of a Major Adverse Cardiovascular Event (MACE) in Participants Who Were Administered DU-176b Compared With Placebo

"Major adverse cardiovascular events (MACE) included a composite of non-fatal myocardial infarction (MI), non-fatal stroke, non-fatal systemic embolic events (SEE), and deaths due to cardiovascular (CV) or bleeding.~Stroke was defined as an abrupt onset, over minutes to hours, of symptoms representing focal neurological deficit in the domain supplied by a single brain artery (including the retinal artery) and that was not due to an identifiable non-vascular cause (such as brain tumor or trauma). The deficit symptoms had to either last for more than 24 hours or result in death within 24 hours of symptom onset.~A SEE was defined as an abrupt episode of arterial insufficiency associated with clinical or radiologic evidence of arterial occlusion in the absence of other likely mechanisms (eg, atherosclerosis and instrumentation)." (NCT02801669)
Timeframe: Randomization up to the time of onset of the initial MACE event, or study discontinuation, or end of study (whichever comes first), up to 3 years 2 months postdose (maximum follow-up time)

InterventionParticipants (Count of Participants)
DU-176b 15 mg51
Placebo72

[back to top]

Number of Participants With Stroke and Systemic Embolic Events (SEE), Including Subcomponents of Stroke and Composite Event of Ischemic Stroke and SEE in Participants Who Were Administered DU-176b Compared With Placebo

"Stroke was defined as an abrupt onset, over minutes to hours, of symptoms representing focal neurological deficit in the domain supplied by a single brain artery (including the retinal artery) and that was not due to an identifiable non-vascular cause (such as brain tumor or trauma). The deficit symptoms had to either last for more than 24 hours or result in death within 24 hours of symptom onset. Subcomponents of stroke (ischemic and hemorrhagic) were also reported.~A systemic embolic event (SEE) was defined as an abrupt episode of arterial insufficiency associated with clinical or radiologic evidence of arterial occlusion in the absence of other likely mechanisms (eg, atherosclerosis and instrumentation)." (NCT02801669)
Timeframe: Randomization up to the time of onset of the initial composite event of stroke or systemic embolic event, or study discontinuation, or end of study (whichever comes first), up to 3 years 2 months postdose (maximum follow-up time)

,
InterventionParticipants (Count of Participants)
StrokeSystemic Embolic Events (SEE)Ischaemic StrokeHemorrhagic StrokeIschemic Stroke/SEE
DU-176b 15 mg12312015
Placebo40639243

[back to top]

Number of Participants With Major Bleeding During On-Treatment Period in Participants Who Were Administered DU-176b Compared With Placebo

Major bleeding was defined as overt bleeding that met at least 1 of the following criteria: fatal bleeding; retroperitoneal, intracranial, intraocular, intrathecal, intraarticular, or pericardial bleeding, or symptomatic intramuscular bleeding accompanied by compartment syndrome; or clinically overt bleeding that decreased hemoglobin by at least 2.0 g/dL and required blood transfusion. (NCT02801669)
Timeframe: Baseline up to study discontinuation or end of study (whichever comes first), up to 3 years 2 months postdose (maximum follow-up time)

,
InterventionParticipants (Count of Participants)
Major bleedingMajor bleeding, Intracranial haemorrhageFatal bleedingFatal bleeding, Intracranial haemorrhageFatal bleeding, Non-Intracranial haemorrhageLife-threatening bleeding
DU-176b 15 mg2020008
Placebo1142114

[back to top]

Number of Participants With Main Efficacy Endpoints For the Overall Study Period Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen

The main efficacy endpoints were defined as the composite of cardiovascular death (ARC), stroke (protocol defined), systemic embolic event (SEE), myocardial infarction (MI), or definite stent thrombosis. (NCT02866175)
Timeframe: Day 1 to 12 months postdose

,
InterventionParticipants (Count of Participants)
Composite MEE eventCardiovascular death (ARC)Stroke (Protocol definition)Systemic Embolic EventMyocardial infarctionDefinite stent thrombosis
Edoxaban Regimen4910100227
Vitamin K Antagonist Regimen4612110185

[back to top] [back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAEs) Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen

Treatment-emergent adverse events (TEAEs) in >1.0% of participants were defined as events which started on or after first dose of the assigned study drug (edoxaban and VKA) or started prior to but then worsened after the first dose of the assigned study drug. (NCT02866175)
Timeframe: Day 1 to 30 days after the last dose

,
InterventionParticipants (Count of Participants)
Any TEAEInfections and InfestationsNasopharyngitisPneumoniaBronchitisUrinary tract infectionRespiratory tract infectionInfluenzaCardiac DisordersCardiac failureAtrial fibrillationBradycardiaCardiac failure congestiveVentricular extrasystolesTachycardiaGeneral Disorders & Administration Site ConditionNon-cardiac chest painOedema peripheralAstheniaChest painFatigueGastrointestinal DisordersDiarrhoeaConstipationAbdominal pain upperGastritisNauseaDyspepsiaRespiratory,Thoracic, and Mediastinal DisordersDyspnoeaCoughDyspnoea exertionalChronic obstructive pulmonary diseaseMusculoskeletal and Connective Tissue DisordersBack painArthralgiaPain in extremityMyalgiaOsteoarthritisInvestigationsBlood creatinine increasedAlanine aminotransferase increasedBlood pressure increasedCreatinine renal clearance decreasedAspartate aminotransferase increasedInternational normalised ratio increasedNervous System DisordersDizzinessHeadacheSyncopeVascular DisordersHypertensionHypotensionHypertensive crisisRenal and Urinary DisordersRenal failureAcute kidney injuryRenal impairmentInjury, Poisoning, and Procedural ComplicationsFallSkin and Subcutaneous Tissue DisordersPruritusRashMetabolism and Nutrition DisordersGoutBlood and Lymphatic System DisordersAnaemiaPsychiatric DisorderInsomniaEar and Labyrinth DisordersVertigo
Edoxaban Regimen4571452520191412101364039108711113303121711110231169888722211866914115897015812127083301985523141149118744855121042114119238128
Vitamin K Antagonist Regimen44714022222019157134474178839824221411683197105537226115108314121385791313871112652212662231485512138441233794243520208165

[back to top]

Number of Participants With Adjudicated Major or Clinically Relevant Non-major Bleeding As First Event Defined by International Society on Thrombosis and Haemostasis Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen

Participants' first major or clinically relevant non-major bleeding (MCRB) events were reported. International Society on Thrombosis and Hemostasis (ISTH) defined bleeding events included: MCRB, major bleeding, including fatal bleeding (intracranial and non-intracranial), symptomatic intracranial hemorrhage, symptomatic bleeding in a critical area or organ, and clinically overt and causing ≥2.0 g/dL adjusted hemoglobin loss, clinically relevant non-major (CRNM) bleeding, minor bleedings, any bleeding (defined as the composite of major, CRNM, and minor bleeding), life-threatening bleeding, provoked (spontaneous, instrumental/traumatic, unknown) bleeding, and spontaneous bleeding. (NCT02866175)
Timeframe: Day 1 to 12 months postdose

,
InterventionParticipants (Count of Participants)
Composite MCRBMajor bleedingClinically relevant non-major bleeding
Edoxaban Regimen1283989
Vitamin K Antagonist Regimen15244108

[back to top]

Number of Participants With Adjudicated Major, Clinically Relevant Non-major and Minor Bleeding (All Events) Defined by International Society on Thrombosis and Haemostasis Following Edoxaban-based Regimen Compared With Vitamin K Antagonist-Based Regimen

All major, clinically relevant non-major and minor bleeding are reported for the secondary outcome. Participants may have experiences more than 1 bleeding event, all occurrences are reported. Participants with International Society on Thrombosis and Hemostasis (ISTH) defined bleeding events included: major or clinically relevant non-major bleeding (MCRB), major bleeding, including fatal bleeding (intracranial and non-intracranial), symptomatic intracranial hemorrhage, symptomatic bleeding in a critical area or organ, and clinically overt and causing ≥2.0 g/dL adjusted hemoglobin loss, clinically relevant non-major (CRNM) bleeding, minor bleedings, any bleeding (defined as the composite of major, CRNM, and minor bleeding), life-threatening bleeding, provoked (spontaneous, instrumental/traumatic, unknown) bleeding, and spontaneous bleeding. (NCT02866175)
Timeframe: Day 1 to 12 months postdose

,
InterventionParticipants (Count of Participants)
Major bleedingClinically relevant non-major bleedingMinor bleedingSymptomatic intracranial hemorrhageFatal major bleedingFatal intracranial hemorrhageLife-threatening bleedingSpontaneous bleeding
Edoxaban Regimen45971164105184
Vitamin K Antagonist Regimen481141259748210

[back to top]

Number of Participants With Adjudicated Major, Minor, and Minimal Bleeding by Thrombolysis in Myocardial Infarction (TIMI) Definition Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen

Thrombolysis in Myocardial Infarction (TIMI) defined bleeding events included: Major bleeding (including fatal bleeding and non-fatal bleeding [fulfilling the TIMI major bleeding definition], major or minor bleeding, minor bleeding, minimal bleeding, and any bleeding (defined as composite of major, minor, and minimal bleeding) (NCT02866175)
Timeframe: Day 1 to 12 months postdose

,
InterventionParticipants (Count of Participants)
Major bleedingFatal bleedingMajor or minor bleedingMinor bleedingMinimal bleeding
Edoxaban Regimen151124113117
Vitamin K Antagonist Regimen244144126131

[back to top]

Number of Participants With Bleeding Academic Research Consortium (BARC) Type 1, 2, 3, and 5 Bleeding According to the BARC Definitions Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen

"Bleeding Academic Research Consortium (BARC) bleeding events included: Bleeding (defined by BARC type 3 or 5), bleeding (defined by BARC type 2, 3, or 5), and any bleeding (defined as the composite of BARC type 1, 2, 3, or 5), where increases in BARC type indicate worse outcome.~Type 1: bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consultation; Type 2: any overt, actionable sign of hemorrhage that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) requiring nonsurgical, medical intervention, (2) leading to hospitalization or increased level of care, or (3) prompting evaluation; Type 3: Overt bleeding plus hemoglobin drop of 3 to ≤5 g/dL (3a), ≥5 g/dl (3b), and intracranial hemorrhage (3c) Type 5: Fatal bleeding" (NCT02866175)
Timeframe: Day 1 to 12 months postdose

,
InterventionParticipants (Count of Participants)
Bleeding (BARC Type 3 or 5)Bleeding (BARC Type 2, 3, or 5)Bleeding (BARC Type 1, 2, 3, or 5)
Edoxaban Regimen36124207
Vitamin K Antagonist Regimen42144242

[back to top]

Number of Participants Who Experienced the Composite of All-cause Death, Stroke (Alternative), and Major Bleeding (ISTH) in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)

"An alternative definition characterized stroke (ischemic, hemorrhagic, or undetermined) as an abrupt onset, over minutes to hours, of a focal neurological deficit in the distribution of a single brain artery that was not due to an identifiable nonvascular cause (ie, brain tumor or trauma), and that either lasted at least 24 hours or resulted in death within 24 hours of onset.~Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability." (NCT02942576)
Timeframe: Day 1 to Day 90

InterventionParticipants (Count of Participants)
Edoxaban-based Regimen1
VKA-based Regimen2

[back to top]

Number of Participants Who Experienced Major Bleeding (International Society on Thrombosis and Hemostasis [ISTH]) in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)

Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability. (NCT02942576)
Timeframe: Day 1 to Day 90

InterventionParticipants (Count of Participants)
Edoxaban-based Regimen10
VKA-based Regimen3

[back to top]

Number of Participants Who Experienced the Composite of All-cause Death, Stroke (VARC-2), and Major Bleeding (ISTH) in the Edoxaban Group Compared With Vitamin K Antagonist (VKA) Group in Participants Undergoing Catheter Ablation (Adjudicated Data)

"Stroke (ischemic, hemorrhagic, or undetermined) was defined by Valve Academic Research Consortium-2 (VARC-2) as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury following hemorrhage or infarction. A stroke event was based on any of the following: duration of neurological dysfunction >24 hours (h), duration of neurological dysfunction <24 h in case of imaging-documented new hemorrhage or infarction, and a neurological dysfunction resulting in death.~Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability." (NCT02942576)
Timeframe: Day 1 to Day 90

InterventionParticipants (Count of Participants)
Edoxaban-based Regimen1
VKA-based Regimen2

[back to top]

Number of Participants Who Experienced the Composite of Stroke (VARC-2), Systemic Embolic Events (SEE), and Cardiovascular (CV) Mortality in the Edoxaban Group Compared With VKA Group Among Participants Undergoing Catheter Ablation (Adjudicated Data)

"Stroke (ischemic, hemorrhagic, or undetermined) was defined by Valve Academic Research Consortium-2 (VARC-2) as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury following hemorrhage or infarction. A stroke event was based on any of the following: duration of neurological dysfunction >24 hours (h), duration of neurological dysfunction <24 h in case of imaging-documented new hemorrhage or infarction, and a neurological dysfunction resulting in death.~SEE was defined as an arterial embolism resulting in clinical ischemia, excluding the central nervous system, coronary, and pulmonary arterial circulation.~CV mortality was defined as cardiac or vascular death according to Academic Research Consortium." (NCT02942576)
Timeframe: Day 1 to Day 90

InterventionParticipants (Count of Participants)
Edoxaban-based Regimen1
VKA-based Regimen0

[back to top]

Number of Participants Who Experienced Major Bleeding (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA

ISTH Bleeding Criteria for Major Bleeding are defined as clinically overt bleeding that is associated with: a fall in hemoglobin of 2 g/dL (1.24 mmol/L) or more, or a transfusion of 2 or more units of whole blood or packed red blood cells, or symptomatic bleeding into a critical site or organ such as intracranial, intraspinal, intraocular, retroperitoneal, pericardial, intra-articular, or intramuscular with compartment syndrome, or a fatal outcome. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose

InterventionParticipants (Count of Participants)
Edoxaban98
Vitamin K Antagonist (VKA)68

[back to top]

Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on TIMI Criteria in Participants Taking Edoxaban vs VKA

The composite endpoint of net adverse event clinical events (NACE) included all-cause death, myocardial infarction (MI), ischemic stroke, systemic embolic events (SEE), valve thrombosis, and major bleeding based on Thrombolysis in Myocardial Infarction (TIMI) criteria. Bleeding by TIMI criteria was defined as the following: (1) Major, any intracranial hemorrhage or any clinically overt bleeding, (including bleeding evident in imaging studies) associated with a fall of hemoglobin (Hb) of ≥ 5g/dL or fatal bleeding and (2) Minor, any clinically overt bleeding associated with a fall in Hb ≥ 3g/dL but < 5 g/dL. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose

,
InterventionParticipants (Count of Participants)
Composite endpoint NACE (TIMI)Composite of major and minor bleeding (TIMI)
Edoxaban15472
Vitamin K Antagonist (VKA)14142

[back to top]

Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on GUSTO Criteria in Participants Taking Edoxaban vs VKA

The composite endpoint of net adverse event clinical events (NACE) included all-cause death, MI, ischemic stroke, SEE, valve thrombosis, and major bleeding based on Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO). GUSTO criteria was defined as the following: severe or life threatening: intracerebral hemorrhage or resulting in substantial hemodynamic compromise requiring treatment and moderate: requiring blood transfusion but not resulting in hemodynamic compromise. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose

,
InterventionParticipants (Count of Participants)
Composite endpoint NACE (GUSTO)Severe or life threatening and moderate bleeding (GUSTO)
Edoxaban16082
Vitamin K Antagonist (VKA)14651

[back to top]

Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on BARC Type 3 or 5 Criteria in Participants Taking Edoxaban vs VKA

The composite endpoint of net adverse event clinical events (NACE) included all-cause death, MI, ischemic stroke, SEE, valve thrombosis, and major bleeding based on Bleeding Academic Research Consortium (BARC) Type 3 or 5 criteria. Major bleeding by BARC criteria was defined as Type 3: clinical, laboratory, and/or imaging evidence of bleeding with provider responses; Type 3a: any transfusion with overt bleeding; overt bleeding plus Hb drop of 3 to < 5 g/dL; Type 3b: overt bleeding plus Hb drop ≥ 5 g/dL; cardiac tamponade; bleeding requiring surgical intervention; bleeding requiring intravenous vasoactive drugs; Type 3c: intracranial hemorrhage; subcategories confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision; Type 5: fatal bleeding; Type 5a: probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious; Type 5b: definite fatal bleeding; overt bleeding or autopsy or imaging confirmation (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose

,
InterventionParticipants (Count of Participants)
Composite endpoint NACE (BARC Type 3 or 5)Major bleeding (BARC Type 3 or 5)
Edoxaban16489
Vitamin K Antagonist (VKA)15157

[back to top]

Number of Participants Who Experienced Valve Thrombosis in Participants Taking Edoxaban vs VKA (Adjudicated Data)

Valve thrombosis was defined as any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose

InterventionParticipants (Count of Participants)
Edoxaban0
Vitamin K Antagonist (VKA)0

[back to top]

Number of Participants Who Experienced Stroke Events (Ischemic, Hemorrhagic, Undetermined) in Participants Taking Edoxaban vs VKA (Adjudicated Data)

Stroke events are categorized as any stroke, fatal stroke, and non-fatal stroke. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose

,
InterventionParticipants (Count of Participants)
Any stroke (ischemic, hemorrhagic, or undetermined)Fatal stroke (ischemic, hemorrhagic, or undetermined)Non-fatal stroke (ischemic, hemorrhagic, or undetermined)
Edoxaban29425
Vitamin K Antagonist (VKA)35332

[back to top]

Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA

The composite endpoint net adverse clinical events (NACE) included all-cause death, myocardial infarction (MI), ischemic stroke, systemic embolic events (SEE), valve thrombosis, and major bleeding per definition of the International Society on Thrombosis and Haemostasis (ISTH]. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose

InterventionParticipants (Count of Participants)
Edoxaban170
Vitamin K Antagonist (VKA)157

[back to top]

Number of Participants Who Experienced Systemic Embolic Events in Participants Taking Edoxaban vs VKA (Adjudicated Data)

Systemic thromboembolism [non-central nervous system] is defined as abrupt vascular insufficiency of an extremity or organ associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms, (e.g., trauma, atherosclerosis, instrumentation). (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose

InterventionParticipants (Count of Participants)
Edoxaban2
Vitamin K Antagonist (VKA)3

[back to top]

Number of Participants Who Experienced Myocardial Infarctions (MI) in Participants Taking Edoxaban vs VKA (Adjudicated Data)

Peri-procedural MI was defined as new ischemic symptoms or signs and elevated cardiac biomarkers within 72 hours after index procedure, consisting of at least one sample post-procedure with a peak value exceeding 15x as the upper reference limit (URL) for troponin or 5x for CK-MB. Spontaneous MI is defined as any one of the following: Detection of rise and/or fall of cardiac biomarkers with at least one value above the 99th percentile URL, together with the evidence of myocardial ischemia with at least one of the following: Symptoms of ischemia; ECG changes indicative of new ischemia; New pathological Q-waves in at least two contiguous leads; Imaging evidence of a new loss of viable myocardium or new wall motion abnormality; Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial ischemia, and accompanied by new ST elevation or new left bundle branch block, and/or evidence of fresh thrombus; Pathological findings of an acute MI. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose

InterventionParticipants (Count of Participants)
Edoxaban12
Vitamin K Antagonist (VKA)7

[back to top]

Number of Participants Who Experienced Major Adverse Cardiac and Cerebrovascular Events (MACCE) in Participants Taking Edoxaban vs VKA (Adjudicated Data)

Major adverse cardiac and cerebrovascular events (MACCE) is defined as the composite of all-cause death (excluding adjudicated non-cardiac death), MI, stroke (ischemic, hemorrhagic, or undetermined), or repeat coronary revascularization of the target lesion (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose

InterventionParticipants (Count of Participants)
Edoxaban86
Vitamin K Antagonist (VKA)80

[back to top]

Number of Participants Who Experienced Major Adverse Cardiac Events (MACE) in Participants Taking Edoxaban vs VKA (Adjudicated Data)

Major adverse cardiac events (MACE) is defined as the composite of all-cause death (excluding adjudicated non-cardiac death), MI, or repeat coronary revascularization of the target lesion. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose

InterventionParticipants (Count of Participants)
Edoxaban61
Vitamin K Antagonist (VKA)53

[back to top]

Number of Participants Who Experienced a Composite of Adverse Events in Participants Taking Edoxaban vs VKA (Adjudicated Data)

A composite of clinical adverse events included cardiovascular death, MI ischemic stroke, SEE, valve thrombosis, and major bleeding as defined by ISTH criteria. (NCT02943785)
Timeframe: Baseline through study completion, up to 36 months post-dose

InterventionParticipants (Count of Participants)
Edoxaban151
Vitamin K Antagonist (VKA)123

[back to top]

Number of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - Overall

Descriptive statistics were used to report the number of participants with at least 1 symptomatic VTE recurrence. Recurrent VTE events were based on adjudicated events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionParticipants (Count of Participants)
ETNA-VTE100

[back to top]

Overview of Participants With Adverse Drug Reactions

Descriptive statistics were used to report an overview of participants with adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionParticipants (Count of Participants)
Death due to ADRParticipants with at least 1 ADRParticipants with at least 1 serious ADRStudy discontinuation due to ADR
ETNA-VTE2142590

[back to top]

Duration of Venous Thromboembolism Events (On Edoxaban Treatment)

Descriptive statistics were used to assess the duration of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

Interventiondays (Median)
Total number of VTE recurrencesDeep vein thrombosis (DVT) onlyPulmonary embolism with DVTPulmonary embolism only
ETNA-VTE11.09.5015.0

[back to top]

Duration of Edoxaban Treatment

Descriptive statistics were used to report the duration of edoxaban treatment. (NCT02943993)
Timeframe: Baseline up to end of observational period (18 months)

InterventionParticipants (Count of Participants)
Month 1 ongoingMonth 3 ongoingMonth 6 ongoingMonth 12 ongoingMonth 18 ongoingParticipants off edoxaban treatment at 18 months
ETNA-VTE25272346184212727131910

[back to top]

Number of Participants With Adverse Drug Reactions by Preferred Term (≥0.2%)

Adverse drug reactions were reported and coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observational period (18 months)

InterventionParticipants (Count of Participants)
HaemorrhageGastrointestinal haemorrhageMenorrhagiaEpistaxisFatigueNauseaDizzinessRashHeadachePruritus
ETNA-VTE35121211887755

[back to top]

Number of Participants Experiencing At Least 1 Real World Safety Event - Overall

Descriptive statistics were used to report the number of participants experiencing recurrent VTE and at least 1 real world safety event. VTE recurrence data were reported by recurrent deep vein thrombosis (DVT), recurrent pulmonary embolism (PE) with DVT, and recurrent PE only. Recurrent VTE events were based on adjudicated events. Real world safety events included all-cause death, cardiovascular (CV)-related death, VTE-related death, stroke, systemic embolic event, and hospitalization related to CV. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionParticipants (Count of Participants)
Recurrent DVT onlyRecurrent PE with DVTRecurrent PE onlyAll-cause deathCardiovascular-related deathVenous thromboembolism-related deathStrokeSystemic embolic eventHospitalization related to CV
ETNA-VTE6173195231262253

[back to top]

Duration of Venous Thromboembolism Recurrences, by Type - Overall

Descriptive statistics were used to assess the duration of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

Interventiondays (Median)
Total number of VTE recurrencesDeep vein thrombosis (DVT) onlyPulmonary embolism with DVTPulmonary embolism only
ETNA-VTE18.044.58.016.0

[back to top]

Number of Systemic Embolic Events - Overall

Descriptive statistics were used to report the number of systemic embolic events (SEE). (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionSystemic embolic events (Number)
Upper/lower extremityRenal
ETNA-VTE11

[back to top]

Total Number of Venous Thromboembolism Recurrences (On Edoxaban Treatment)

Descriptive statistics were used to assess the number of recurrent VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionVTE recurrences (Number)
Total number of VTE recurrencesDeep vein thrombosis (DVT) onlyPulmonary embolism with DVTPulmonary embolism only
ETNA-VTE392819

[back to top]

Total Number of Venous Thromboembolism Recurrences By Type - Overall

Descriptive statistics were used to describe the number of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionVTE recurrences (Number)
Total number of VTE recurrencesDeep vein thrombosis (DVT) onlyPulmonary embolism with DVTPulmonary embolism only
ETNA-VTE10564732

[back to top]

Number of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - On Edoxaban Treatment

Descriptive statistics were used to report the number of participants with overall symptomatic VTE recurrence. VTE recurrence data were further reported by recurrent deep venous thrombosis (DVT), recurrent pulmonary embolism (PE) with deep venous thrombosis (DVT), and recurrent PE only. Recurrent VTE events were based on adjudicated events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionParticipants (Count of Participants)
Recurrent VTERecurrent DVT onlyRecurrent PE with DVTRecurrent PE onlyAll-cause deathCV-related deathVTE-related deathStrokeSystemic embolic eventHospitalization-related to cardiovascular
ETNA-VTE37271950111151167

[back to top]

Number of Participants With Risk Factors for Thromboembolic Events at Baseline

Descriptive statistics were used to assess the number of participants with risk factors for thromboembolic events. (NCT02943993)
Timeframe: at Baseline

InterventionParticipants (Count of Participants)
PuerperiumProlonged immobilisation>5 days in bedHistory of major surgery traumaKnown thrombophilic conditions
ETNA-VTE9401218359111

[back to top]

Number of Stroke Events

Descriptive statistics were used to report the number of stroke events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

Interventionevents (Number)
Overall treatment: Total number of stroke eventsOverall treatment: Ischemic eventsOverall treatment: Haemorrhagic eventsOverall treatment: Unknown eventsOn treatment: Total number of stroke eventsOn treatment: Ischemic eventsOn treatment: Haemorrhagic eventsOn treatment: Unknown events
ETNA-VTE271755161231

[back to top]

Number of Participants With Pre-defined Adverse Drug Reactions

Descriptive statistics were used to report the number of participants with pre-defined adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionParticipants (Count of Participants)
StrokeBleeding eventsSystemic embolic eventsNon-valvular atrial fibrillationMalignancyOthers
ETNA-VTE2750004

[back to top]

Number of Participants With Bleeding Events (Adjudicated) While On Edoxaban Treatment

Descriptive statistics were used to report the number of participants with bleeding events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)

InterventionParticipants (Count of Participants)
Participants with any bleeding eventsAt least 1 major bleeding eventClinically relevant non-major bleeding eventMinorGastrointestinal bleeding eventEpidural or subdural haematoma bleeding eventIntra-ocular bleeding eventIntra-articular bleeding eventPleural bleeding eventOther bleeding eventSpontaneous bleedingProvoked bleedingUnknown bleeding
ETNA-VTE304388230077453131928711518

[back to top]

The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma.

The number of patients with emergency surgery and major bleeding due to fracture or trauma. Where emergency surgery defined as any surgical procedure (International Classification of Diseases (ICD) 10 code K000-879) performed on the same day as hospital admission with additional claims, major bleeding due to fracture is any bleeding associated with hospitalization or blood transfusion (ICD10 code E83.111) accompanied by any fracture, and major bleeding due to trauma is any bleeding associated with hospitalization or blood transfusion (ICD10 code E83.111) accompanied by any trauma. (NCT03254147)
Timeframe: One year

InterventionNumber of Patients (Number)
Age <=64Age 65-74Age >=75
Patients Prescribed With Non-warfarin Oral Anti Coagulants143584

[back to top]

The Number of Patients With Cardiac Tamponade and Pericardiocentesis.

The number of patients with cardiac tamponade and pericardiocentesis. Cardiac tamponade diagnosis (ICD 10 code 4200001) on the same or next day as catheter ablation or percutaneous coronary intervention (PCI), Pericardiocentesis (Medical Data Vision (MDV) procedure code 140010510) on the same or next day as catheter ablation or PCI. (NCT03254147)
Timeframe: One year

InterventionNumber of Patients (Number)
Patients Prescribed With Non-warfarin Oral Anti Coagulants1

[back to top]

Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir.

The primary efficacy endpoint is the percent change in the anti-FXa activity from baseline to the end of infusion (EOI) nadir. (NCT03310021)
Timeframe: Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours

Interventionpercent change (Median)
Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet-94.50
Cohort 1 Apixaban 5 mg BID/Placebo-29.00
Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet-98.00
Cohort 2 Rivaroxaban 15 mg BID/Placebo-37.00
Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet-81.00
Cohort 3 Edooxaban 60 mg QD/Placebo-47.50
Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet-75.50
Cohort 4 Edooxaban 60 mg QD/Placebo-37.00
Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet-93.00
Cohort 5 Apixaban 5 mg BID/Placebo-34.00
Cohort 6 Apixaban 10 mg BID/High Dose Andexanet-97.00
Cohort 6 Apixaban 10 mg BID/Placebo-31.00
Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet-52.50
Cohort 7 Edoxaban 30 mg QD/Placebo-37.00
Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet-92.00
Cohort 8 Apixaban 10 mg BID/Placebo-24.00
Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet-93.50
Cohort 9 Rivaroxaban 15 mg BID/Placebo-37.00
Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet-63.50
Cohort 10 Edoxaban 60 mg QD/Placebo-27.00

[back to top]

Percent Change in Anti-Fxa Activity From Baseline to the End of Bolus (EOB) Nadir.

The percent change from baseline in anti-FXa activity at its end of bolus (EOB) nadir. (NCT03310021)
Timeframe: Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours

Interventionpercent change (Median)
Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet-94.50
Cohort 1 Apixaban 5 mg BID/Placebo-14.00
Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet-97.50
Cohort 2 Rivaroxaban 15 mg BID/Placebo-18.00
Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet-65.50
Cohort 3 Edooxaban 60 mg QD/Placebo-16.00
Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet-22.50
Cohort 4 Edooxaban 60 mg QD/Placebo-15.00
Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet-94.00
Cohort 5 Apixaban 5 mg BID/Placebo-10.00
Cohort 6 Apixaban 10 mg BID/High Dose Andexanet-96.00
Cohort 6 Apixaban 10 mg BID/Placebo-18.00
Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet-58.00
Cohort 7 Edoxaban 30 mg QD/Placebo-8.00
Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet-94.50
Cohort 8 Apixaban 10 mg BID/Placebo-5.00
Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet-95.00
Cohort 9 Rivaroxaban 15 mg BID/Placebo-11.00
Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet-73.00
Cohort 10 Edoxaban 60 mg QD/Placebo-4.00

[back to top]

Change in Thrombin Generation From Baseline to the End of Infusion (EOI) Nadir.

The change in thrombin generation from baseline to its EOI peak. (NCT03310021)
Timeframe: Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours

InterventionnM.min (Median)
Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet1000.630
Cohort 1 Apixaban 5 mg BID/Placebo171.220
Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet1329.580
Cohort 2 Rivaroxaban 15 mg BID/Placebo207.590
Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet804.405
Cohort 3 Edooxaban 60 mg QD/Placebo347.535
Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet910.935
Cohort 4 Edooxaban 60 mg QD/Placebo236.610
Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet1130.575
Cohort 5 Apixaban 5 mg BID/Placebo118.130
Cohort 6 Apixaban 10 mg BID/High Dose Andexanet1119.41
Cohort 6 Apixaban 10 mg BID/Placebo108.67
Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet833.46
Cohort 7 Edoxaban 30 mg QD/Placebo175.72
Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet1058.09
Cohort 8 Apixaban 10 mg BID/Placebo138.14
Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet1173.38
Cohort 9 Rivaroxaban 15 mg BID/Placebo293.15
Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet793.44
Cohort 10 Edoxaban 60 mg QD/Placebo-72.69

[back to top]

Change in Thrombin Generation From Baseline to the End of Bolus (EOB) Nadir.

The change in thrombin generation from baseline to its EOB peak. (NCT03310021)
Timeframe: Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours

InterventionnM.min (Median)
Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet1145.03
Cohort 1 Apixaban 5 mg BID/Placebo179.94
Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet1337.28
Cohort 2 Rivaroxaban 15 mg BID/Placebo209.99
Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet758.92
Cohort 3 Edooxaban 60 mg QD/Placebo215.71
Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet815.07
Cohort 4 Edooxaban 60 mg QD/Placebo48.59
Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet1244.30
Cohort 5 Apixaban 5 mg BID/Placebo103.13
Cohort 6 Apixaban 10 mg BID/High Dose Andexanet1177.47
Cohort 6 Apixaban 10 mg BID/Placebo0.16
Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet781.42
Cohort 7 Edoxaban 30 mg QD/Placebo67.97
Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet1184.62
Cohort 8 Apixaban 10 mg BID/Placebo2.69
Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet1306.23
Cohort 9 Rivaroxaban 15 mg BID/Placebo117.50
Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet902.17
Cohort 10 Edoxaban 60 mg QD/Placebo-92.82

[back to top]

Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Infusion (EOI) Nadir.

The percent change from baseline in free FXa inhibitors concentration (ng/mL) at its EOI nadir. (NCT03310021)
Timeframe: Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours

Interventionpercent change (Median)
Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet-92.940
Cohort 1 Apixaban 5 mg BID/Placebo-33.550
Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet-98.650
Cohort 2 Rivaroxaban 15 mg BID/Placebo-39.390
Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet-85.005
Cohort 3 Edooxaban 60 mg QD/Placebo-48.710
Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet-81.040
Cohort 4 Edooxaban 60 mg QD/Placebo-42.755
Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet-93.495
Cohort 5 Apixaban 5 mg BID/Placebo-31.830
Cohort 6 Apixaban 10 mg BID/High Dose Andexanet-96.65
Cohort 6 Apixaban 10 mg BID/Placebo-29.02
Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet-62.72
Cohort 7 Edoxaban 30 mg QD/Placebo-24.34
Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet-90.63
Cohort 8 Apixaban 10 mg BID/Placebo-31.45
Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet-94.89
Cohort 9 Rivaroxaban 15 mg BID/Placebo-37.82
Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet-67.10
Cohort 10 Edoxaban 60 mg QD/Placebo-34.25

[back to top]

Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Bolus (EOB) Nadir.

The percent change from baseline in free FXa inhibitors concentration (ng/mL) at its EOB nadir. (NCT03310021)
Timeframe: Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours

Interventionpercent change (Median)
Cohort 1 Apixaban 5 mg BID/Low Dose Andexanet-93.00
Cohort 1 Apixaban 5 mg BID/Placebo-11.94
Cohort 2 Rivaroxaban15 mg BID/High Dose Andexanet-97.72
Cohort 2 Rivaroxaban 15 mg BID/Placebo-28.57
Cohort 3 Edoxaban 60 mg QD/High Dose Andexanet-78.20
Cohort 3 Edooxaban 60 mg QD/Placebo-17.60
Cohort 4 Edoxaban 60 mg QD/High Dose Andexanet-56.05
Cohort 4 Edooxaban 60 mg QD/Placebo-2.49
Cohort 5 Apixaban 5 mg BID/Low Dose Andexanet-94.45
Cohort 5 Apixaban 5 mg BID/Placebo5.80
Cohort 6 Apixaban 10 mg BID/High Dose Andexanet-93.57
Cohort 6 Apixaban 10 mg BID/Placebo-12.94
Cohort 7 Edoxaban 30 mg QD/Low Dose Andexanet-70.88
Cohort 7 Edoxaban 30 mg QD/Placebo-5.48
Cohort 8 Apixaban 10 mg BID/Low Dose Andexanet-91.61
Cohort 8 Apixaban 10 mg BID/Placebo-0.32
Cohort 9 Rivaroxaban 15 mg BID/Low Dose Andexanet-95.51
Cohort 9 Rivaroxaban 15 mg BID/Placebo-14.02
Cohort 10 Edoxaban 60 mg QD /Low Dose Andexanet-75.80
Cohort 10 Edoxaban 60 mg QD/Placebo-17.91

[back to top]

Number of Participants Who Died as a Result of Any Cause (All-Cause Mortality) Within the Main Treatment Period

Death due to any cause (all-cause mortality) was assessed. (NCT03395639)
Timeframe: Date of first dose of study drug up to the Month 4 or to the date of last dose of study drug if study treatment was discontinued, whichever was earlier

InterventionParticipants (Count of Participants)
Edoxaban0
Standard of Care (SOC)0

[back to top]

Number of Participants Who Died as a Result of Any Cause (All-Cause Mortality) During the Extension Period

Death due to any cause (all-cause mortality) was assessed. (NCT03395639)
Timeframe: Month 4 up to Month 13

InterventionParticipants (Count of Participants)
Edoxaban2

[back to top]

Number of Participants Who Died as a Result of Thromboembolic Event Within the Main Treatment Period

Symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus, and myocardial infarction (MI). (NCT03395639)
Timeframe: Date of first dose of study drug up to the Month 4 or to the date of last dose of study drug if study treatment was discontinued, whichever was earlier

InterventionParticipants (Count of Participants)
Edoxaban0
Standard of Care (SOC)0

[back to top]

Number of Participants With Symptomatic Thromboembolic Events (TE) in the Systemic Arterial or Venous Pathways Within the Main Treatment Period

Symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus, and myocardial infarction (MI). (NCT03395639)
Timeframe: Date of first dose of study drug up to the Month 4 or to the date of last dose of study drug if study treatment was discontinued, whichever was earlier

,
InterventionParticipants (Count of Participants)
Thromboembolic event, Any EventDeep vein thrombosisPulmonary embolismStrokeSystemic embolic eventIntracardiac thrombusMyocardial infarctionAsymptomatic intracardiac thrombus identified by cardiac imagingDeath as a result of TE
Edoxaban000000000
Standard of Care (SOC)111000000

[back to top]

Number of Participants With Symptomatic Thromboembolic Events (TE) in the Systemic Arterial or Venous Pathways During the Extension Period

Symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus, and myocardial infarction (MI). (NCT03395639)
Timeframe: Month 4 up to Month 13

InterventionParticipants (Count of Participants)
Thromboembolic event, Any EventDeep vein thrombosisPulmonary embolismStrokeSystemic embolic eventIntracardiac thrombusMyocardial infarctionAsymptomatic intracardiac thrombus identified by cardiac imagingDeath as a result of TE
Edoxaban400200200

[back to top]

Number of Participants With Adjudicated Bleeding Events Within the Main Treatment Period

Adjudicated bleeding events included major and clinically-relevant non-major (CRNM) bleeding events per International Society on Thrombosis and Haemostasis (ISTH) definition occurring within the main treatment period. Based on modified ISTH recommendations, major bleeding is defined as a composite (ie, any) of the following: fatal bleeding; and/or symptomatic bleeding in a critical area or organ; and/or bleeding causing a decrease in hemoglobin level of >2 g/dL, or leading to transfusion of the equivalent of ≥2 units of whole blood or red cells. A CRNM bleed is an acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding, or a physician guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy. Minor bleeding is any other overt bleeding event that does not meet criteria for either major or CRNM bleeding. (NCT03395639)
Timeframe: Date of first dose of study drug up to the Month 4 or to the date of last dose of study drug if study treatment was discontinued, whichever was earlier

,
InterventionParticipants (Count of Participants)
Major or CRNM bleeding eventsMajor bleeding eventsAll bleeding events (Major, CRNM, minor)
Edoxaban104
Standard of Care (SOC)102

[back to top]

Number of Participants With Adjudicated Bleeding Events During the Extension Period

Adjudicated bleeding events included major and clinically-relevant non-major (CRNM) bleeding events per International Society on Thrombosis and Haemostasis (ISTH) definition occurring within the main treatment period. Based on modified ISTH recommendations, major bleeding is defined as a composite (ie, any) of the following: fatal bleeding; and/or symptomatic bleeding in a critical area or organ; and/or bleeding causing a decrease in hemoglobin level of >2 g/dL, or leading to transfusion of the equivalent of ≥2 units of whole blood or red cells. A CRNM bleed is an acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding, or a physician guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy. Minor bleeding is any other overt bleeding event that does not meet criteria for either major or CRNM bleeding. (NCT03395639)
Timeframe: Month 4 up to Month 13

InterventionParticipants (Count of Participants)
Major or CRNM bleeding eventsMajor bleeding eventsAll bleeding events (Major, CRNM, minor)
Edoxaban114

[back to top]

Number of Participants Who Died as a Result of Thromboembolic Event During the Extension Period

Symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus, and myocardial infarction (MI). (NCT03395639)
Timeframe: Month 4 up to Month 13

InterventionParticipants (Count of Participants)
Edoxaban0

[back to top]

Andexanet Apparent Terminal Elimination Half-life (t1/2)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. t1/2 was determined by linear regression of the log concentration on the terminal portion of the plasma concentration-time curve. (NCT03551743)
Timeframe: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

Interventionhr (Mean)
Module 4 PlaceboNA
Module 4 (600mg)8.21
Module 4 (800 mg Bolus + 480 mg Infusion)6.90
Module 4 (800 mg)8.06

[back to top]

Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. AUC0-inf was calculated using a non-compartmental approach (NCT03551743)
Timeframe: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

Interventionng*hr/mL (Mean)
Module 4 PlaceboNA
Module 4 (600mg)129000
Module 4 (800 mg Bolus + 480 mg Infusion)315000
Module 4 (800 mg)241000

[back to top]

Andexanet Maximum Observed Plasma Concentration (Cmax)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Maximum observed plasma concentration was taken directly from the raw data. (NCT03551743)
Timeframe: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

Interventionng/mL (Mean)
Module 4 PlaceboNA
Module 4 (600mg)111000
Module 4 (800 mg Bolus + 480 mg Infusion)176000
Module 4 (800 mg)235000

[back to top]

Andexanet Time of Maximum Observed Plasma Concentration (Tmax)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Tmax was taken directly from the raw data. (NCT03551743)
Timeframe: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

Interventionhr (Median)
Module 4 PlaceboNA
Module 4 (600mg)0.38
Module 4 (800 mg Bolus + 480 mg Infusion)0.49
Module 4 (800 mg)0.50

[back to top]

Andexanet Total Systemic Clearance (CL)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. CL was calculated using a non-compartmental approach. (NCT03551743)
Timeframe: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

InterventionL/hr (Mean)
Module 4 PlaceboNA
Module 4 (600mg)4.80
Module 4 (800 mg Bolus + 480 mg Infusion)NA
Module 4 (800 mg)3.57

[back to top]

Andexanet Total Volume of Distribution (Vss)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Vss was calculated using a non-compartmental approach. (NCT03551743)
Timeframe: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

InterventionL (Mean)
Module 4 PlaceboNA
Module 4 (600mg)6.16
Module 4 (800 mg Bolus + 480 mg Infusion)NA
Module 4 (800 mg)4.34

[back to top]

Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration

Anti-fXa activity was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Anti-fXa activity was measured using a commercial kit (Coamatic Heparin-82 33 9363, DiaPharma) (NCT03551743)
Timeframe: Baseline to 2 minutes following the end of andexanet/placebo administration

InterventionPercent change in anti-fXa activity (Mean)
Module 4 Placebo-27.64
Module 4 (600mg)-51.71
Module 4 (800 mg Bolus + 480 mg Infusion)-72.60
Module 4 (800 mg)-82.04

[back to top]

Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration

Thrombin generation was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Thrombin generation was measured using a TF-initiated thrombin generation assay. (NCT03551743)
Timeframe: Baseline to 2 minutes following the end of andexanet/placebo administration

InterventionPercent change in thrombin generation (Mean)
Module 4 Placebo18.09
Module 4 (600mg)143.37
Module 4 (800 mg Bolus + 480 mg Infusion)252.92
Module 4 (800 mg)238.16

[back to top]

Efficacy: Percent Change From Baseline in Unbound Edoxaban Plasma Concentration at 2 Mins Following Andexanet/Placebo Administration

Unbound edoxaban concentrations was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Unbound plasma concentrations for edoxaban was determined by a rapid equilibrium dialysis method followed by Liquid chromatography- Mass Spectrometry. (NCT03551743)
Timeframe: Baseline to 2 minutes following the end of andexanet/placebo administration

InterventionPercent change in unbound edoxaban conce (Mean)
Module 4 Placebo-17
Module 4 (600mg)-56
Module 4 (800 mg Bolus + 480 mg Infusion)-66
Module 4 (800 mg)-76

[back to top] [back to top] [back to top] [back to top] [back to top]

Time to Treatment Discontinuation

Treatment discontinuation (complete discontinuation; no reinitiation) was defined as when a participant who ended their first continuous treatment episode with the index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. The time to treatment discontinuation was defined as the period from the index date to the date of treatment discontinuation. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event. (NCT05022563)
Timeframe: From index date up to treatment discontinuation, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

,,,,,,
InterventionDays (Median)
Without Active CancerWith Active Cancer
NOAC-Based Therapy119101
NOAC-Based Therapy: Apixaban8499
NOAC-Based Therapy: Dabigatran134118
NOAC-Based Therapy: Edoxaban154112
NOAC-Based Therapy: Rivaroxaban11997
PAC Only225
Warfarin-Based Therapy12975

[back to top]

Overall Index Anticoagulant Treatment Duration

Overall anticoagulant treatment duration was defined as the time period from the index date to the earliest of treatment interruption, switch, or discontinuation. Treatment interruption: when a participant had a gap with no new treatment within 30 days of estimated end of supply of index treatment, but subsequently restarted index treatment after this period of 30 days. Treatment switching: a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Treatment discontinuation: when a participant who ended their first continuous treatment episode with index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event. (NCT05022563)
Timeframe: From index date up to the earliest of treatment interruption, switch, or discontinuation; during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

,,,,,,
InterventionDays (Median)
Without Active CancerWith Active Cancer
NOAC Based Therapy: Apixaban96104
NOAC Based Therapy: Dabigatran137105
NOAC Based Therapy: Edoxaban164123
NOAC-Based Therapy140111
NOAC-Based Therapy: Rivaroxaban128102
PAC Only334
Warfarin-Based Therapy13980

[back to top]

Number of Participants With Interruption in Index Anticoagulant Treatment

Treatment interruption was defined as when a participant had a gap with no new treatment within 30 days of the estimated end of supply of index treatment, but subsequently restarted the index treatment after this period of 30 days. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event. (NCT05022563)
Timeframe: From index date up to treatment interruption, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

,,,,,,
InterventionParticipants (Count of Participants)
Without Active CancerWith Active Cancer
NOAC-Based Therapy8169961
NOAC-Based Therapy: Apixaban965115
NOAC-Based Therapy: Dabigatran49251
NOAC-Based Therapy: Edoxaban43938
NOAC-Based Therapy: Rivaroxaban5973728
PAC Only1226401
Warfarin-Based Therapy3429172

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event thromboembolism are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active Cancer
NOAC-Based Therapy591599

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event thromboembolism are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to NOAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to NOAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
PAC Only125163636481115

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event thromboembolism are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to NOAC: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to NOAC: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
Warfarin-Based Therapy1085897851271308

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event thromboembolism are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Apixaban61191410010

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event thromboembolism are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Dabigatran3011600003

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event thromboembolism are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Edoxaban2143901000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event thromboembolism are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active Cancer
NOAC-Based Therapy: Rivaroxaban481330152588411

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major surgery are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active Cancer
NOAC-Based Therapy13623

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major surgery are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to NOAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to NOAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
PAC Only146511510362182529

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major surgery are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to NOAC: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to NOAC: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
Warfarin-Based Therapy26314318310012

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major surgery are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Apixaban0004201000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major surgery are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Dabigatran2112100001

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major surgery are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Edoxaban1020100001

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major surgery are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active Cancer
NOAC-Based Therapy: Rivaroxaban105115822113

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major bleeding are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active Cancer
NOAC-Based Therapy5111

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major bleeding are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to NOAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to NOAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
PAC Only5111127000000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major bleeding are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to NOAC: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to NOAC: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
Warfarin-Based Therapy17023012000000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major bleeding are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Apixaban0003000000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major bleeding are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Dabigatran0010100000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major bleeding are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Edoxaban1010000000

[back to top] [back to top]

Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption

Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment interruption. Treatment interruption was defined as when a participant had a gap with no new treatment within 30 days of the estimated end of supply of index treatment, but subsequently restarted the index treatment after this period of 30 days. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. (NCT05022563)
Timeframe: Within 30 days before treatment interruption during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

,,,,,,
InterventionParticipants (Count of Participants)
Major Bleeding: Without Active CancerComplications of VTE: Without Active CancerThromboembolism: Without Active CancerMajor Surgery: Without Active CancerCancer-related Event: Without Active CancerKidney Function Changes: Without Active CancerLiver Function Change: Without Active CancerMajor Bleeding: With Active CancerComplications of VTE: With Active CancerThromboembolism: With Active CancerMajor Surgery: With Active CancerKidney Function Changes: With Active CancerLiver Function Change: With Active Cancer
NOAC-Based Therapy53133285661268715881213389
NOAC-Based Therapy: Apixaban5050126141012303113
NOAC-Based Therapy: Dabigatran23199587001201
NOAC-Based Therapy: Edoxaban201817476000100
NOAC-Based Therapy: Rivaroxaban4210233407995512940172775
PAC Only45209171100447220955109
Warfarin-Based Therapy2761589262457911121512

[back to top]

Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation

Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment discontinuation. Treatment discontinuation (complete discontinuation; no reinitiation) was defined as when a participant who ended their first continuous treatment episode with the index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. (NCT05022563)
Timeframe: Within 30 days before treatment discontinuation during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

,,,,,,
InterventionParticipants (Count of Participants)
Major Bleeding: Without Active CancerComplications of VTE: Without Active CancerThromboembolism: Without Active CancerMajor Surgery: Without Active CancerCancer-related Event: Without Active CancerKidney Function Changes: Without Active CancerLiver Function Change: Without Active CancerMajor Bleeding: With Active CancerComplications of VTE: With Active CancerThromboembolism: With Active CancerMajor Surgery: With Active CancerKidney Function Changes: With Active CancerLiver Function Change: With Active Cancer
NOAC-Based Therapy118257771691307240452362122666450
NOAC-Based Therapy: Apixaban1341235084039654014773
NOAC-Based Therapy: Dabigatran724818141334209112
NOAC-Based Therapy: Edoxaban5353252011280011553
NOAC-Based Therapy: Rivaroxaban9015537113823217232129287525142
PAC Only2018734625291383441140891904834
Warfarin-Based Therapy4210258781331041587117111416

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major bleeding are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active Cancer
NOAC-Based Therapy: Rivaroxaban4192311102

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event liver function change are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active Cancer
NOAC-Based Therapy361130

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event liver function change are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to NOAC: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to NOAC: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
Warfarin-Based Therapy63736351130010

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event liver function change are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Apixaban3002610000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event liver function change are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Dabigatran4111200000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event liver function change are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Edoxaban1012600001

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event liver function change are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active Cancer
NOAC-Based Therapy: Rivaroxaban28101342020201

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event kidney function change are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active Cancer
NOAC-Based Therapy13524

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event kidney function change are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to NOAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to NOAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
PAC Only541012121010

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event kidney function change are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to NOAC: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to NOAC: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
Warfarin-Based Therapy22631117201001

[back to top]

Number of Participants Who Switched to Another Anticoagulant Therapy

Treatment switching was defined as a prescription of another anticoagulant therapy that was started after the treatment initiation of the index anticoagulant treatment and within 30 days after the estimated end of supply of the index anticoagulant drug (exposure to the new anticoagulant treatment must last for at least 30 days to be considered as a treatment switch). The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event. (NCT05022563)
Timeframe: From index date up to treatment switch, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

,,,,,,
InterventionParticipants (Count of Participants)
Without Active CancerWith Active Cancer
NOAC-Based Therapy1273173
NOAC-Based Therapy: Apixaban31933
NOAC-Based Therapy: Dabigatran27630
NOAC-Based Therapy: Edoxaban20426
NOAC-Based Therapy: Rivaroxaban1777208
PAC Only535208
Warfarin-Based Therapy1541144

[back to top]

Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months

Participants were considered to be persistent on index anticoagulant treatment if a participant had evidence of a repeat prescription within 30 days of the end of their prescription and does not experience any of the events that included treatment interruption (participant had a gap with no new treatment within 30 days of estimated end of supply of index treatment, but subsequently restarted index treatment after 30 days), switch (prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug), or discontinuation (participant ended their first continuous treatment episode with index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time). Index date: date of first prescription for anticoagulants within 30 days after the index VTE event. (NCT05022563)
Timeframe: Within 3 months of index date, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

,,,,,,
InterventionParticipants (Count of Participants)
Without Active CancerWith Active Cancer
NOAC Based Therapy: Apixaban2390290
NOAC Based Therapy: Dabigatran1225120
NOAC Based Therapy: Edoxaban1395148
NOAC-Based Therapy198482405
NOAC-Based Therapy: Rivaroxaban140371770
PAC Only222673
Warfarin-Based Therapy6313388

[back to top]

Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months

Participants were considered to be persistent on index anticoagulant treatment if a participant had evidence of a repeat prescription within 30 days of the end of their prescription and does not experience any of the events that included treatment interruption (participant had a gap with no new treatment within 30 days of estimated end of supply of index treatment, but subsequently restarted index treatment after 30 days), switch (prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug), or discontinuation (participant ended their first continuous treatment episode with index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time). Index date: date of first prescription for anticoagulants within 30 days after the index VTE event. (NCT05022563)
Timeframe: Within 6 months of index date, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

,,,,,,
InterventionParticipants (Count of Participants)
Without Active CancerWith Active Cancer
NOAC-Based Therapy105571089
NOAC-Based Therapy: Apixaban1213125
NOAC-Based Therapy: Dabigatran60646
NOAC-Based Therapy: Edoxaban81791
NOAC-Based Therapy: Rivaroxaban7209773
PAC Only75221
Warfarin-Based Therapy4393217

[back to top]

Time to Treatment Switch

Treatment switching was defined as a prescription of another anticoagulant therapy that was started after the treatment initiation of the index anticoagulant treatment and within 30 days after the estimated end of supply of the index anticoagulant drug (exposure to the new anticoagulant treatment must last for at least 30 days to be considered as a treatment switch). The time to treatment switch was defined as the period from the index date to the date of treatment switch. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event. (NCT05022563)
Timeframe: From index date up to treatment switch, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

,,,,,,
InterventionDays (Median)
Without Active CancerWith Active Cancer
NOAC-Based Therapy17976
NOAC-Based Therapy: Apixaban6644
NOAC-Based Therapy: Dabigatran10560
NOAC-Based Therapy: Edoxaban8798
NOAC-Based Therapy: Rivaroxaban9953
PAC Only2749
Warfarin-Based Therapy5736

[back to top]

Time to Treatment Interruption

Treatment interruption was defined as when a participant had a gap with no new treatment within 30 days of the estimated end of supply of index treatment, but subsequently restarted the index treatment after this period of 30 days. The time to treatment interruption was defined as the period from the index date to the date of treatment interruption. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event. (NCT05022563)
Timeframe: From index date up to treatment interruption, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

,,,,,,
InterventionDays (Median)
Without Active CancerWith Active Cancer
NOAC-Based Therapy129137
NOAC-Based Therapy: Apixaban86123
NOAC-Based Therapy: Dabigatran137119
NOAC-Based Therapy: Edoxaban130159
NOAC-Based Therapy: Rivaroxaban128134
PAC Only361
Warfarin-Based Therapy163129

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event liver function change are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to NOAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to NOAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
PAC Only102954516171006

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event complications of VTE are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active Cancer
NOAC-Based Therapy: Rivaroxaban11010200000

[back to top] [back to top] [back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event kidney function change are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Apixaban1310200000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event kidney function change are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Dabigatran0000201000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event kidney function change are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Edoxaban0010100000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event kidney function change are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active Cancer
NOAC-Based Therapy: Rivaroxaban122101123001

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event complications of VTE are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active Cancer
NOAC-Based Therapy12000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event complications of VTE are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to NOAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to NOAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
PAC Only120002000000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event complications of VTE are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to NOAC: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to NOAC: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
Warfarin-Based Therapy200100000000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event complications of VTE are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Apixaban0001000000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event complications of VTE are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Edoxaban: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Edoxaban: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Dabigatran0000000000

[back to top]

Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE

"Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event complications of VTE are reported." (NCT05022563)
Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

InterventionParticipants (Count of Participants)
Switched to Warfarin: Without Active CancerSwitched to PAC: Without Active CancerSwitched to Apixaban: Without Active CancerSwitched to Dabigatran: Without Active CancerSwitched to Rivaroxaban: Without Active CancerSwitched to Warfarin: With Active CancerSwitched to PAC: With Active CancerSwitched to Apixaban: With Active CancerSwitched to Dabigatran: With Active CancerSwitched to Rivaroxaban: With Active Cancer
NOAC-Based Therapy: Edoxaban0000000000

[back to top]

Number of Participants Who Completely Discontinued Index Anticoagulant Treatment

Treatment discontinuation (complete discontinuation; no reinitiation) was defined as when a participant who ended their first continuous treatment episode with the index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event. (NCT05022563)
Timeframe: From index date up to treatment discontinuation, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

,,,,,,
InterventionParticipants (Count of Participants)
Without Active CancerWith Active Cancer
NOAC-Based Therapy198262570
NOAC-Based Therapy: Apixaban2828279
NOAC-Based Therapy: Dabigatran1028115
NOAC-Based Therapy: Edoxaban1164147
NOAC-Based Therapy: Rivaroxaban141701968
PAC Only45341449
Warfarin-Based Therapy4707444

[back to top]